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In contrast to the well-studied process of nucleocytoplasmic transport of soluble 
macromolecules, little is known about the targeting of integral membrane proteins to the inner 
nuclear membrane (INM), therefore the targeting of INM-proteins was studied in this work. 
Two major models haven been proposed for INM-protein transport, the diffusion-retention 
model, which assumes passive diffusion of proteins from the ER membrane, across the nuclear 
pore complex (NPC) to the INM and the transport factor-mediated model, where membrane 
proteins are believed to translocate across the NPC into the nucleus upon binding to nuclear 
import receptors. 
In this work, the targeting of proteins to the INM was studied for several tail-anchored (TA)-
proteins, which contain only a single C-terminal transmembrane domain (TMD). As a model 
protein, the well-established INM-protein emerin was used. With the help of membrane 
insertion assays, we showed that emerin, expressed in bacteria or a cell-free lysate, can be post-
translationally integrated into ER membranes by the TRC40-pathway. 
The involvement of the TRC40-system was shown by use of inhibitory fragments of the ER-
membrane receptors WRB and CAML in the membrane insertion reaction. An interaction 
between emerin and TRC40 could further be confirmed by proximity ligation assays. Additionally, 
TRC40 knockdown experiments demonstrated a reduction of emerin localized at the nuclear 
envelope. 
An important objective of this work was to verify correct targeting of emerin and other integral 
membrane proteins to the INM. 
To accomplish this, we performed differential permeabilization experiments, and established a 
rapamycin-based dimerization assay. These experiments allowed us to confirm the localization 
of emerin at the INM in a microscopy based approach.  
In addition to wild type emerin, we also analyzed mutants. Mutations in the emerin gene in the 
TMD or in the C-terminal part lead to the neuromuscular disease Emery-Dreifuss muscular 
dystrophy. As the TMD of emerin is crucial for anchoring of emerin in a membrane, several C-
terminal emerin mutations were selected and studied for their post-translational membrane 
insertion and localization at the INM. Several of these mutants showed severely disturbed TRC40-
binding, membrane integration and INM-targeting.  
The efficiency of targeting to the INM might therefore rely on properties within the TMD or at 
least the C-terminal region of emerin. The disease could therefore be a consequence of an 
impaired transport process or a reduced retention at the INM. 
Apart from emerin, other putative tail-anchored INM-proteins like LAP2β, LEMD1, PTP1B, VAPB 
and LRRC59 were confirmed to localize to the INM using the rapamycin assay. Furthermore, some 






1.1. The Nucleus and the Nuclear Envelope 
1.1.1. Nuclear Architecture 
The nucleus contains most of the genetic information of a cell and is one of the most important 
organelles in eukaryotic cells. It is enclosed by a double phospholipid bilayer. The nuclear interior 
is defined as nucleoplasm. Inside the nucleoplasm, a specialized substructure for ribosome 
biogenesis, the nucleolus, is located (Cooper, 2000). 
Figure 1: The nucleus and the nuclear envelope composition. The nucleus of a cell is surrounded by a 
double membrane system (inner and outer nuclear membrane (INM, ONM)), in which the nuclear pore 
complexes (NPCs) are embedded. This entity is referred to as the nuclear envelope (NE) (box, zoom in). 
The endoplasmic reticulum (ER) itself is shown to be continuously connected with the ONM. From the 
inside, the nucleus is wrapped by the nuclear lamina meshwork (grey), which interacts with proteins of 
the INM and chromatin (shown as DNA). 
In contrast to prokaryotic cells, which do not possess a nuclear compartment, in eukaryotic cells, 
the nucleus as an entity provides spatially segregation and protection of the genetic material 
from influences in the cytoplasm. Furthermore, this segregation enables a highly regulated gene 
expression, transport of molecules e.g. transcripts or proteins and controlled signal transduction 
(Cho et al., 2016). 
The nuclear envelope (NE) (Figure 1) comprises the following structural components. The outer 
nuclear membrane (ONM), the inner nuclear membrane (INM) and many nuclear pore complexes 
(NPCs), which are embedded in these membranes. Depending on the cell type, about 2000 NPCs 
can be found in vertebrate cells (Beck et al., 2011; Maul and Deaven, 1977). These huge, 125 
MDa (Reichelt et al., 1990) multimeric protein complexes are spanning both membranes and 
present a natural barrier for molecule diffusion and protein trafficking. 
In between the ONM and INM, a 30 to 50 nm region is referred to as perinuclear space (PNS) 





Underlying the INM, the nuclear lamina (NL) faces the nucleoplasmic side. The filamentous 
lamina network is intertwining with the proteins of the INM and provides structural robustness 
to the nucleus against mechanical forces. This meshwork consists of two major components, the 
A- and B-type lamins, which are members of the intermediate filament family (Gerace and Burke, 
1988; Gerace et al., 1978). Additionally, roles of the lamina in organization and anchoring of 
chromatin and an influence on the cytoskeleton via the LINC complex have been reported (Crisp 
et al., 2006; Haque et al., 2006; Burke and Stewart, 2013). 
The ONM is continuously connected with the membrane of the endoplasmic reticulum (ER). 
Therefore, the ONM-protein composition is similar to that of the ER and can be studded with 
ribosomes. On the contrary, the INM is decorated by unique membrane proteins (Dreger et al., 
2001; Schirmer et al., 2003; Schirmer and Gerace, 2005; Senior and Gerace, 1988). Linkage points 
of the outer and inner nuclear membrane are represented by regions, where NPCs span the 
membranes. 
 
1.1.2. Nuclear pore complexes and their role in nucleocytoplasmic transport 
Transport and exchange of molecules between the cytoplasm to the nucleus is restricted by the 
nuclear envelope. The NE is perforated by a huge number of nuclear pore complexes. These 
macromolecular complexes are comprised of about thirty distinct proteins termed nucleoporins 
(Nups), occurring in multiple copies per NPC (Cronshaw et al., 2002). 
NPCs function as a selective barrier in terms of nucleocytoplasmic trafficking of soluble cargo 
molecules like proteins, RNA and ribonucleoprotein (RNP) particles (Johnson et al., 2002; Köhler 
and Hurt, 2007; Daneholt, 2001). Due to the association of NPCs with chromatin, they are further 
reported to serve as platforms for gene expression regulation (Ptak et al., 2014). With regard to 
transport of different kinds of cargo (e.g. histones, RNA) through the NPCs, nuclear transport was 
characterized to be a bidirectional process (Feldherr et al., 1984). 
Vertebrate NPCs are arranged in an eight-fold-symmetrical ring (Hinshaw et al., 1992; Akey and 
Radermacher, 1993). In general, the composition of the NPC is based on the discrimination of 
three different “layers” of Nups (Figure 2), whose main components are conserved in eukaryotes 
(Neumann et al., 2010). Between a thin “nucleoplasmic ring” and a “cytoplasmic ring”, the 
channel forming “spoke ring” is located (Alber et al., 2007). 
 
Nucleocytoplasmic transport through the NPCs can happen in a diffusion-driven or active 
manner. The size of the cargo was described to be a limiting factor for nuclear transport. 
Molecules smaller than 40 kDa were reported to diffuse through the NPC (Paine et al., 1975), but 
larger molecules instead, like proteins or RNAs need to be transported actively (Kutay et al., 
1998). With respect to the size of cargoes transported through the NPC, it was found that 
molecules with a 39 nm diameter can be transported through NPCs in vertebrate cells (Pante and 
Kann, 2002). The inside of the central channel is lined with nucleoporins (Nups) and is 
characterized by intrinsically disordered phenylalanine-glycine repeats, which contribute to the 







Figure 2: Schematic view on the nuclear pore complex architecture. A scheme of the different units of 
the NPC as a vertical section within the nuclear envelope (grey) is shown. The nucleoporins of the 
“cytoplasmic ring” and filaments are shown in light blue, the Nups of the “spoke ring” forming a central 
transport channel in dark blue and purple (central channel). Nucleoporins of the “nuclear ring” and the 
nuclear basket facing the interior are depicted in brown and orange.  
For classical nucleocytoplasmic-transport in addition to NPCs, soluble nuclear transport receptors 
(NTRs) are essential (Pemberton and Paschal, 2005). The major transport processes are 
performed by NTRs belonging to the karyopherin β superfamily, like importin β1 (Görlich et al., 
1995; Radu et al., 1995; Chi et al., 1995; Imamoto et al., 1995) or transportin 1 (Pollard et al., 
1996). These transport receptors are divided in those performing only import (importins) and 
export (exportins). Only few NTRs were shown to be involved in bidirectional transport as for 
example importin 13 (Mingot et al., 2001). Whether a cargo is an import or export substrate is 
determined by a nuclear targeting sequence. There are two types of classical nuclear localization 
signal (NLS) bound by importin α/β. They can be divided into mono- and bipartite NLSs (Lange et 
al., 2007). The first consists of a single cluster of basic amino acids (lysine/arginine) and the latter 
of two clusters separated by a linker of 10-12 amino acids (aa). In addition to NLSs recognized by 
the importin β transport receptors, other non-classical nuclear localization sequences like the 38 
aa signal, termed M9, exist and can be recognized by transportin (Pollard et al., 1996). 
Besides the possibility of diffusion for molecules below the exclusion size of the NPC, for instance 
even small molecules like histones were shown to be actively imported by different transport 
receptors like importinβ/importin 7 via the recognition of an NLS with comparatively few basic 
amino acids (Baake et al., 2001; Muhlhausser et al., 2001; Bauerle et al., 2002). 
 
Export of proteins from the nuclear compartment to the cytoplasm relies on the recognition of a 
leucine-rich nuclear export signal (NES), which contains four to five hydrophobic residues within 





al., 1997). In both nuclear import and export, the transport receptor-cargo complex interacts 
with the FG-repeats of the Nups in the center of the NPC. As mentioned above, for molecules 
larger than 40-50 kDa an active transport through the NPC is required. The NTRs bind cargo, 
interact with NPCs and circulate between both compartments. For import as well as export, the 
Ran-GTP cycle (Melchior et al., 1993) plays an important role. The small GTPase Ran (25 kDa) can 
cycle between a GDP- and a GTP-bound form (Görlich et al., 1996). A Ran-GTP gradient across 
the nuclear envelope exists and controls the binding and release of cargo in the respective 
compartment. In the cytoplasm, the Ran-GTPase activating protein (RanGAP) and inside the 
nucleus the protein Ran guanine nucleotide exchange factor (RanGEF), as well as nuclear 
transport factor 2 (NTF2) are responsible for establishing a Ran-GTP gradient. In this, the 
cytoplasm displays lower cytoplasmic and higher nuclear concentrations of Ran-GTP and can be 
recognized by the Ran-GTP-binding domains of the NTRs. 
 
 
Figure 3: Nucleocytoplasmic transport. Left: Import of soluble cargoes into the nucleus is carried out via 
the recognition of a nuclear localization sequence (NLS) by the transport receptors importin α/β 
(green/yellow). Importin α/β-cargo complex passes the NPC via FG-Nup (black filaments) interactions and 
is disassembled due to RanGTP (blue) binding in the nucleus. Right: Nuclear export of soluble proteins 
requires the binding of a nuclear export sequence (NES) to an exportin-RanGTP complex (red/blue). After 
translocation through the NPC RanGTP hydrolysis occurs and removes the NES-cargo (light green) from 
the transport receptor. Both nuclear transport receptors are recycled back to either cyto- or nucleoplasm, 
whereas the specific cargoes accumulate at their destination (modified from Kabachinski and Schwartz 
(2015)). 
In the case of nuclear import, after translocation through the NPC, importin β binds to Ran-GTP. 
Due to a conformational change, the cargo protein can be released into the nucleoplasm. Then 
importin bound to RanGTP exits the nucleus and bound GTP is hydrolysed, the import receptor 





Nuclear export of proteins is carried with the help of this gradient as well. The exportin-cargo 
complex passes the NPC and in the cytoplasm, GTP hydrolysis occurs and the complex of Ran, 
export cargo and exportin disassembles. Free Ran-GDP can be imported back to the nucleus via 
NTF2 and a re-charging of Ran with GTP by RanGEF takes place (Cho et al., 2016; Bischoff and 
Ponstingl, 1991). 
 
Currently, there are different models available trying to explain how FG-Nups and transport 
receptors are involved in mediating translocation of cargoes through the NPC: The “virtual gating 
model” (Rout et al., 2000; Rout et al., 2003; Yamada et al., 2010), the “selective phase model” 
(Ribbeck and Görlich, 2001) and the “oily-spaghetti model” (Macara, 2001). 
The “virtual gating model” (Rout et al., 2003) is based on unstructured non-cohesive FG-repeat 
filaments, which fill the NPC. Inert macromolecules, which are not bound by nuclear transport 
receptors, are excluded by “non-interacting”-FG-filaments, also termed FG-bristles. The 
interaction of NTRs with these FG-brushes would allow the macromolecule (bound to the NTR) 
to overcome the virtual entropic barrier and speed up transit through the NPC. Therefore, non-
cohesive FG-domains would be adequate to provide the selectivity characteristics of the NPC 
(Weis, 2007; Schmidt and Görlich, 2016). 
In the “selective-phase or hydrogel” model, the permeability of the NPC is proposed to be limited 
by FG-Nups, which form a sieve-like hydrogel due to their interaction with each another. 
Transport receptors can bind to the hydrophobic FG-repeats and transiently and locally interact 
with this meshwork and become a part of it. By doing this, they are capable of passing the NPC 
(Ribbeck and Görlich, 2001; Hülsmann et al., 2012; Ribbeck and Görlich, 2002, 2002). 
In the last model, the “oily spaghetti-model” (Macara, 2001), the Nups with its FG-repeat regions 
reaching into the central channel of the NPC not like a meshwork described in the other model, 
but instead more loosely separated. It is proposed that NTRs interact with the FG-repeats and 
pass the central channel of the NPC by binding and “jumping” from FG to FG repeat. All of these 
models try to explain the biophysical properties of the NPC as a barrier for nucleocytoplasmic 
transport of soluble macromolecules. In the field, it is still a highly discussed topic (Kabachinski 







1.2. Membrane proteins 
Contrary to the well-studied process of nuclear transport of soluble proteins, the transport of 
membrane proteins to the inner nuclear membrane is not as well understood (Zuleger et al., 
2012; Laba et al., 2014). Therefore, this chapter deals with integral membrane proteins, 
especially inner nuclear membrane proteins, their biogenesis and a detailed view on tail-
anchored proteins. 
1.2.1. Classes of integral membrane proteins 
Integral membrane proteins can be discriminated into different classes based on their structural 
features (Ott and Lingappa, 2002). Generally, monotopic proteins with only one transmembrane 
domain (TMD) can be distinguished from polytopic proteins, which are multi-spanning proteins. 
The first group can be divided into several protein types with respect to their topology, the 
specific orientation inside a lipid bilayer with regard to their TMD (van Geest and Lolkema, 2000). 
Proteins, which have their C-terminus oriented to the cytoplasm belong to the type I integral 
membrane proteins. Type II proteins instead have their amino-terminus facing the cytoplasmic 
side and their C-terminus directed away from the cytoplasm (e.g. a protein at the ER would have 
the C-terminus facing the ER-lumen). A specialized version of type II proteins is termed signal-
anchor Type II proteins, which use their N-terminal TMD as both a signal sequence and a stop 
transfer sequence. 
The last class of monotopic proteins are called C-terminal anchor or tail-anchored (TA) proteins, 
because the TMD is found to be very close to the carboxy-terminus of the protein. 
According to their structural characteristics, the biogenesis of transmembrane proteins can occur 
in different ways. Either a co- or post-translational membrane insertion depending on the protein 
type is possible (see 1.2.2). The first entry site of the protein being properly integrated into a 
membrane is not necessarily the membrane of its final destination. Commonly the ER provides 
such a place, because many proteins might undergo modifications in the ER or Golgi-network. 
There, integral membrane proteins can exhibit specific localization signals as for instance ER-
retention, NLS or Golgi-retrieval signals (Laba et al., 2014). 
 
1.2.2. Biogenesis of membrane proteins 
1.2.2.1. Co-translational membrane protein insertion at the ER 
Poly- as well as monotopic (type I, II and signal-anchor type II) membrane proteins can be inserted 
into the ER membrane via a co-translational pathway, also termed as SRP-Sec61-pathway 
(Görlich and Rapoport, 1993; Wickner and Schekman, 2005). However, soluble and secretory 
proteins can as well use a signal recognition particle (SRP)-dependent or an Sec62-mediated 
pathway (Park and Rapoport, 2012; Jadhav et al., 2015). Generally, three stages of this 
mechanism can be distinguished: The recognition of the substrate, the association with the target 
membrane (ER membrane) and the integration of the protein (Keenan et al., 2001; Shao and 
Hegde, 2011). 
When an integral membrane protein is synthesized, the nascent polypeptide chain emerges from 
the ribosome and immediately a component of the SRP-Sec61-pathway needs to recognize the 
substrate. This step is performed by the signal recognition particle (SRP) (Walter and Blobel, 





by the protein and is bound by SRP. After binding of SRP to the polypeptide chain a short arrest 
in elongation occurs, then the SRP-protein-ribosome complex is targeted to the ER membrane. 
At the membrane, the SRP receptor can interact with SRP and transfer the protein in a GTPase-
dependent manner (Keenan et al., 2001). Subsequently, the SRP is released from the complex in 
its GDP-bound state. The SRP-receptor transfers the polypeptide chain-ribosome complex to the 
Sec61 translocon. While translation finishes, the polypeptide chain is released from the ribosome 
directly into the channel of the translocon. The fact that protein translation is directly coupled to 
the translocon minimizes the possibilities of misfolding of a TMD-protein in the cytosolic 
environment. Finally, the mature protein is integrated from the Sec61 channel into the lipid 
bilayer of the ER through a lateral opening. 
 
 
Figure 4: Scheme of co-translational membrane protein insertion. An integral membrane protein 
(depicted here: monotopic protein (dark green), its TMD (red)) is recognized via the SRP (green) emerging 
from the ribosome (light blue). Targeted to the ER membrane, the SRP receptor (dark blue) binds to SRP 
under GTP hydrolysis. The SRP receptor transfers the ribosome-protein complex to the Sec61 translocon 
(beige). After translation termination, a lateral integration of the mature membrane protein is performed 
at the Sec61 channel (modified from (Shao and Hegde, 2011)). 
 
1.2.2.2. Post-translational membrane insertion in mammals 
Especially the group of C-terminal or tail-anchored (TA) proteins requires a post-translational 
mechanism for insertion, but also very small monotopic proteins were reported to use this way 
of insertion (Shao and Hegde, 2011). By virtue of the position of their transmembrane domain 
(TMD) in TA-proteins, a mechanism other than the co-translational membrane insertion system 
is needed. Because TA-proteins do not possess a signal-peptide in their N-terminal half and their 
very C-terminal, hydrophobic transmembrane segment does not emerge out of the ribosomal 
tunnel until translation is terminated, the targeting and insertion into the ER membrane needs 





The SRP binds only signal peptides and signal anchors as long as they are part of the nascent 
polypeptide chain, therefore, this class of proteins cannot be recognized via the SRP and insert 
into the ER via the common Sec61-pathway (Borgese et al., 2003). 
Post-translational integration of membrane proteins into the ER has been described to occur via 
different pathways, which can be divided into assisted and unassisted mechanisms (Borgese and 
Fasana, 2010). 
One of the assisted pathways is the TRC40 (or ASNA1)-mediated insertion (GET3-pathway in 
yeast) (Figure 5) (Favaloro et al., 2010). There are three main components of this pathway. The 
arsenical pump-driving ATPase protein (ASNA1) was identified playing a role in TA-protein 
delivery and therefore renamed as Transmembrane Recognition Complex subunit of 40 kDa 
(TRC40) (Stefanovic and Hegde, 2007; Favaloro et al., 2008). 
As soon as the translation of a TA-protein is terminated, a three-component pre-targeting 
complex, consisting of Bag6, TRC35 and Ubl4A in mammals facilitates capturing of the TA-protein 
from the ribosome via the TMD and hand-off to TRC40 (Mariappan et al., 2010). After binding 
the substrate, the ATPase TRC40 can be found in its ATP-bound state and the pre-targeting 
complex disassembles from TRC40. This complex of TRC40 (Appen et al., 2015) and TA-protein is 
delivered to the ER.  
At the ER membrane, the proteins WRB (tryptophan-rich basic protein) and CAML (calcium-
modulating cyclophilin ligand) function as receptors for TA-protein integration (Yamamoto and 
Sakisaka, 2012; Vilardi et al., 2011). For proper insertion of proteins into the ER membrane, the 
binding of WRB to the transmembrane segments of CAML was reported to be crucial (Vilardi et 
al., 2014). 
There, TRC40 docks onto the WRB-CAML complex and releases the protein under ATP hydrolysis. 
The membrane integration is synergistically performed by the receptors WRB and CAML, but not 
studied in detail so far. After binding to the receptors, TRC40 exists in its nucleotide free form 
and can be recycled for a novel round of substrate binding. The Get3 (guided entry of tail-
anchored proteins 3; yeast homologue of TRC40) structural features of an open or closed 
conformation of its complex have been investigated and a crystal structure of the complex 
consisting of a homodimer binding the TA-protein as its substrate, was analyzed (Hu et al., 2009; 
Mateja et al., 2009; Yamagata et al., 2009; Appen et al., 2015; Mateja et al., 2015). 
Recently it has been reported that the membrane receptors WRB and CAML could influence each 
other’s expression, which makes the regulation of the TRC40-pathway an even more complex 
process (Colombo et al., 2016). Furthermore, the core component TRC40 functions not only in 
membrane integration but also in quality control mechanisms. In case translation results in a 
misfolded protein, the TRC40-complex can also bind this protein and distribute it for 
ubiquitination and degradation processes (Hessa et al., 2011). In connection to this, Get3 was 
found at places of deposition for protein aggregates under conditions where membrane targeting 
was blocked (Powis et al., 2013), as well a chaperone function under oxidative stress conditions 
has been reported (Voth et al., 2014). 
Another assisted option for post-translational membrane insertion is a chaperone-mediated 
pathway involving heat-shock proteins (Abell et al., 2007). Here, Hsp40/Hsc70 bind to a TA-
protein released from the ribosome in a ATP-dependent manner and shield their hydrophobic 
TMD. The insertion into the membrane could happen unassisted or via a so far unknown receptor 





state (Rabu et al., 2009). It was shown that proteins with a low hydrophobicity favor this pathway 
(Rabu et al., 2008). 
A further mode describes membrane integration to happen in an unassisted manner. In this case, 
substrates with a TMD of low hydrophobicity can spontaneously integrate into the lipid bilayers 
such as the TA-proteins cytochrome b5 and PTP1B (Brambillasca et al., 2006; Colombo et al., 
2009). 
Figure 5: Post-translational membrane insertion of TA-proteins via the TRC40-pathway. The TA-protein 
(blue with TMD in green) emerges from the ribosome and can be bound immediately via its TMD by a pre-
targeting complex (Bag6-TRC35-Ubl4A). The pre-targeting complex binds to TRC40 (dark blue) in an ATP-
bound conformation. After dissociation from the pre-targeting complex, TRC40 mediates delivery to the 
ER membrane. The membrane receptors WRB (orange) and CAML (yellow) bind to the substrate under 
ATP hydrolysis. Via a synergistic mode, the WRB-CAML complex integrates the TA-protein into the 
membrane such that the small C-terminal stretch is facing the ER lumen. TRC40 is available in its open, 
nucleotide unbound form and cycles back into the cytosol to be available for a new delivery processes. 
 
1.2.2.2.1. Tail-anchored proteins 
This work focuses on the special type of integral membrane proteins called tail-anchored (TA) 
proteins or C-terminal anchor proteins. In a bioinformatics approach applied to the human 
genome, about 400 TA-proteins derived from about 300 genes have been identified and in this 
study the group of SNARE-TA-proteins were found to share a distinctive composition of their 





have been reported (Beilharz et al., 2003). Generally, TA-proteins can be found as well 
throughout plants and bacteria (Kriechbaumer et al., 2009; Borgese and Righi, 2010). 
They have been first described as a class of proteins having a single C-terminal membrane anchor, 
which at the same time acts as some kind of targeting signal (Figure 5). The single transmembrane 
domain is characterized to consist of a stretch of 20 hydrophobic amino acids very close to the 
C-terminal end (Kutay et al., 1993). It has been shown that this group can be characterized 
biochemically with respect to their ER membrane insertion mechanism in vitro (Favaloro et al., 
2010; Vilardi et al., 2011). Due to the fact that they have only one TMD, their topology is easier 
to predict compared to other type II or even polytopic proteins located at the ER and their larger 
N-terminal region is always oriented to the cytosolic side. 
This class of proteins was shown to be involved in various cellular processes like vesicle fusion 
and transport (SNARE proteins) and apoptosis (Bcl-2 proteins). In eukaryotes, TA-proteins can be 
found at nearly every compartmental membrane of the cell including mitochondria or 
peroxisomes (Chen et al., 2014a). For a few TA-proteins a dual localization to ER and 
mitochondrial outer membrane was observed and it was supposed that generally, a competition 
between diverse compartments for TA-protein integration exists (Borgese et al., 2003). As 
explained above, different routes of membrane insertion can be taken by TA-proteins (Leznicki 
et al., 2011; Borgese and Fasana, 2010). A main route is the post-translational insertion via the 
TRC40-pathway (or GET pathway in yeast) (see 1.2.2.2) (Stefanovic and Hegde, 2007). Another 
could be a chaperone-dependent route (e.g. via Hsc70 and Hsp40) (Abell et al., 2007; Rabu et al., 
2008) or an insertion in an unassisted manner (shown for cytochrome b5) (Leznicki et al., 2011; 
Brambillasca et al., 2006; Colombo et al., 2009). Furthermore, the strength of hydrophobicity of 
the TMD might have an impact on the mode of membrane insertion as it is seen and compared 
for the proteins VAMP2, RAMP4 and cytochrome b5 (Rabu et al., 2009). A study by Ott et al. 
(2011) indeed revealed that for proper post-translational insertion a minimal length of 15 aa of 
the TMD was required for the Herpes virus TA-protein pUL34. 
 
1.2.3. Proteins of the inner nuclear membrane 
The inner nuclear membrane, as a part of the NE, plays an important role in maintenance of the 
nuclear structure due to its linkage to chromatin and the nuclear lamina. It provides a connection 
to the cytoskeleton and can regulate and influence gene expression as well as cell signaling 
(Haque et al., 2006; Gomez-Cavazos and Hetzer, 2012). 
Early on, the INM was reported to be a part of the NE characterized by its distinct set of proteins 
when compared to the ER and the outer nuclear membrane (Senior and Gerace, 1988). Several 
proteomics approaches have been performed to elucidate the composition of the nuclear 
envelope and the inner nuclear membrane in particular (Dreger et al., 2001; Schirmer et al., 2003; 
Schirmer and Gerace, 2005; Malik et al., 2010; Wilkie et al., 2011). 
Furthermore, the NE proteome was found to vary between different tissues (Korfali et al., 2012; 
de Las Heras, Jose I et al., 2013), which might be interesting in the context that INM-proteins 
were linked to human diseases and can lead to tissue-specific phenotypes (Mejat and Misteli, 
2010; Dauer and Worman, 2009). 
In the above-mentioned proteomics screens for identification of new nuclear envelope proteins, 
well-studied and typical INM-proteins like the lamin B receptor (LBR) with multiple 





(Figure 6). LBR itself is one of the best studied proteins of the INM, having eight TMDs (Worman 
et al., 1990). It is involved in tethering the nuclear lamina and chromatin to the NE. As for other 
INM-proteins, mutations in the LBR gene can lead to specific diseases and abnormal membrane 
morphology (Zwerger et al., 2010) as mentioned in the beginning of this chapter. 
Over 200 proteins of the INM were identified for the human genome, among them several tail-
anchored membrane proteins. With regard to this, potential TA-proteins of the INM should be 
investigated in this work for their membrane insertion and localization. 
 
 
Figure 6: Schematic view of prominent INM-proteins and their unique features. Human, yeast and              
C. elegans inner nuclear membrane proteins are depicted and arranged via similarities in their structural 
features and sorting motifs as well as orientation at the INM (illustrated specific features are explained in 
the white box) (modified from (Katta et al., 2014)). 
 
1.2.4. Targeting of membrane proteins to the INM 
So far, it is not fully understood, how proteins are able to enrich at the INM compared to the ER 
or ONM. In this context, two essential mechanisms of INM targeting can be envisioned for cells 
in open mitosis and interphase cells (Antonin et al., 2011). 
Since studies of integral membrane proteins during mitosis are available, INM-proteins were 
reported to be distributed throughout the mitotic ER serving as an intermediate place of storage 
after NE breakdown (Yang et al., 1997; Ellenberg et al., 1997). In telophase, the NE-material was 
reported to be found surrounding the condensing chromosomes and it was shown that INM-
proteins can interact with chromosome surfaces and therefore allow diffusion from the mitotic 
ER to the reforming nuclear envelope (Yang et al., 1997; Ellenberg et al., 1997; Antonin et al., 
2011). The lamin B receptor (LBR), MAN1, LAP2 as well as the nucleoporin Ndc1, POM121 were 





(Haraguchi et al., 2000; Haraguchi et al., 2001; Anderson and Hetzer, 2008; Anderson et al., 
2009). 
During interphase instead, the ER and the ONM are continuously connected and NPCs are the 
linkage points of both INM and ONM, thus an alternative mechanism for INM-protein targeting 
is required to exist. Depending on the integral membrane protein, different models for INM 
targeting (Katta et al., 2014; Laba et al., 2014; Burns and Wente, 2012; Gonzalez and Andres, 
2011; Antonin et al., 2011) have been proposed for interphase cells (Figure 7). 
Early on, transport to the INM has been observed to be an energy- and temperature-dependent 
process (Ohba et al., 2004) speaking against a pure diffusion process from the inner to the outer 
nuclear membrane. Along these lines, based on the transport mechanisms known for soluble 
proteins, a transport-factor-mediated model (Figure 7, B) has been proposed, because for the 
yeast INM-proteins Heh1 and Heh2, an import receptor-dependent, NLS-based transport to the 
INM as well as an involvement of nucleoporins was shown (King et al., 2006; Laba et al., 2015; 
Turgay et al., 2010). In this model, INM-proteins containing an NLS are proposed to interact with 
classical import receptors of the karyopherin family. At this point, the protein is already bound 
to the ER membrane and shuttles together in a complex with the importin to the NPCs. At NPCs, 
the importin-INM-protein complex could either pass through the central channel via a very long 
linker (Meinema et al., 2011) or use one of the small, peripheral channels of the pore though 
with assistance of a membrane-associated import receptor version (Saksena et al., 2006). 
Similar to the transport-factor dependent model, a sorting-motif-based model (not illustrated) 
also includes the recognition of a small and specifically charged domain (Figure 6) within the INM-
protein by a shortened version of importin α directly after protein synthesis at the ER membrane 
(Saksena et al., 2006). This complex could then be directed along the membrane and through a 
peripheral channel of the NPCs. An interaction with Nup50/Nup2 could facilitate the cargo 
release inside the nucleus. Braunagel et al. (2007) showed that the INM-sorting-motif of LBR can 
be bound by short importin α-16, when LBR is integrated at the ER membrane adjacent to the 
Sec61 translocon. 
The other major diffusion-retention model (Figure 7, A), was proposed very early and suggested 
to apply for lamin- and chromatin- binding INM-proteins (Powell and Burke, 1990; Smith and 
Blobel, 1993; Soullam and Worman, 1993; Torrisi et al., 1987). With this path, proteins are 
supposed to passively diffuse from the ER membrane, where they are inserted via a co- or post-
translational insertion mode (section 1.2.2), to the ONM. There, translocation from the ONM to 
INM can occur through peripheral channels of the NPC. These 10 nm channels have been found 
for NPCs of humans and the amoeba Dictyostelium (Maimon et al., 2012; Beck et al., 2007). 
Proteins transported via this model should not exceed a limit 60 kDa (Terry and Wente, 2009). At 
the INM, the proteins are proposed to be retained via interaction partners (e.g. lamins, 
chromatin) (Holaska et al., 2002; Lee et al., 2001; Foisner and Gerace, 1993; Dechat et al., 2000). 
The observation of differences in the INM-protein mobility in the ER and INM supports this model 
(Zuleger et al., 2011). Quite recently, this model has been strongly supported by two studies 
investigating the transport of the INM-proteins LBR, LAP2β and SUN2 with the help of targeting 
assays considering real-time measurements and kinetics of this process (Boni et al., 2015; 







Figure 7: Major models of membrane protein trafficking to the INM. Integral membrane proteins are co- 
or post-translationally inserted into the ER membrane and believed to be transported to the INM via two 
main models. (A) The passive diffusion-retention mechanism. The cargo protein (yellow) diffuses from the 
ER membrane via a peripheral channel of the NPC to the INM and is sequestered there by interactions 
with e.g. lamins (grey) (B) The active transport receptor mediated model is based on the recognition of an 
NLS (green) by a nuclear transport receptor (orange). The translocation occurs as an active process 
through the central channel of the NPC, the cargo protein (red) -transport receptor complex disassembles. 
Finally, a vesicle-mediated mechanism (not illustrated) has been suggested. Vesicles budding 
from the ONM to the perinuclear space and might dock and fuse with the INM, there the INM-
protein can diffuse into the INM without any involvement of NPCs. Speese et al. (2012) could 
show that at least for the export of RNP complexes such a pathway is possible. 
 
Besides the main models explained, studies also showed that other properties of INM-proteins 
can have an influence on the route of transport. Wu et al. (2002) showed for the LEM-domain 
protein MAN1 (Lin et al., 2000) that also the size of the N-terminal portion of proteins influence 
transport to the INM. In yeast, NE transmembrane proteins (NETs) having internal FG-motifs, 
which interact with Nup35 in the peripheral channel, could mediate passage through the NPC 
and transport to the INM by themselves (Zuleger et al., 2011). 
Taken together, to date no uniform or standard mode of INM-trafficking has been found. 
Depending on the structural features as well as possible interaction partners of individual INM-






1.2.5.  Putative tail-anchored proteins of the INM 
As delineated in section 1.2.2.2.1, over 400 human TA-proteins have been identified for several 
compartments like ER, mitochondria and peroxisomes but among them, also proteins localizing 
to the NE and particularly to the INM (Kalbfleisch et al., 2007). The following paragraph describes 
the depicted putative TA-proteins of the INM (Table 1), which were characterized in this work. 
 
 
Table 1 Integral membrane proteins studied throughout this work including properties of their trans-










TMD - aa sequence 
Predicted 
 Δ G* 
[kcal/mol]  





























Cytochrome b5 ‡ 
(134 aa) 




*Calculations were obtained by Membrane Protein Explorer (MPEX) (Snider et al., 2009) based on Uniprot database 
entries (window size: 19, Wilmey-White Scale: interfacial, water to bilayer). Predicted ΔG provides an alternative 
indication of biological hydrophobicity (Hessa et al., 2007). The more negative the value, the more hydrophobic the 
TMD shown. 
◊ reference protein; confirmed TA-protein using the TRC40-pathway for membrane insertion at the ER  
(Favaloro et al., 2008). 
‡ reference protein; confirmed TA-protein using an unassisted mode of membrane insertion at the ER  






In this project, emerin is focused on as the model protein, because it is a well-studied protein of 
the INM, which was proposed to be a TA-protein (Laba et al., 2014). It has a size of 29 kDa and is 
encoded by the STA gene. Its gene was identified by genetic mapping (in context of the recessive 
X-linked form of Emery-Dreifuss muscular dystrophy (EDMD) (Emery and Dreifuss, 1966; Emery, 
1989), a neuromuscular disease associated with muscle weakness and cardiomyopathy (Vohanka 
et al., 2001). The disease is inherited either as an autosomal-dominant or an X-linked recessive 
form. In the latter, Emerin is either absent or defective in EDMD patients as a result of mutations 
in the gene (Manilal, 1999; Nagano et al., 1996). 
Shortly after a link to the responsible gene was made, emerin was found to be a protein of the 
nuclear envelope, more precisely the INM (Manilal, 1996; Nagano et al., 1996). Besides the 
ubiquitous expression, it is present in the heart as well as in skeletal muscles at very high 
amounts, speaking for the strong effect seen in EDMD. Emerin contains a single stretch of 23 
hydrophobic amino acids (Table 1) at its very C-terminal end, which indicates emerin to 
potentially be a TA-protein. Furthermore, it belongs to the family of LEM- domain proteins, 
whose name originates from the INM-proteins LAP2, emerin, MAN1 (LEM). Most of the present 
known members are anchored to the INM via one TMD. For LEM-domain proteins, as it is the 
case for emerin, an interaction with barrier-to -autointegration factor (BAF) (Haraguchi et al., 
2001; Furukawa, 1999; Zheng et al., 2000; Shumaker et al., 2001), a DNA-binding factor, and the 
nuclear lamina was reported (Berk et al., 2013b; Barton et al., 2015). In this context, lamin 
interactions were shown to function as an INM retention signal (Vaughan et al., 2001; Östlund et 
al., 2006; Wu et al., 2002) for emerin or MAN1. Moreover, N- and C-terminal regions of homology 
between emerin with the family of thymopoetins like LAP2β, which is described below, were 
identified (Manilal et al., 1996). 
Based on the many interaction partners at the INM and the behavior of emerin in a mobility study 
(Östlund et al., 1999)), it is proposed to use a diffusion-retention mode for trafficking to the INM 
(different models of INM-targeting are described in section 1.2.4). 
Many diverse functions have been shown for emerin, ranging from contributing to nuclear 
architecture, influencing gene regulation, mRNA splicing, mechanotransduction and to regulating 
signaling pathways (Markiewicz et al., 2006; Holaska and Wilson, 2007). Beyond this, emerin itself 
is a highly post-translationally regulated protein. Due to its serine/threonine-, tyrosine-rich 
sequence, it can be easily phosphorylated and is regulated e.g. during the cell cycle (Foisner and 
Gerace, 1993). In interphase cells, emerin localizes to the INM, but can be found mainly at the ER 
membranes at the end of mitosis. Haraguchi et al. (2001) observed that for the re-assembly of 
the NE, the chromatin-binding protein BAF is required. Other studies showed that emerin-
laminA/C interactions are important for proper localization of emerin at the NE (Vaughan et al., 
2001; Sakaki et al., 2001). 
Even though the major fraction of emerin is found at the INM, there are reports about a pool at 
the ONM. There, emerin contributes to controlling spacing between nucleus and the centrosome 
(Salpingidou et al., 2007). Especially in the heart, emerin has a unique localization to desmosomes 
and fasciae adherens of the intercalated discs (Cartegni et al., 1997). Recently, the self-assembly 
ability of emerin was studied and it turned out to be crucial for proper function of emerin. As a 
consequence, emerin mutations interfering with this self-assembly, were reported to cause 





variants related to EDMD are explicitly analyzed in this study with respect to membrane insertion 
and targeting to the INM. 
 
1.2.5.2. LAP2β 
Lamina-associated polypeptide 2 (LAP2) exists in six alternatively spliced forms in mammalian 
cells. In this study, the protein LAP2β is analyzed, because it contains a single, C-terminal 
transmembrane domain (Table 1), rendering it a potential TA-protein (Foisner and Gerace, 1993) 
and because it was shown to localize to the nuclear envelope (Furukawa et al., 1995). With a size 
of 51 kDa it is larger than emerin. Recent studies provided evidence for a diffusion-retention 
based mode of INM-transport (Ungricht and Kutay, 2015; Boni et al., 2015). As a member of the 
LEM-domain family, it can bind to the lamina, whereby the region coincides with the 76 aa region 
needed for stable INM targeting (Furukawa et al., 1998; Furukawa, 1999). The N-terminal part 
was shown to be directly involved in chromatin association (Furukawa et al., 1997) and as 
reported for emerin also the chromatin-binding factor BAF was reported to mediate this 
interaction (Furukawa, 1999; Shumaker et al., 2001). Not much about the function of Lap2β is 
known, but a role of LAP2 in regulation of the lamina growth has been implicated and it therefore 
could contribute to NE reassembly and nuclear growth (Yang et al., 1997; Gant et al., 1999). 
Additionally, in Drosophila LAP2β was observed to mediate transcriptional repression (Nili et al., 
2001). Even though LAP2 is a ubiquitously expressed protein, it was found to be highly expressed 
in digestive tract cancers (Kim et al., 2012) and lately, it was even discussed as a marker for breast 
cancer (Marrero-Rodriguez et al., 2015). 
 
1.2.5.3. LEMD1 
LEM domain-containing 1 (LEMD1) is about 20 kDa in size and belongs to the group of LEM-
domain proteins of the INM. Due to its very C-terminal TMD (Table 1) it is seen as a potential TA-
protein. However, not much is known about this protein so far. There are six alternatively spliced 
forms of LEMD1 transcripts found and it is predominantly expressed in testis and reported to 
play a role in different kinds of cancer (Yuki et al., 2004; Sasahira et al., 2016; Ghafouri-Fard et 
al., 2010). Further, a co-localization with the DNA binding factor BAF was reported like for other 
LEM-domain inner nuclear membrane proteins (Yuki et al., 2004). 
 
1.2.5.4. PTP1B 
Protein tyrosine phosphatase 1B (PTP1B), originally isolated from human placenta (Tonks et al., 
1988b, 1988a), belongs to the protein tyrosine phosphatase family. Besides a catalytic domain, 
it has one moderately hydrophobic TMD (Table 1) close to its C-terminal end compared to the 
more hydrophobic TA-protein VAMP2 (Synaptobrevin 2) (Chen et al., 2011). Because of its TMD, 
it belongs to the receptor-like membrane bound subgroup of protein tyrosine phosphatases 
(Walton and Dixon, 1993) and is able to insert into the ER membrane unassisted like cytochrome 
b5 (Brambillasca et al., 2006). In another in vitro approach however, it was observed that addition 
of Hsc40/Hsp70 could promote the membrane insertion of PTP1B into ER-derived membranes 
(Rabu et al., 2008). Further, full-length endogenous or recombinant PTP1B was shown to localize 





cyto- or nucleoplasmic localization. An important finding was made by Kuchay et al. (2007), when 
PTP1B was observed to be cleaved by the protease calpain, which cuts off the hydrophobic tail 
of PTP1B and releases a soluble, more active form of the enzyme. 
PTP1B has a size of about 50 kDa and does not contain any organellar targeting motif (Frangioni 
et al., 1992). With respect to a possible function of the protein, an in vitro interaction with the 
cell cycle protein p34cdc2 has been observed (Morla et al., 1989; Flint et al., 1993) and a role in 
nerve growth factor signaling has been reported (Brobeil et al., 2015). Interestingly, for the 
Drosophila orthologue PTP61F two variants with identical catalytic domains exist. The variants 
are shown to be differentially targeted to either the ER or nucleus accompanied by differences 
in their ability to regulate signaling pathways (Buszard et al., 2013). Yip et al. (2012) found PTP1B 
localized to the INM and there, it was shown to regulate the tyrosine phosphorylation of the 
model protein of this work, emerin. 
 
1.2.5.5. VAPB 
The human VAMP-associated protein B (VAPB) has a molecular weight of about 28 kDa. 
Characteristic for this protein is an N-terminal MSP (Major Sperm Protein) domain followed by a 
coiled-coil domain and a C-terminal membrane anchor. As sites of localization inside the cell the 
ER, Golgi, ERGIC, endosomes and the plasma membrane have been demonstrated (Skehel et al., 
2000; Soussan et al., 1999). 
Via the MSP domain, interactions with FFAT-motif (two phenylalanines (FF) in an Acidic Tract) 
containing proteins are possible e.g. oxysterol-binding proteins (Baron et al., 2014). 
Concomitantly, it was shown that VAPB can bind an FFAT-like motif of TRC40 (ASNA1) via its MSP 
domain, but not with the C-terminal TMD of VAPB (even though it is a TA-protein). In the same 
study, a perinuclear distribution of overexpressed TRC40 together with endogenous VAPB was 
observed, indicating another possible function of the TRC40-VAPB complex than membrane 
insertion. Regarding the known functions of VAPB, it was shown to be involved as an adaptor 
protein in regulation of lipid transport, membrane trafficking, release of neurotransmitters and 
the unfolded protein response (Lev et al., 2008). 
Defects in the STA gene encoding for emerin may result in the neuromuscular disease EDMD, 
likewise a mutation in the VAPB gene can cause the neurodegenerative disease amyotrophic 
lateral sclerosis (ALS8) (Nishimura et al., 2004). A VAPB disease mutant was investigated for its 
membrane insertion capacity, but no effect on membrane insertion compared to the wild type 
was found for defective VAPB. Nevertheless, Fasana et al. (2010) showed evidence for VAPB using 
an assisted post-translational insertion mode. Interestingly, as seen for the protein PTP1B a link 
between the proteins VAPB and emerin can be made. VAPB was described to have an influence 
on the transport of NE components like emerin and Nups and these proteins were shown to be 
accumulated in the ER-Golgi intermediate compartment (ERGIC) (Tran et al., 2012). 
 
1.2.5.6. LRRC59 
Leucine rich repeat-containing protein 59 (LRRC59) was first identified as ribosome-binding-
protein 34 (p34) (Ohsumi et al., 1993). According to its name, it contains four leucine rich repeats, 
a coiled-coil and a C-terminal transmembrane segment. It was shown to be integrated into ER-





the nuclear envelope in an osteosarcoma cell line (Skjerpen et al., 2002; Zhen et al., 2012). Early 
on, LRRC59 has been implicated in the binding of ribosomes to microsomal membranes and was 
reported to be present in close proximity to the protein translocation site for secretory proteins 
(Ichimura et al., 1993). Furthermore, LRRC59 seems to be involved in the transport of the 
fibroblast growth factor FGF1 and cancerous inhibitor of PP2A (CIP2A) to the nucleus and the 







AIM OF WORK 
 
 
1.3. Aim of this Work 
The transport of soluble proteins from the cytoplasm to the nucleus across NPCs is a well-studied 
process. However, little is known about the targeting of integral membrane proteins upon their 
synthesis in the cytoplasm to the INM. Therefore, a central aim of this thesis was to characterize 
the targeting of proteins to the INM. For a better understanding of this process, emerin is used a 
model protein, as it is one of the best characterized INM proteins. 
Emerin is proposed to belong to the group of tail-anchored proteins and therefore a post-
translational insertion mechanism into the ER membrane as a first site of membrane integration 
can be envisioned. Following membrane insertion emerin and other INM proteins need to be 
targeted to the INM. However, standard fluorescence microscopy does not allow for a clear 
differentiation between an INM and ONM localization, as the two membranes are only separated 
by a distance of 30-50 nm (Franke et al., 1981). 
Therefore, a simple and robust assay was developed, which confirms a correct localization of a 
protein of interest to the INM. The established method of differential permeabilization is limited 
due to the prerequisite of available and reliable antibodies. A possible approach could be the use 
of the rapamycin-dimerization mechanism (Chiu et al., 1994; Stan et al., 1994; Choi et al., 1996). 
Using these assays, emerin and other putative TA-proteins could be tested for their localization 
to the INM as well as their post-translational insertion into ER membranes.  
To get a better understanding of the targeting process of emerin to the INM, emerin mutants 
associated with Emery-Dreifuss muscular dystrophy which are reported to have mutations within 
or close to their TMD, could be analyzed in more detail by means of the developed assay.  
Overall, these experiments should provide valuable insights on the transport of specific proteins 









2. Material and Methods 
2.1. Material 
2.1.1. Technical equipment 
Equipment Company 
Agarose gel documentation GelSTICK touch INTAS Science Imaging Instruments 
Agarose gel running chamber Home-made, Workshop, UMG 
Autoclave DX-200 Systec 
BioPhotometer  Eppendorf 
Cell culture hood Herasafe™ KS  ThermoScientific 
Cell culture incubator Heracell™ 150i ThermoScientific 
Cell culture incubator Cytoperm 2 Heraeus Instruments 
Centrifuge 5415R  Eppendorf 
Centrifuge 5424 Eppendorf 
Centrifuge Sigma Sigma 
Centrifuge Allegra® X-15R with rotor 
SX4750 
Beckman Coulter 
Centrifuge Allegra® X 22 with rotor SX4250 Beckman Coulter 
Centrifuge Avanti™ J-30I with rotor 
JA30.50Ti 
Beckman Coulter 
Centrifuge J6-MI with rotor JS 4.2 Beckman Coulter 
Centrifuge Optima MAX-XP with rotor TLA 
120.1 
Beckman Coulter 
Confocal microscope LSM 510 meta Zeiss 
Decon FS-100 ultrasonic bath Decon Laboratories 
Developer machine CURIX60 Agfa 
Dual Gel Caster for Mini Vertical Units Hoefer 
EmulsiFlex-C3 Avestin 
FACSAria™ II (Cell Sorting Facility/UMG) BD Bioscience 
FACSCanto™ II BD Bioscience 
Fluorescence microscope Axioskop 2 Zeiss 
Incubator Heraeus function line Heraeus 
Incubator Shaker INNOVA 4430 New Brunswick Scientific 
Incubation/Inactivation Water Bath Model 
1003 
GFL 
Mini Trans-Blot® Cell Bio-Rad 
Odyssey® Sa Infrared Imaging System LI-COR 
Olympus CK40 Culture Microscope Olympus 
SE250 Mighty Small II Mini Vertical 
Electrophoresis Unit 
Hoefer 
SDS-gel documentation LAS-3000 Fujifilm 
Spectrophotometer NanoDrop 2000c ThermoScientific 
Thermocycler FlexCycler2 Analytik Jena AG 
Thermocycler PTC-200 DNA Engine MJ Research 
Thermocycler Tprofessional  Biometra 
Thermomixer comfort Eppendorf 
Thermomixer compact Eppendorf 





UV sterilizer Biometra 
UV transilluminator Uvitec 
Vortexer MS2 Minishaker IKA 
Western blot incubation boxes LI-COR 




5ml Polystyrene Round-Bottom Tubes BD Biosciences 
Amersham Hybond ECL Nitrocellulose 
Blotting Membrane 
GE Healthcare 
Amersham Hyperfilm™ ECL GE Healthcare 
Amersham Protran 0.45 μm NC 
Nitrocellulose Blotting Membrane 
GE Healthcare 
Cell culture consumables  Sarstedt, Greiner bio-one 
Cell culture plastic ware  Sarstedt, Greiner bio-one, Nalge Nunc 
International 
Centrifuge Bottle Assembly, Polycarbonate 
50 ml 
Beckman Coulter 
Centrifuge tube, thickwall, Polycarbonate 
500 µl 
Beckman Coulter 
Casy cups with lids Roche Diagnostics (Fisher Scientific) 
Medix XBU medical x-ray film  FOMA Bohemia 
Microscope cover slips (10 mm, 12 mm Ø)  Marienfeld 
Microscope slides (76x26 mm)  Glaswarenfabrik Karl Hecht GmbH & Co KG 
Microscope slides ThermoScientific 
Minisart RC 15, single use syringe filters 
(0.45 μm, 0.20 μm) 
Sartorius Stedim Biotech 
 
Minisart single use filter units (0.45 μm) Sartorius Stedim Biotech 
NuPAGE® Novex® 4-12% Bis-Tris Protein 
Gels  
life technologies 
Parafilm "M" Bemis Company, Inc. 
pH indicator strips  Macherey-Nagel 
Reaction tubes (1.5, 2 ml) Sarstedt, greiner bio-one 
Syringes and needles  B. Braun, Servoprax 




Adobe Illustrator CS6 Adobe 
Citavi 5 Swiss Academic Software 
FACS Diva 6.1.1 BD Biosciences 
GraphPad Prism 5.01 GraphPad Software Inc. 
Genome Compiler Genome Compiler Corporation 
Image Reader LAS-3000  Fujifilm 
ImageJ  NIH 





ImageStudio/ ImageStudio Lite 4.0.21  LI-COR 
Lasergene 10.1.1 (3) DNASTAR 
LSM 510 Release Version 4.0 SP2 Zeiss 
LSM Image Browser Zeiss 
Microsoft Office Home and Student 2016 Microsoft 
MPEX-Membrane Protein Explorer 3.2.15 Snider et al., 2009 
NanoDrop 2000 Software  ThermoScientific 
SnapGene Viewer 3.1.4 GSL Biotech LLC 




CloneJET PCR Cloning Kit  ThermoScientific 
NucleoBond™ Xtra Midi  Macherey-Nagel 
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel 
NucleoSpin® Plasmid Macherey-Nagel 




2.1.5. Buffers, solutions, media 
2.1.5.1. Buffers 
Buffers Composition 
Carbonate buffer  
(membrane insertion) 
0.2 M Na2CO3 pH 11.0, 4 mM EDTA, 0.5 mM 
PMSF 
Coomassie fixing solution 40% ethanol, 10% acetic acid 
Coomassie staining 5% aluminum sulfate-(14-18)-hydrate, 10% 
ethanol, 2% ortho-phosphoric acid, 0.02% CBB-
G250 
DNA loading buffer (6x) 0.2% bromophenol blue, 0.2% xylene cyanole, 
 60% glycerol, 60 mM EDTA 
Glycoprotein Denaturing buffer (10x) 5% SDS, 0.4 M DTT 
G5 Reaction Buffer (10x) 0.5 M Sodium Citrate, pH 5.5 at 25°C 
G7 Reaction Buffer (10x) 0.5 M Sodium Phosphate, pH 7.5 at 25°C 
TA-protein high salt (HS) buffer 50 mM HEPES, 500 mM KOAc, 5 mM Mg(OAc)2, 
10% glycerol, 1 mM PMSF, 1 mM DTT, pH 7.0 
freshly added: 20 mM imidazole 
Laemmli running buffer (10x) 250 mM Tris, 1.92 M glycine, 0.5% SDS 
TA-protein low salt (LS) buffer  50 mM HEPES, 150 mM KOAc, 5 mM Mg(OAc)2, 
10% glycerol, 1 mM PMSF, 1 mM DTT, pH 7.0 
freshly added: 20 mM imidazole 
PBS (10x) 1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4,  
18 mM KH2PO4, pH 7.5 
PBST 1x PBS + 0.1 % Tween-20 
PonceauS staining solution 0.5% PonceauS in 1 % acetic acid 





SDS sample buffer (4x) 125 mM Tris pH 6.8, 4% SDS, 0.02% 
Bromophenol blue, 10% glycerol 
TAE buffer (50x) 2 M Tris, 0.05 M EDTA, 5.71% acetic acid 
Transport buffer (10x) 200 mM HEPES, 1.1 M KOAc, 20 mM Mg(OAc)2, 
10 mM EGTA, pH 7.3 
Western blot transfer buffer (10x) 250 mM Tris, 1.93 M glycine, 0.2% SDS 
HK buffer (microsome assay) 50 mM HEPES, 50 mM KOAc 
 
 
2.1.5.2. Stock solutions 
Solution Composition 
1,4-Dithiothreitol (DTT) 1 M in H2O 
Ammonium persulfate (APS) 10% APS (Sigma) in H2O 
Ampicillin 100 mg/ml in H2O 
Aprotinin  1 mg/ml in 20 mM HEPES pH 7.4 
Adenosine triphosphate (ATP)  100 mM ATP in 100 mM Mg(OAc)2, 20 mM 
HEPES (pH 7.4) 
0.5 M ATP in TA-protein LS buffer  
(protein purification) 
Creatine phosphokinase  2000 U/ml in 50% glycerol, 20 mM HEPES pH 
7.4 
Creatine Phosphate  80 mg/ml in H2O 
Digitonin  10% (w/v) in DMSO 
Hoechst 33258 10 mg/ml in H2O 
Isopropyl b-D-1-thiogalactopyranoside 
(IPTG) 
1 M in H2O 
 
Kanamycin  60 mg/ml in H2O 
Leupeptin/Pepstatin 1 mg/ml each, in DMSO 
Phenylmethylsulfonyl fluoride (PMSF) 100 mM in 2-propanol 
Puromycin 10 mg/ml in H2O 
Tetracyclin (DH5α BL21A1) 12.5 µg/ml 
WGA (wheat germ agglutinine/lectin) 2 mg/ml in TPB 
 
 
2.1.5.3. Bacterial media 
Medium Composition 
LB  1% (w/v) bacto-tryptone, 0.5% (w/v) yeast 
extract, 1% (w/v) NaCl, pH 7.0 
LB agar plates LB supplemented with 1.5% (w/v) bacto-agar 
SOC 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 
10 mM NaCl, 2.5 mM KaCl, 10 mM 
MgCl2, 10 mM MgSO4, 0.36% (w/v) glucose, 
pH 7.0 
  




2.1.5.4. Cell culture solvents 
 
Solvent/Medium Company/ source 
Cytosol (9 mg/ml) prepared as described in Kehlenbach et al., 
1998 
Calcium chloride buffer 250 mM CaCl2 
FBS Superior (fetal bovine serum) Biochrom 
Gentamycin (G418) 1 mg/ml in HEPES 
Gibco® DMEM (1x)  life technologies 
Gibco® Opti-MEM® (1x)  life technologies 
Gibco® Penicillin Streptomycin  
(Pen Strep) 
life technologies 
HEPES buffer (2x) 50 mM HEPES, 250 mM NaCl, 1.5 mM 
Na2HPO4, pH 6.98 
L-Glutamine 200 mM  Gibco (life technologies) 
PBS (10x) Gibco (life technologies) 
 








Endoglycosidase H (EndoH) NEB 
Fast alkaline phosphatase (FastAP) Thermo Scientific 
Pfu Ultra II polymerase  Agilent 
Phusion High-Fidelity DNA Polymerase  Thermo Scientific 
Restriction enzymes (various) Thermo Scientific 
T4 DNA ligase  Thermo Scientific 
Gibco® Trypsin/ EDTA 0.25% (1x) life technologies 
Peptide -N-Glycosidase F (PNGaseF) NEB 
 
 




Acrylamide 4K Solution (30%) AppliChem 
Adenosine 5’-triphosphate disodium salt 
hydrate (A3377) 
Sigma-Aldrich 
Advanced protein assay reagent 5x Cytoskeleton Inc. 
Amylose Resin High Flow New England BioLabs 





Bio-Rad Protein Assay dye reagent 
concentrate 
Bio-Rad Laboratories GmbH 
Bovine Serum Albumin (BSA) (20 mg/ml)  Thermo Scientific 
BSA, fraction V AppliChem 
D-Maltose Serva Electrophoresis GmbH 
Dako Fluorescent Mounting Medium Dako 
DAPI (D9542) Sigma-Aldrich 
dNTP Set, 100 mM solutions Thermo Scientific 
Ethanol (analytical grade) Roth 
Formaldehyde solution min. 37% Millipore 
G418 disulfate salt (A1720) Sigma-Aldrich 
Gelatin from cold water fish Sigma-Aldrich 
GeneRuler 100bp DNA Ladder Thermo Scientific 
GeneRuler 1kb DNA Ladder Thermo Scientific 
Imidazole Roth 
Immobilon™ Western Chemiluminescent 
HRP Substrate 
Millipore 
IPTG Thermo Scientific 
L-Arabinose Roth 
Lipofectamine® 2000 life technologies 
Methanol (technical grade) Roth 
MOWIOL ® 4-88 Calbiochem 
Ni-NTA Agarose Qiagen 
NP-40 10% solution 
NuPAGE® MES SDS Running Buffer (20x) life technologies 
NuPAGE® MOPS SDS Running Buffer (20x) life technologies 
Oligofectamine™ Reagent life technologies 
Oligonucleotides Sigma-Aldrich 
ortho-Phosphoric acid 85% p.A. AppliChem 
PageRuler Prestained Protein Ladder Thermo Scientific 
PageRuler Unstained Protein Ladder Thermo Scientific 
Poly-L-lysine solution 0.1% (w/v) Sigma-Aldrich 
Powdered milk Roth 
Puromycin dihydrochloride  
from Streptomyces alboniger (P8833) 
Sigma-Aldrich 
Rapamycin Ready Made Solution,  
2.5 mg/ml in DMSO (2.74 mM),  
from Streptomyces hygroscopicus 
Sigma-Aldrich 
SafeView™ Classic (DNA stain) Applied Biological Materials Inc. 
Trypan blue solution 0.4% Sigma-Aldrich 
Tris (buffer grade) AppliChem 
  





2.1.7.1. Primary antibodies 
 
Name Species Origin Application Dilution Number 
α-Calnexin rabbit Enzo WB 1:1000 Ab220 
α-Emerin rabbit Proteintech IF/WB 1:300-1:1000 Ab083 
α-Emerin rabbit Genosphere IF/WB 1:500 Ab209 
α-Emerin mouse Santa Cruz IF/WB 1:200-1:1000 Ab301 
α-GAPDH rabbit Proteintech WB 1:1000 Ab080 
α-GFP rat Chromotek IF/WB 1:500 Ab015 
α-HA mouse Convance IF/WB 1:1000 Ab186 
α-HA rabbit Sigma IF 1:500 Ab134 
α-Hsc70 rat Stressgen WB 1:1000 --- 
α-LaminA/C mouse Abcam IF/WB 1:200 Ab095 
α-LAP2β rabbit Millipore IF 1:100 Ab199 
α-LBR rabbit Proteintech IF/WB 1:300-1:500 Ab085 
α-LRRC59 rabbit Sigma IF/WB 1:200 Ab090 
α-myc mouse Santa Cruz IF 1:200 Ab191 
α-opsin mouse (Adamus et al., 
1991) 
IF/WB 1:500 Ab092 
α-RFP rat Chromotek IF/WB 1:1000 Ab060 
α-Sec61β rabbit Bernhard 
Dobberstein, 
Heidelberg 
IF 1:1000 --- 
α- STT3B rabbit Stephen High, 
Manchester 
IF 1:200 --- 
α-TRC40 mouse Sigma IF 1:200 Ab222 
α-TRC40 rabbit (Favaloro et al., 
2010) 
WB 1:1000 --- 
α-alpha 
Tubulin 
rabbit Proteintech WB 1:1000 Ab081 





WB 1:200 --- 
 
 
2.1.7.2. Secondary antibodies 
 
Name Species Origin Application Dilution 
a-mouse HRP goat Jackson ImmunoResearch WB 1:10000 
a-rabbit HRP goat Jackson ImmunoResearch WB 1:10000 
a-mouse 680 donkey LI-COR WB 1:10000 
a-mouse 800 donkey LI-COR WB 1:10000 
a-rabbit 680 donkey LI-COR WB 1:10000 
a-rabbit 800 donkey LI-COR WB 1:10000 




Name Species Origin Application Dilution 
a-mouse AlexaFluor® 
488 conjugated 
donkey Molecular Probes IF 1:1000 
a-mouse AlexaFluor® 
594 conjugated 
donkey Molecular Probes IF 1:1000 
a-mouse AlexaFluor® 
633 conjugated 
goat Molecular Probes IF 1:1000 
a-rabbit AlexaFluor® 
488 conjugated 
donkey Molecular Probes IF 1:1000 
a-rabbit AlexaFluor® 
594 conjugated 
donkey Molecular Probes IF 1:1000 
a-rabbit AlexaFluor® 
647 conjugated 
donkey Molecular Probes IF 1:1000 
a-rat AlexaFluor® 488 
conjugated 
goat Molecular Probes IF 1:1000 
 
2.1.8. siRNAs 
Name siRNA sequence 5’→3’ Target Company 
siRNA ASNA1_75 GCCCUUUCAUCUCACAGAUTT ASNA1/TRC40 Ambion 
siRNA ASNA1_77 CAACAUCUCAGAUGCUUUUTT ASNA1/TRC40 Ambion 
siRNA CAMLG UAAUGAACGAGUCCAAUUUGUCUCC 
(Yamamoto and Sakisaka, 2012) 
CAMLG Ambion 
siRNA emerin GAAGAAGAUCUUCGAGUAC emerin Eurofins 
MWG Operon 




Silencer Negative Control#1 siRNA 




siRNA WRB AAAUCCAACAGGUAAUUCCAACACC 




All oligonucleotides used in this work were ordered either in a lyophilized state or in a ready-to-
use 100 µM solution (purification grade: desalted) from Sigma-Aldrich and used in a 10 µM 
working solution. 
2.1.9.1. Oligonucleotides used for cloning 
Number Name Sequence 5’→3’ 
G901 Emerin XhoI 
forward 
TTTCTCGAGCTACCATGGACAACTACGCAGATCT 
G902 Emerin BamHI –
stop rev 
TTTGGATCCCGGAAGGGGTTGCCTTCTTCAG 
G903 Emerin BamHI 
+stop rev  
TTTGGATCCCTAGAAGGGGTTGCCTTCTTCAG 
G912 Emerin KpnI 
forward 
TTTGGTACCACCATGGACAACTACGCAGATCTT 




Number Name Sequence 5’→3’ 




G914 LAP2 NheI 
forward 
TTTGCTAGCACCATGCCGGAGTTCCTAGAG 
G915 LAP2 BamHI 
minus stop rev 
TTTGGATCCCGGTTGGATATTTTAGTATCTTG 
G916 LAP2 KpnI 
forward 
TTTGGTACCATGCCGGAGTTCCTAGAG 
G917 LAP2 BamHI 
+stop rev 
TTTGGATCCCTAGTTGGATATTTTAGTATCTTG 




G1061 Emerin_r_SpeI AAAACTAGTTCAGAAGGGGTTGCCTTCTTCAGC 
G1062 LAP2_f_NcoI AAAACCATGGTTATGCCGGAGTTCCTAGAG 







G1060 Emerin_f_NcoI AAAACCATGGTTATGGACAACTACGCAGATCTTTCG 
G1061 Emerin_r_SpeI AAAACTAGTTCAGAAGGGGTTGCCTTCTTCAGC 
G1062 LAP2_f_NcoI AAAACCATGGTTATGCCGGAGTTCCTAGAG 







G1261 FRB KpnI fwd TTTGGTACCGAGATCTGGCATGAAGGC 
G1262  FRB XhoI rev TTTCTCGAGCTGCTTTGAGATTCGTCG 




G1269 FRB fwd SpeI TTTACTAGTGAGATGTGGCATGAAGGC 
G1270 Emerin Forward 
XhoI (FRB) 
TTTCTCGAGATGGACAACTACGCAGATCT 
G1271 Emerin minus 
start fwd XhoI 
TTTCTCGAGGACAACTACGCAGATCTTTCG 
G1314 Emerin mut C_H 
BamHI + stop rev 
TTTGGATCCCTAGCCTGCATGAAGTGGTAAATG 
G1315 Emerin mut D 
BamHI + stop rev 
TTTGGATCCCTAGAGCGGGACCTGGCGATCCTG 
G1316 Emerin mut E 
BamHI + stop rev 
TTTGGATCCCTAGCCCCAGAGCGGGACCTGGCG 
G1363 LEMD1 minus 
start fwd XhoI 
TTTCTCGAGGTGGATGTGAAGTGTCTGAGT 




Number Name Sequence 5’→3’ 
G1364 LEMD1 BamHI 
stop rev 
TTTGGATCCTTAACCAAACAGCGACTTATTTTC 






G1385 VAPB Forward 
(KpnI) 
TTTGGTACCGCGAAGGTGGAGCAG 
G1386 VAPB Reverse 
(BamHI) 
GGATGGATCCCTACAAGGCAATCTTCCCAAT 
G1390 VAPB fwd KpnI 
corr 
TTTGGTACCAGCGAAGGTGGAGCAGGTC 















G1424 LBR fwd XhoI TTTCTCGAGTTATGCCAAGTAGGAAATTTGCC 
G1425 LBR rev BamHI 
stop 
TTTGGATCCCTAGTAGATGTATGGAAATATACG 
G1452 LRRC59 forw XhoI TTTCTCGAGCTACCATGACCAAGGCCGGTAGC 
G1453 LRRC59 rev EcoRI TTTGAATTCTCACTGCTGAGAGTCGGTC 




HI rev pET 
TTTGGATCCTCAGCCCGTCTTGTTGGAGAAAGGCACGTAGAA
GTTTGGGCCACCAAACAGCGACTTATTTTC 
G1471 FKBP12 BspEI 
(Kpn2I) fwd 
TTTTCCGGAATGGGAGTGCAGGTGGAGACT 
G1472 FKBP12 BglII rev TTTAGATCTTTCCAGTTTTAGAAGCTCCAC 
G1473 FRB NcoI fwd TTTCCATGGAAGAGATGTGGCATGAAGGC 
G1474 FRB EcoRI rev TTTGAATTCTGCTTTGAGATTCGTCGGAA 
G1475 Emerin XhoI fwd 
(pEF) 
TTTCTCGAGAATGGACAACTACGCAGATCTT 
G1476 Emerin SpeI stop 
rev 
TTTACTAGTCTAGAAGGGGTTGCCTTCTTC 
G1477 LBR XhoI_fwd TTTCTCGAGATGCCAAGTAGGAAATTTGCC 
G1502 Histone1 HindIII 
fwd 
TTTAAGCTTAATGACCGAGAATTCCACGTCC 
G1503 Histone1 BamHI 
rev 
TTTGGATCCTTCTTCTTCTTGCCGGCCCTCTT 
G1504 FKBP12 NheI fwd TTTGCTAGCAAATGGGAGTGCAGGTGGAGACC 




Number Name Sequence 5’→3’ 
G1505 FKBP12 HindIII 
rev 
TTTAAGCTTAATTCCAGTTTTAGAAGCTC 








G1508 LEMD1 SpeI stop 
rev 
TTTACTAGTCTAACCAAACAGCGACTTATT 




G1510  PTP1B SpeI stop 
rev 
TTTACTAGTCTATGTGTTGCTGTTGAACAG 
G1511 VAPB SpeI stop 
rev 
TTTACTAGTCTACAAGGCAATCTTCCCAAT 
G1512 VAPB EcoRI fwd 
(pEF) 
TTTGAATTCAATGGCGAAGGTGGAGCAGGTC 
G1514 FKBP12 BglII fwd TTTAGATCTATGGGAGTGCAGGTGGAGACC 
G1518 FRB KpnI fwd TTTGGTACCAGAGATGTGGCATGAAGGC 
G1519 FRB BamHI rev TTTGGATCCTGCTTTGAGATTCGTCGGAA 
G1522 LAP2b ClaI 
(Bsu15I) fwd pEF 
TTTATCGATACCGGAGTTCCTAGAGGAC 
G1523 LAP2b SpeI stop 
rev 
TTTACTAGTCTAGTTGGATATTTTAGTATC 
G1540 M9 EcoRI fwd TTTGAATTCAGGGAATTACAACAATCAGTCT 
G1541 M9 SalI rev TTTGTCGACATAGCCACCTTGGTTTCG 
G1542 M9 KpnI fwd TTTGGTACCGGGAATTACAACAATCAGTCT 
G1543 M9 BamHI rev TTTGGATCCATAGCCACCTTGGTTTCGTG 
G1544 M9 SalI_fwd TTTGTCGACGGGAATTACAACAATCAGTCT 
 
 
2.1.9.2. Oligonucleotides for mutagenesis 
The listed primers were used for site-directed mutagenesis to obtain a plasmid for mCherry-FRB-
emerin Gln228His expression in cells. 
 
Name Sequence 5’→3’ 
Emerin Mut F_Gln228His_fwd CGCTCTGGGGCCATCTGCTGCTTTTCC 










2.1.9.3. Oligonucleotides for sequencing 
Sequencing oligonucleotides were either obtained from Sigma-Aldrich or standard sequencing 
primers from GATC were used (PrimerScout tool was used, see https://www.gatc-
biotech.com/de/). 
 
Number Name Sequence 5’→3’ 
G545 pmCherry_seq_f CGCTGAGGTCAAGACCACC 
GATC T7minus1 AATACGACTCACTATAGGG 
GATC pQE-FP CGGATAACAATTTCACACAG 
GATC pQE-RP GTTCTGAGGTCATTACTGG 
GATC pET-RP CTAGTTATTGCTCAGCGG 
GATC pEGFP_C2-FP GATCACATGGTCCTGCTG 
GATC pcDNA3.1-RP/1 CAAACAACAGATGGCTGGC 
GATC pcDNA3.1-FP CTCTGGCTAACTAGAGAAC 
 
2.1.10. Vectors and plasmids 










1417 mCherry-FRB-emerin Pro183Thr 
1418 mCherry-FRB- emerin Pro183His 
1419 mCherry-FRB- emerin Leu225Arg-FS 
1420 mCherry-FRB- emerin Trp226* 
1489 mCherry-FRB- emerin Gln228His 
1422 mCherry-FRB- emerin ΔVal236-Phe241 
1423 mCherry-FRB- emerin Phe240His-FS 
1581 HA-FRB-emerin 
 HA-emerin Pro183Thr 
 HA-emerin Pro183His 
 HA-emerin Leu225Arg-FS 
 HA-emerin Trp226* 
 HA-emerin Gln228His 
 HA-emerin ΔVal236-Phe241 
 HA-emerin Phe240His-FS 
1241 WRB-FRB-HA 
1604 pcDNA3-VAPB-ops28 

















1058 pET328-HZZ-tev- LAP2β-op 









Cy3-BSA-NLS Kehlenbach lab 
Atto488-BSA-NLS Kehlenbach lab 
GST-CAML-N Schwappach lab, 
(Yamamoto and 
Sakisaka, 2012) 
MBP-tev-TRC40/His-ZZ-tev-emerin-opsin Plasmid #1053 
MBP-tev-TRC40/His-ZZ-tev-emerin-opsin Mut Pro183Thr Schwappach lab 
MBP-tev-TRC40/His-ZZ-tev-emerin-opsin Mut Pro183His Schwappach lab 
MBP-tev-TRC40/His-ZZ-tev-emerin-opsin Mut Leu225Arg-FS Schwappach lab 
MBP-tev-TRC40/His-ZZ-tev-emerin-opsin Mut Trp226* Schwappach lab 
MBP-tev-TRC40/His-ZZ-tev-emerin-opsin Mut Gln228His Schwappach lab 
MBP-tev-TRC40/His-ZZ-tev-emerin-opsin Mut ΔVal236-Phe241 Schwappach lab 
MBP-tev-TRC40/His-ZZ-tev-emerin-opsin Mut Phe240His-FS Schwappach lab 
MBP-tev-TRC40/mCherry-tev-emerin-opsin Plasmid #1055 
MBP-tev-TRC40/mCherry-tev-Δ1-106 emerin-opsin Plasmid #1226 
MBP-tev-TRC40/mCherry-tev-FRB-emerin Plasmid #1236 
MBP-tev-TRC40/His-ZZ-tev-FRB-PTP1B-opsin Plasmid #1498 
MBP-tev-TRC40/His-ZZ-tev-FRB-VAPB-opsin Plasmid #1503 
MBP-WRBcc Schwappach lab, 
(Vilardi et al., 2011) 
Ran Kehlenbach lab, 
(Melchior et al., 1995) 




2.1.12. Cell lines 
2.1.12.1. Mammalian cell lines 
 
Cell line Characteristics Origin 
HeLa P4 
(P4 MAGI CCR5+ 
Cells) 
Human adenocarcinoma cell line; 
modified expressing CD4; adherent; 
derived from cervix of a 31-year-old 
woman 
NIH AIDS Reagent 
Program; 
(Charneau et al., 1994) 
U2-OS (U2OS) Human osteosarcoma cell line; adherent; 
derived from a moderately differentiated 
sarcoma of the tibia of a 15-year-old girl 
ATCC® HTB96 
 
2.1.12.2. Bacterial strains 
For cloning and protein expression different E. coli strains were used. 
 
Strain Features 
BL21-AI F- ompT hsdSB (rB– mB–) gal dcm araB::T7RNAP tetA 
DH5α F- Φ80lacZΔM15 Δ (lacZYA-argF) U169 recA1 endA1 hsdR17 (rK-,mK+) 
phoA supE44 λ- thi-1 gyrA96 relA1 
JM109 endA1 glnV44 thi-1 relA1 gyrA96 recA1 mcrB+ Δ(lac-proAB) e14-  
[F’ traD36 proAB + lacIq lacZΔM15] hsdR17(rK- mK+) 
 





2.2.1. Molecular Biology techniques 
2.2.1.1. Transformation of plasmid- DNA into E. coli DH5α 
Chemically competent E. coli strains were thawed on ice for about 10 to 15 minutes. The plasmid 
DNA or ligation reaction was added to the cells and mixed. After this, an incubation time of 30 
minutes on ice followed. The cells were exposed to a heat shock at 42 °C for 90 seconds and 
cooled down for another minute on ice. In the next step, cells were incubated with 450 µl SOC 
medium without antibiotic selection for 35 to 60 minutes at 37 °C on a Thermomixer (800 rpm) 
for recovery and bacterial growth. Afterwards, cells were plated on LB-agar containing the 
respective antibiotic and incubated at 37 °C overnight. With respect to the purpose of 
transformation (ligation or re-transformation), the amounts of cell suspension plated onto the 
LB-agar plates therefore varied. 
 
2.2.1.2. Isolation of plasmid-DNA 
The isolation of plasmid DNA was performed with either NucleoSpin® Plasmid (Macherey-Nagel) 
for small scale isolations and with the NucleoBond™ Xtra Midi kit (Macherey-Nagel) in case of 
large scale purifications. 
 
For mini-preparations of DNA, 5 ml bacterial cultures were prepared by using LB medium 
containing the appropriate antibiotic and a single bacterial colony was picked from an LB-agar 
plate for inoculation overnight at 37 °C, shaking at 140 rpm. The next day, 2 ml of this bacterial 
culture were pelleted at 11000 g for one minute at 4 °C (Centrifuge 5415R, Eppendorf) in 2 ml 
tubes. The mini-preparation of DNA was purified according to the manufacturer’s protocol (see 
section 2.1.4). The DNA elution step was performed with two times 25 µl elution buffer heated 
to 70 °C and incubated 2 minutes at 70 °C prior to centrifugation. 
For DNA purifications in a large scale, 250 ml bacterial cultures were set up. The LB medium was 
supplemented with an antibiotic (according to the plasmids resistance) and inoculated with one 
bacterial clone (picked from an LB-agar plate) overnight in an Erlenmeyer flask at 37 °C at             
140 rpm. The bacterial culture was pelleted by centrifugation at 5250 g for 15 minutes at 4 °C 
(Allegra® X-15R with rotor SX4750, Beckman-Coulter). The midi-preparation of DNA was 
extracted according to the manufacturer’s protocol (see section 2.1.4). The isopropanol 
precipitated DNA was resuspended in 100 µl of desalted water. 
 
Plasmid concentrations and purity were measured with the NanoDrop (NanoDrop 2000c 
software, Thermo Scientific) and adjusted to 1 µg/µl with desalted water in case of DNA produced 
in midi-preparations. 
 
2.2.1.3. Polymerase chain reaction 
The polymerase chain reaction (PCR) is used to amplify DNA sequences from a template DNA by 
means of thermostable DNA polymerases. For amplification of specific DNA regions small 
oligonucleotides, termed primers, are needed. Primers used in this work were designed to be 




complementary to the sequence of interest (about 20 nucleotides) and contained an overhang 
at the 5’-end. For cloning reasons restriction enzyme sequence motifs were inserted as well. In 
the reverse oligonucleotide, also sequences coding for translation termination were inserted 
when desired. In general, the length of an oligonucleotide did not extent more than 30 base pairs 
including the features like restriction sites. For primer design and characterization, the Lasergene 
software as well as the Tm calculator, Multiple primer analyzer and PCR reaction setup tool for 
Phusion (Thermo Scientific homepage) were used. Another important factor needed for PCR are 
deoxyribonucleotide triphosphates (dNTPs) for the amplification. 
PCR reactions were performed with the proof-reading Phusion High-Fidelity DNA Polymerase 
(Thermo Scientific) in a 50 µl volume and set up according to manufacturer’s instructions. The 
amount of DNA used as a template did not exceed 200 ng, primers were used at a concentration 
of 0.5 µM and dNTPs at a concentration of 200 µM and one unit of Phusion polymerase was 
added. 
PCR amplification was done in a thermocycler with an initial DNA denaturation step at 98 °C for 
30 seconds. A routine PCR was performed for 35 cycles, consisting of denaturation (98 °C for       
10 seconds), annealing (65 to 72 °C for 15 - 30 seconds, depending on the G/C content of the 
primer) and elongation (72 °C for 15 - 30 seconds, adjusted to the construct’s expected size). 
Typically, a final extension step followed at 72 °C for 10 minutes and the reactions were cooled 
to 4 °C for further processing. 
PCR reactions were mixed with 6 x DNA loading buffer and analyzed by agarose gel-
electrophoresis (see section 2.2.1.5). 
 
2.2.1.4. Site-directed mutagenesis 
Site-directed mutagenesis was used to induce specific changes into a DNA sequence. In this work, 
the emerin mutant Gln228His was cloned by using this method. The primers, which were used 
for the PCR can be found in section 2.1.9.2. 
The PCR - protocol used is based on the polymerase Pfu Ultra II (Agilent) and a standard 35 cycle 
PCR - protocol was run with an elongation temperature of 60 °C, which was adjusted to the 
templates size. Afterwards the PCR- product was digested with 1 µl DpnI (Thermo Scientific) for 
three hours at 37 °C. Then, a transformation of 10 µl reaction was performed in E. coli DH5α for 
one hour (see section 2.2.1.1) and plated onto LB-agar plates. An overnight incubation at 37 °C 
followed and the next day six clones were analyzed for correct insertion of the mutation. 
 
2.2.1.5. Agarose gel electrophoresis 
Agarose gel-electrophoresis is a method to separate nucleic acids according to their size. The 
different DNA fragments were visualized by the SafeView™ Classic DNA stain. 
During cloning in this work, 1 to 2% agarose gels were used. The agarose was dissolved in 1x TAE 
buffer using the microwave. After the gel solution was cooled to 60 °C, the DNA stain was added 
at a dilution of 1:20000 and the gel was casted into a chamber including a comb for loading 
pockets. The solidified gel was placed into a running chamber filled with 1x TAE buffer and 
samples supplemented with 6x DNA loading buffer were loaded onto the gel next to a suitable 
marker (GeneRuler 100 bp/1 kb DNA Ladder). Gel electrophoresis was performed depending on 
the degree of DNA separation at 120 V for about 45 minutes. DNA fragments determined for 




further cloning were cut out of the gel with a scalpel during visualization on a UV transilluminator 
and were purified with the NucleoSpin® Gel /PCR Clean-up kit (Macherey-Nagel) according to the 
manufacturer’s instructions. In case DNA fragments resulted from an analytical restriction 
enzyme digestion, agarose gels were documented with the INTAS GelSTICK "touch" system. 
 
2.2.1.6. Restriction enzyme digestion 
Restriction enzymes (Thermo Scientific) were used to specifically cut DNA in order to insert or 
remove designed or gene based DNA sequences into vectors. Cloning strategies were planned 
with the DoubleDigest tool provided by Thermo Scientific. There, enzyme combinations, ratios 
and appropriate reaction buffers were suggested. 
For preparative digestions, the whole amount of purified PCR - product (50 µl) and about 4 to      
5 µg of plasmid DNA (20 to 30 µl final volume) was used for digestion. The appropriate restriction 
enzyme buffer and not more than 1 unit of the enzymes were added for two hours at 37°C. 
For analytical digestions (e.g. analyzing DNA plasmids from mini-preparation) only 0.5 to 1 µg of 
DNA was used per reaction and respectively less enzymes (0.2 units) were used for one hour at        
37 °C. 
After the digestion reaction, 6x DNA loading buffer was added to the restriction enzyme reaction 
mixture. Via agarose gel-electrophoresis the digested DNA was analyzed and simultaneously 
cleaned from enzymes. Bands with the correct size were cut from the gel with a scalpel after 
visualization with an UV transilluminator and purified for further cloning steps. For 
documentation, the GelSTICK "touch" system (INTAS) was used. 
 
2.2.1.7. Dephosphorylation of vectors 
During cloning of different constructs some cloning strategies were based on using one 
restriction enzyme only to digest at multiple sites and remove a DNA sequence and linearize DNA. 
In particular, these vectors were prone to re-ligate and normal ligation reactions could be 
impeded. To prevent this, a dephosphorylation reaction was performed with FastAP 
Thermosensitive Alkaline Phosphatase (Thermo Scientific). After digestion and purification from 
agarose gels, the plasmid DNA was dephosphorylated for 10 minutes at 37 °C in AP reaction 
buffer and an enzyme inactivating step for 5 min at 75 °C followed. The dephosphorylated DNA 
was immediately used for DNA ligation reactions. 
 
2.2.1.8. Ligation of DNA 
The ligation reaction was used to link an insert DNA sequence with the backbone of a plasmid 
DNA, both of which display complementary restriction overhangs. Here, specifically the T4 DNA 
ligase (Thermo Scientific) was used. A standard ligation reaction volume of 10 µl contained of  
1 µl ATP (100 mM), 1 µl T4 DNA ligase reaction buffer (10x) (provided along with the enzyme), 
0.5 µl T4 DNA ligase as well as 20 - 50 ng of backbone vector DNA and the insert DNA.  
The DNA sequences were ligated in a molar ratio of 1:3 (vector to insert) and the reaction was 
carried out for one hour at room temperature. Half of the mixture was transformed into E. coli 
DH5α. 
  




2.2.1.9. Sequencing of DNA 
All plasmid DNA cloned was sent for sequencing to the company GATC. A standard 1.5 ml reaction 
tube was used to dilute the DNA in a final concentration of 30 to 100 ng per µl in a final volume 
of 20 µl. Either GATC-standard sequencing primers (PrimerScout tool at GATC homepage) were 
chosen or customer specific primers (lab internal primers) were sent to GATC at a concentration 
of 10 pmol/ µl as well in a volume of 20 µl. 
 
2.2.2. Biochemical techniques 
2.2.2.1. SDS-PAGE 
A method used to separate proteins according to their molecular weight in an electric field is 
termed SDS (sodium dodecyl sulfate) polyacrylamide gel electrophoresis (SDS-PAGE) and was 
first described by Laemmli (1970). This system is based on a non-continuous, two-parted gel, 
which is placed in a Tris-HCl/Tris-glycine buffer environment and allows separation of proteins in 
a denatured and reduced state. The gel consists of a stacking and a resolving part. For the 
resolving gel concentrations between 8 to 15% acrylamide were chosen depending on the 
protein size. The samples were combined with SDS sample buffer and boiled at 95°C for                      
5 minutes. The gels were placed into the Hoefer SE250 chamber and filled with Laemmli running 
buffer (1x). Besides the samples, a protein ladder (PageRuler Unstained or PageRuler Prestained 
(Thermo)) was loaded onto the gel. The gel was run with an electric current of 25 mA per gel and 
300 V for about one hour. For pre-cast gradient gels (NuPAGE®Novex Bis-Tris (4 - 12%)) MOPS 
SDS buffer (1x) was used as running buffer. For electrophoresis XCell SureLock® Mini-Cell 
chambers were used for about 50 minutes at 200 V. After the protein separation was finished, 
the proteins were visualized by immunoblotting or Coomassie staining (for protein purification 
samples). 
 
2.2.2.2. Coomassie staining 
After SDS-PAGE was completed, the gels were washed once with desalted water. The proteins 
were fixed by using the Coomassie fixing solution for about 5 minutes on a shaker. After removal 
of the fixing solution, the actual Coomassie staining solution was applied. The incubation time 
can vary between minutes to hours, depending on the amount of protein separated on the gel. 
Hereafter, the gel is destained with desalted water. Only if there is a very high background 
staining, a Coomassie destaining solution is applied. The SDS gels stained with Coomassie were 
imaged with the LAS-3000 Imager (Fujifilm) and analyzed with ImageJ. 
 
2.2.2.3. Western Blotting and detection of proteins 
Western Blotting (Immunoblotting) 
After protein separation via SDS-PAGE, the gels were blotted under wet conditions onto a 
Hybond ECL nitrocellulose membrane (GE Healthcare). This method is used to detect membrane-
bound proteins via HRP- or fluorophore-coupled secondary antibodies as described below. 
The gel was assembled for transfer (sponge, Whatman paper sheets, SDS gel, membrane, 
Whatman paper sheets, sponge) directly in Western blot transfer buffer (1x, supplemented with 




20% methanol). The cassette including the gel and the membrane (facing the positive electrode) 
was placed into the blotting chamber and transfer was performed at 300 V and 400 mA. When 
transfer was performed in a Mini Trans-Blot® Cell (Bio-Rad) chamber the voltage was lowered to 
150 V and the current was set to 350 mA. The transfer time depended on the size of the protein 
(gel percentage), but was at least 1.5 h. 
 
Ponceau staining 
After blotting, the membrane was washed once with PBST (1x). To control the quality of protein 
transfer, a PonceauS staining solution was applied to the membrane for one minute. The dye was 
removed and the membrane was rinsed with 1% (v/v) acetic acid. For further processing, the 
membrane was washed again with PBST. 
 
Immunological detection of proteins 
To reduce unspecific binding of antibodies, the nitrocellulose membrane was blocked with 4% 
milk powder in PBST (1x) for 30 minutes. Afterwards the primary antibodies were diluted 
appropriately in 4% milk-PBST solution (see section 2.1.7.1) and incubated 3 h at room 
temperature or overnight at 4 °C. For an incubation on a rolling device, the membranes were 
placed in a 50 ml tube. 
After washing the blots three times for 10 minutes with PBST, the secondary antibodies were 
applied. 
Either HRP- or fluorophore-coupled secondary antibodies (see section 2.1.7.2) were used for 
detection of proteins. In both cases, the secondary antibody (1:10000 diluted in 4% milk-PBST) 
was incubated for one hour at room temperature. 
 
The horseradish-peroxidase (HRP) -coupled antibodies were mainly used in experiments, where 
low protein amounts were known to be present and a very sensitive detection was needed. After 
the secondary antibody incubation, three washing steps, each 5 minutes, with PBST followed. 
Immobilon™ Western Chemiluminescent HRP Substrate (Millipore) was applied onto the 
membrane and proteins were detected by using light sensitive Amersham Hyperfilm ECL (GE 
Healthcare) or Medix XBU medical x-ray films (FOMA Bohemia) in combination with the 
automated CURIX60 (Agfa) developing machine. 
 
For detection of fluorophore-coupled secondary antibodies bound to the primary antibody the 
LI-COR system was used. After secondary antibody incubation, which was done in dark LI-COR 
incubation boxes, the membrane was washed three times for 10 minutes with PBST and kept in 
the boxes. As a last step, the membrane was placed into 1x PBS. For protein detection, the 
membrane was transferred to the Odyssey® Sa Infrared Imaging System (LI-COR) and analyzed 
with the ImageStudio software (version 4.0.21, LI-COR). 
 
2.2.2.4. Expression and purification of tail-anchored proteins 
Tail-anchored proteins used in this work were co-expressed and co-purified in a complex with 
the ATPase TRC40 (e.g. MBP-tev-TRC40/His-ZZ-tev-emerin-opsin). The protocol for protein 
expression and purification is based on the method used by Favaloro et al. (2010). 




Plasmids for TA - protein expression (see section 2.1.10) were transformed in the E. coli strain 
BL21AI (Invitrogen) using the standard protocol (see section 2.2.1.1). An overnight pre-culture 
was prepared using LB medium supplemented with ampicillin at 37 °C. By using 5% of the pre-
culture the large scale bacterial culture (ranging from 3 to 6 liter) was grown in LB medium 
supplemented with ampicillin at 30 °C shaking at 130 rpm until an OD600 of 0.6 was obtained. The 
expression of MBP-tev-TRC40 (under control of a T5 promotor) was induced with 0.05 mM IPTG 
for one hour at 30 °C. Then, the TA-protein (T7 promotor under control of an arabinose-inducible 
araBAD promotor) expression was induced with 0.25% (w/v) L-Arabinose for four hours at 30 °C. 
Cells were harvested by centrifugation at 5020 g for 30 minutes. 
 
The first step of protein purification was the resuspension of the bacterial cells in TA-protein low 
salt (LS) buffer with freshly added protease inhibitors (1 µg/ml Aprotinin, Leupeptin-Pepstatin), 
1 mM PMSF and 20 mM imidazole as well as 10 µg/ml DNase I. Cells were lysed using an 
Emulsiflex - C3 (Avestin) and pelleted by centrifugation at 100000 g for 30 minutes in an Avanti™ 
J-30I centrifuge with rotor JA 30.50Ti (Beckman Coulter). The supernatant was incubated on a 
rotator with Ni-NTA agarose (Qiagen) pre-equilibrated with LS buffer, at 4 °C to bind the His-
tagged TA-protein. After one hour, the resin was centrifuged at 250 g for 2 minutes and washed 
once with LS buffer containing 5 mM ATP to remove bacterial heat shock proteins. Then a 
washing step with TA-protein high salt (HS) buffer was followed by another LS buffer washing 
step. The resin was loaded onto a column and protein was eluted with LS buffer containing         
300 mM imidazole. Fractions were collected and controlled for protein content with the Bradford 
assay solution. The eluted fractions were pooled and incubated with a pre-equilibrated amylose 
resin (NEB) for one hour at 4 °C to bind to the MBP-tagged TRC40, which in turn should be in 
complex with the TA-protein. Again, the amylose beads were washed with LS buffer including 
ATP, HS buffer and another time with LS buffer. The recombinant protein complex consisting of 
MBP-TRC40 and the His-tagged - TA-protein were eluted with LS buffer containing 20 mM              
D-maltose. The purified protein complex was dialyzed overnight against TPB (1x) including 
protease inhibitors (1 µg/ml each) and 2 mM DTT. 
 
2.2.2.5. In vitro transcription and translation system 
For the in vitro transcription and translation of a tail-anchored protein, the TnT Quick Coupled 
Transcription/Translation system (Promega) was used according to the manufacturer’s protocol. 
The amount of reagents used per reaction was reduced as described below. The plasmids used 
for this kit required a T7- or SP6-promotor and were diluted to 200 ng/µl. 
 
 
Reaction (total volume: 10 µl) 
1 µl DNA (200ng/µl) 
8.8 µl TnT Master Mix 
0.2 µl Methionine (1mM stock) 
 
The reaction was incubated for 90 minutes at 30 °C and was used to analyze the integration of 
the protein into microsomal membranes. To inhibit protein translation before performing further 
membrane integration steps, the reaction was incubated with 2.5 mM puromycin for 10 minutes 




at 30 °C. One equivalent* of rough microsomes (1 µl) (see below 2.2.2.6.1) was added to the 
reaction for another hour at 30 °C to see, whether the in vitro translated proteins can be 
integrated into microsomal membranes (Walter and Blobel, 1983). By using puromycin only 
protein, which is post-translationally inserted into membranes, can be detected. Compared to 
TA-proteins produced in bacteria (2.2.2.4), this system benefits from the fact not being pre-
determined for the path of membrane insertion like TA-proteins being in complex with TRC40. 
Therefore, other post-translational routes for membrane insertion could be studied given that 
isolated rough microsomes, used as an ER-membrane source, contained all components like 
TRC40- and chaperones of other assisted pathways. 
 
2.2.2.6. Membrane integration assay 
In this work, membrane integration assays are based on the glycosylation of a C-terminal tag of 
the putative TA-INM-protein of interest and were performed either with microsome- or cell-
derived membranes. Similar C-terminal protease protection and glycosylation assays were 
intensively used to study the membrane insertion of ER proteins (Yabal et al., 2003; Brambillasca 
et al., 2005; Brambillasca et al., 2006). 
 
2.2.2.6.1. Rough microsomes 
The membrane integration of tail-anchored proteins was analyzed by using dog pancreas rough 
microsomes (Walter and Blobel, 1983). As established by Favaloro et al. (2010) and Vilardi et al. 
(2011), rough microsomes (RM) were incubated with the protein of interest for one hour at 30°C 
(shaking at 300 rpm on a Thermomixer). Due to the fact that our protein of interest, e.g. MBP-
tev-TRC40/ His-ZZ-tev-emerin-opsin has a small opsin (op) tag at the C-terminal end, it can be 
glycosylated on this tag (Adamus et al., 1991). As a consequence, a shift in molecular weight can 
be detected via western blotting upon membrane integration and proper orientation in the 
membrane. As a prerequisite for the detection of proteins inserted into ER-derived microsomal 
membranes, the main enzyme performing N-glycosylation on the ER-lumenal side, the 
oligosaccharyltransferase (Aebi, 2013), need to be present and intact inside the isolated 
microsomes. For detection of the protein via Western blot, an anti-opsin antibody was used 
(Adamus et al., 1991). 
The reaction was set up the following: 
 
 
20 µl reaction volume in HK buffer: 
200 ng MBP-tev-TRC40/ His-ZZ-tev-emerin-op 
1 µl rough microsomes (1 equivalent *) 
1 mM ATP (lithium salt) 




* One equivalent (eq) is defined as the amount of a fraction derived from 1µl of RM suspension at a concentration 
of 50 A280 units/ml. One eq is roughly derived from 1 mg of tissue (dog pancreas) (Walter and Blobel, 1983).  




2.2.2.6.2. Semi-permeabilized cells 
Instead of microsomes, semi-permeabilized cellular membranes can be used for membrane 
integration experiments. Trypsinized HeLa P4 cells were resuspended in PBS. The cells were 
counted with Casy 1 (Schärfe System) and centrifuged at 300 g. Four million cells were 
resuspended in 400 µl ice cold TPB including 2 mM DTT, 0.1 mM PMSF and protease inhibitors  
(1 µg/ml each). The detached cells were permeabilized with 0.01% digitonin for 5 min on ice and 
the reaction tube was inverted several times. The permeabilized cells were washed three times 
with cold TPB and resuspended in TPB, counted again and diluted in TPB to a final concentration 
of 10000 cells/µl. The reaction for the membrane integration assay using HeLa cell membranes 
was prepared as described below. 
 
100 µl reaction volume in TPB (1x): 
200000 HeLa cells 
200 ng TA-protein complexed with TRC40 
1 mM lithium ATP 
 
The reaction was placed on a thermomixer at 30 °C for one hour at 300 rpm shaking. A control 
reaction was kept for one hour at 4 °C 
The mixture was centrifuged at 16000 g for 20 minutes at 4 °C and the cells were washed with 
100 µl TPB. After 10 minutes of centrifugation at 16000 g, the pellet fraction containing the 
cellular membranes was dissolved in SDS sample buffer and placed into an ultrasonic bath to 
completely solubilize the cell membranes. Samples were subjected to SDS-PAGE and Western 
Blotting. 
 
Deglycosylation of membrane-integrated proteins 
 
An additional step before addition of SDS sample buffer could be the deglycosylation of the 
membrane integrated protein. The TA-protein of interest should be integrated into microsomal 
and cellular membranes. The C-terminal opsin-tag of these proteins would be facing the ER lumen 
and an N-glycosidic linkage of an oligosaccharide to the side chain amide of the asparagine 
residue of the opsin tag could only be catalyzed by the ER- luminal oligosaccharyltransferase 
(Aebi, 2013). The N-glycosylation of the opsin tag can be cleaved off by endoglycosidases. Either 
Endoglycosidase H (EndoH), which specifically cleaves high mannose carbohydrates, or the more 
general acting enzyme Peptide -N-Glycosidase F (PNGase F) was used (see section 2.1.6.1). 
Deglycosylation was performed with 1/10 of the final sample volume (100 µl). First, the sample 
was incubated with 1 µl of glycoprotein denaturing buffer at 99 °C for 10 minutes. In case of 
EndoH, 2 µl of G5 reaction buffer (sodium citrate based) were added and filled up to 20 µl with 
water. When PNGase F was used, 2 µl of G7 reaction buffer (sodium phosphate based) and 2 µl 
of NP-40 (10% stock) were added. Deglycosylation reactions were performed for 1.5 hours at     
37 °C. After dissolving the samples in SDS sample buffer, they were analyzed as described in 
section 2.2.2.6.1. The comparison of a sample lacking the enzyme with the deglycosylated sample 
should reveal a reduction of the higher molecular weight band of the protein. This can be 
detected by SDS-PAGE followed by immunoblotting using of the anti-opsin antibody. 
  




2.2.2.6.2.1. Fractionation of cellular membranes by using a carbonate buffer 
Carbonate extraction allows the discrimination between proteins stable integrated into the 
membrane, meaning interacting with lipids and such membrane proteins only associated via 
protein-protein interactions with the membrane (Fujiki et al., 1982). When using sodium 
carbonate at pH 11, protein-protein interactions are disrupted, but interactions between protein 
and lipid remain unaffected. In membrane integration experiments described in the above 
section 2.2.2.6.2, only protein, which was stably inserted into the membrane was of interest. 
Therefore, a carbonate treatment should enrich the membrane inserted protein, which is 
displayed in case of the membrane integration assays by a glycosylated, higher molecular weight 
band of the protein by immunoblotting and using an anti-opsin antibody. 
After membrane integration assays were performed either with rough microsomes or semi-
permeabilized cell membranes, cells were spun down at 16000 g for 10 minutes at 4 °C and 
washed once with TPB. To the pellet fraction, 50 µl carbonate buffer was added to dissolve the 
pellet followed by the addition of 50 µl H2O (final carbonate concentration: 100 mM). The 
extraction was performed for 30 minutes at 4 °C while the tube was inverted several times. Next, 
an ultracentrifugation at 100000 g followed for 30 minutes at 4 °C. The supernatant as well as 
the pellet fraction was dissolved in equivalent amounts of SDS sample buffer and prepared for 
SDS-PAGE and immunoblotting. 
 
2.2.3. Cell biology techniques 
2.2.3.1. Cultivation of adherent cells 
The adherent cell lines HeLa P4 and U2OS (Charneau et al., 1994, ATCC® HTB96) (see 2.1.12.1) 
were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (FCS) (v/v), 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. In case of 
siRNA transfections cells were grown without antibiotics as indicated. These cell lines were 
cultured at 37 °C and 5% CO2 in a humid atmosphere. 
Cells were cultured in a 10 cm cell culture plate and for most experiments seeded either in a 24- 
or 6-well plate. Generally, they were passaged twice a week at 80% confluency. HeLa cells were 
diluted at a ratio of 1:10, U2OS cells at a ratio of 1:5. For passaging, cells were washed once with 
PBS and incubated with 0.025% trypsin/EDTA at 37 °C until cells detached. Trypsin was 
inactivated by addition of cell culture medium. After resuspension and dilution of the cells, they 
were transferred to a new culture plate. All cell culture work was performed under a tissue 
culture hood. 
 
2.2.3.2. Coating coverslips with Poly-L-lysine 
For most of the experiments, coated coverslips were used. To improve the attachment of the 
cells to the glass surface, the positively charged synthetic amino acid Poly-L-lysine is used. The 
glass coverslips were washed with isopropanol for a few minutes. After aspiration, they were 
washed with sterile, deionized water and incubated with a Poly-L-lysine solution (1:10 dilution in 
water) for at least 30 minutes. A last washing step with water followed and the coverslips were 
dried on a Whatman paper. They were sterilized by exposing them to UV light for 3 minutes at 
0.12 J/ cm2.  




2.2.3.3. Transient transfection of DNA 
Transient transfection of plasmid DNA into HeLa P4 cells was performed with the calcium 
phosphate (Ca-P) method (Chen and Okayama, 1987). This method was used for DNA 
transfection with the purpose of protein localization studies and for creating a stable U2OS cell 
line. 
For transfection in a 24-well scale, the cells were seeded one day prior transfection to obtain a 
confluency of about 50 - 60% on the day of transfection. For sterile working conditions, all cell 
culture work including the preparation of transfection mixtures were performed under a laminar 
flow cabinet. 
The culture volume of one well of a 24-well plate is 500 µl. For a transfection mixture in this 
format, 20 µl CaCl2 (250 mM sterile solution) were added to 0.7 µg plasmid DNA in a reaction 
tube and mixed on a vortexer for 5 seconds at reduced power. Then, 20 µl sterile HEPES buffer 
(2x) was added and immediately vortexed for 10 seconds at full speed. This was followed by an 
incubation period of 25 minutes at room temperature to allow the formation of calcium-
phosphate-DNA complexes. The mixture was added to the cells and they were grown at 3 or       
5% CO2 at 37°C for another 20 to 40 hours. For co-transfections of two plasmids, 0.4 µg of each 
was used, unless indicated otherwise. 
  




2.2.3.4. RNA interference (RNAi) 
For reduction of mRNA and protein levels of a distinct target protein (Tuschl, 2001), two different 
transfection methods were used. A list of all used duplex short interfering RNAs (siRNAs) can be 
found in section 2.1.8. 
2.2.3.4.1. Transfection of siRNAs with calcium phosphate method 
This kind of siRNA transfection was performed according to the method described in section 
2.2.3.3 and cells were used at a confluency of about 70% at the day of transfection. The 
respective siRNA was diluted from a 100 µM stock to a 20 µM working solution in RNase - free 
water. For one 24-well (final volume: 500 µl) 40 to 80 nM of duplex siRNA was added to 20 µl 
CaCl2 (250 mM sterile solution) and vortexed at a low speed for 5 seconds in a reaction tube.      
20 µl of HEPES buffer were added and mixed for another 10 seconds at high speed. After                 
25 minutes of incubation, the culture medium was changed to DMEM lacking antibiotics. The 
cells were cultured at 3% CO2 at 37 °C overnight and washed twice with PBS. Normal DMEM was 
added and cells were kept at 5% CO2 again. Depending on the target, the period of knockdown 
(KD) varied from 48 to 72/96 hours and therefore cells were split after the first day of 
transfection. After a defined knockdown period, cells were used for immunofluorescence studies 
or cell lysates were taken for protein level analysis. 
 
2.2.3.4.2. Transfection of siRNAs with Lipofectamine 2000 
Cells were seeded one day before transfection to obtain cells at about 50% confluency for 
transfection. For a 24-well (final volume: 500 µl), the siRNA (40 - 80 nM) was diluted in 50 µl Opti-
MEM and mixed gently. 1.5 µl Lipofectamine 2000 was diluted in 50 µl Opti-MEM as well. After 
5 minutes of incubation, the two solutions were combined in one reaction tube and gently mixed. 
An incubation period of 20 minutes followed. Before adding the mixture to the cells, the medium 
was changed to DMEM lacking antibiotics. In order to reduce the toxicity for the cells, the 
medium was changed again after 5 hours. Cells were further kept at 37 °C and 5% CO2 for the 
desired time span. 
 
2.2.3.5. Indirect Immunofluorescence for protein detection 
HeLa P4 or U2OS cells were grown on coverslips for 24 to 48 hours in a 24-well format. The 
coverslips were washed once with PBS and cells were fixed with 3.7% formaldehyde for                    
10 minutes at room temperature. Cells were washed with PBS twice and permeabilized with 0.5% 
triton X-100 in PBS for 5 minutes at room temperature. After two washing steps with PBS, the 
cells were incubated with a blocking solution containing 2% bovine serum album (BSA) in PBS for 
30 minutes at room temperature to reduce unspecific binding of the antibodies applied in the 
further procedure. From the blocking step on, the cells were kept in a humid, light-protected 
chamber. Primary antibodies were added in an appropriate dilution for one hour in 2% BSA-PBS 
solution at RT. After two washing steps (one short and two for 3 minutes), the secondary 
antibody was diluted in 2% BSA-PBS again and applied for another hour under the same 
conditions. Then the slides were washed three times with PBS and once with water. At this point, 




either a Hoechst 33258 staining (stock: 1 mg/ml; 1:6000 in PBS) was performed for 2 min at RT 
or mounting medium containing DAPI was used. Cells were dried before mounting. 
 
2.2.3.6. In vitro protein import assay 
First described by Adam et al., 1990, permeabilized cells are used to study the import of proteins 
into nuclei. This assay allows to specifically analyze and reconstitute the individual requirements 
for nuclear transport of soluble proteins (import and export) for example energy - and 
temperature - dependence, existence of an NLS/NES or additional other cytosolic factors 
(Kehlenbach et al., 1998). 
In the present work, the in vitro import assay was used to study the integration of membrane 
proteins into the ER and to the nuclear envelope in a microscopy-based approach. The transport 
of a recombinant INM-protein together in a complex with TRC40 to the ER and the INM was 
analyzed. 
HeLa P4 cells were seeded on Poly-L-lysine coated coverslips one day before the import assay 
was performed. On the day of the experiment, cells showed about 60 to 70% confluency. They 
were washed once with PBS and then rinsed with transport buffer (TPB, 1x) supplemented with 
protease inhibitors (1 µg/ml Aprotinin, Leupeptin-Pepstatin, 0.1 mM PMSF) and 2 mM DTT. The 
coverslips were transferred to an ice-cold metal block. Permeabilization was performed with 
0.007% digitonin for 5 min. The status of permeabilization was controlled by a trypan blue 
staining. After three washing steps with cold TPB, the reaction mixture for protein import was 
prepared as follows: 
 
40 µl final volume in TPB (1x): 
1 µl ATP regenerating system (ATP; creatine phosphokinase, creatine phosphate (2:1:2)) 
7 µl cytosol (9 mg/ml stock) 
(1.9 µM Ran) 
0.5 - 2 µM TRC40/INM-protein complex 
 
The coverslips were moved to a dark, humid incubation chamber and the reaction mixture was 
added immediately. The transport reaction was performed at 37 °C for 1.5 hours. Additionally, 
to the substrate of interest control proteins like Cy3- or Atto488-BSA-NLS were used and a control 
reaction at 4 °C was prepared for the main and the control substrate as well. Afterwards, cells 
were washed once with TPB and once with PBS and were fixed with formaldehyde. 
 
2.2.3.7. Development of a stable cell line expressing the FKBP12-reporter protein 
The osteosarcoma cell line U2OS is well known for its very large and flat cell morphology and 
therefore can be very useful for microscopy approaches. For the rapamycin-based INM 
localization assay (see section 2.2.4.2.2), a stably expressing EGFP2-GST-NLS-FKBP12 cell line was 
thus created. As a positive selection marker G418 (Gentamycin) was used. Resistance to G418 is 
conferred by a neomycin resistance gene, which was delivered with the transfected plasmid 
containing the gene of interest (FKBP12). 
First, the sensitivity of U2OS cells to the selection marker G418 was tested to determine the 
optimal concentration of drug for the selection. One day prior introducing the antibiotic 




selection, cells were seeded in a 24-well plate with a density of 80000 cells/well to obtain a 
confluency of about 70% when selection is started. Increasing amounts of G418 were added to 
duplicate wells of cells plated in culture medium (see above, DMEM including supplements). 
Concentrations ranging from 100 µg/ml up to 1 mg/ml were used and a non-treated well was 
included as a control. The appropriate concentration for selection was found with respect to the 
following criteria.  
With a low dose, cells were still viable after one week and did not show any signs of toxicity. As 
opposed to this, a high dose would result in clear signs of toxicity and all cells would be dead 
early on. The optimal dose of G418 should be found in between and is determined to be the 
lowest concentration at which no living cells are found after the course of one week.  
In case of the U2OS cells, with 800 µg/ml of G418 all cells were dead after 7 days, therefore it 
was used as the optimal dose for selection. 
For transfection of the cells with the FKBP12 construct, several DNA concentrations were tested 
beforehand and a 10 cm plate was transfected with 24 µg of plasmid DNA with the calcium 
phosphate method and a control plate, only transfected with the reagents, was cultured as well. 
Cells were about 70% confluent on the day of transfection. Two days after transfection selection 
was started after passaging the cells and using the G418 containing culture medium. The cell 
growth and state was observed daily and medium was replaced every three days. After two 
weeks colonies of surviving cells began to appear. These cells were trypsinized, combined and 
seeded on new plates. They were further cultivated for one week with optimal dose of G418 and 
were frozen as a mixture of cells positive for EGFP2-GST-NLS-FKBP12. At the same time, the cells 
were analyzed for their expression of the FKBP12-reporter construct. Localization of the FKBP12-
reporter was examined by immunofluorescence and protein levels were controlled by SDS-PAGE 
followed by immunoblotting. After confirmation of correct localization (see Appendix, 
Supplementary figure 1, B) and size of the GFP-FKBP12 reporter protein of the stable transfected 
cells, the cells were controlled for their actual reporter protein expression with the FACSCanto™ 
II (BD). About 30 % of the cells were positive for GFP-reporter protein expression. To increase the 
amount of G418 resistant and GFP-positive cells, the GFP-positive cells were sorted with a FACS 
Aria II (BD) at the cell sorting facility of the UMG (Appendix, Supplementary figure 1, A). Finally, 
a mixture of stably expressing EGFP2-GST-NLS-FKBP12 U2OS cells was obtained and they were 
cultivated with only 300 µg/ml G418 to maintain the selection pressure until expansion of the 
cell line was completed. Afterwards, they were frozen at -80°C and were transferred to liquid 
nitrogen for long-term storage. A part of the cells was further cultivated and used in rapamycin-
INM-localization studies (Appendix, Supplementary figure 2). 
 
2.2.4. Microscopy techniques 
2.2.4.1. Confocal microscopy 
Images were acquired with the Zeiss LSM 510 meta confocal microscope based on the Axiovert 
200M. In general, images were taken with the LCI Plan-Neofluar 63x/1.3 Imm Corr DIC M27 
objective. The objective was adjusted to the water-based Immersol W 2010 immersion oil. As an 
excitation light source for visualization at the microscope the X-cite 120 mercury lamp series was 
used.  




Depending on the fluorophores or fluorescent proteins used in the specimen, distinct filter 
settings in combination with lasers were used to exclude cross-talk between the channels. In 
general, up to four different channels were imaged. A Diode-laser was used to excite molecules 
at a wavelength of 405 nm like the DNA intercalating dyes Hoechst 33258 or DAPI. For detection 
of secondary antibodies conjugated to AlexaFluor488 dye or EGFP/YFP constructs the Argon488 
laser and for AlexaFluor594 and mCherry-tagged proteins the HeNe594 laser was used. The far-
red spectrum for secondary antibodies AlexaFluor633 and-647 was covered with the HeNe633 
laser. Settings for the output of a laser were kept at a pre-adjusted level to reduce bleaching 
effects. The channel intensity was controlled either by the amplifier gain value (fine adjustment) 
or the transmission value. The degree to which background signals were reduced (amplifier offset 
value) was controlled with the palette tool in the LSM software. 
For co-localization studies, the optical slice was kept at an equal value by regulation of the 
pinhole size for the different channels. Generally, the scan speed was set to a value of six and 
four images were taken and averaged. To obtain a higher resolution image, a lower scan speed 
was used. When working with non-fixed cells, a faster scan speed was used than for fixed-cell 
specimens and the temperature-correction ring of the 63x objective was set to 37 °C, when 
working with a heated chamber. 
 
2.2.4.2. Localization studies 
2.2.4.2.1. Differential permeabilization of cells 
Using different reagents for permeabilization of cells is an established method to gain insights 
how a protein of interest is distributed and localized inside the cell and additional information 
about the topology of a protein can be obtained (Adam et al., 1990). This assay is based on the 
epitope accessibility under certain treatments and has been used for many INM-protein studies 
(Bengtsson and Otto, 2008; Buch et al., 2009). 
HeLa P4 cells were seeded on coverslips (24-well format) and transfected with a plasmid 
containing the membrane protein and a tag (either hemagglutinin (HA) or mCherry). After 24 h 
of transfection, coverslips were washed with PBS and the different kinds of permeabilization 
techniques were applied to the cells. 
In case of permeabilizing cells with digitonin, a non-ionic detergent, a 0.007% digitonin-TPB 
solution was applied onto the cells for 5 min on ice. After two washing steps with TPB and once 
with PBS, the cells were fixed with 3.7% formaldehyde in PBS for 10 min at RT and washed once 
with PBS. Using this permeabilization method, selectively the plasma membrane is 
permeabilized, whereas organellar membranes like the nuclear and the ER membrane remain 
intact due to their low levels of cholesterol, therefore only proteins facing the cytoplasm can be 
detected.  
For Triton X-100 permeabilization, cells were initially fixed with 3.7% formaldehyde in PBS for 10 
min at RT and washed once with PBS. Followed by two washing steps with PBS the cells were 
permeabilized with 0.5% Triton X-100 in PBS for 5 min at room temperature. 
This kind of treatment allows to permeabilize all membranes of cellular compartments like the 
nucleus. Thus, nuclear as well as ER-lumenal epitopes of proteins are accessible for antibody 
binding. 
After both permeabilization protocols, cells were subjected to immunofluorescence and were 
subsequently mounted with Mowiol including DAPI or Dako Fluorescent mounting medium.  




2.2.4.2.2. Rapamycin-based INM-localization assay 
In order to study the localization of a protein of interest to the inner nuclear membrane, a 
rapamycin-based dimerization mechanism was used. An INM-localization assay was therefore 
established, which is generally based on the binding a two component-system induced by the 
addition of rapamycin. The detailed information about the mechanism can be found in section 
3.2.2.1. The basis of rapamycin-induced dimerization was used in several studies in another 
context (Ohba et al., 2004; Haruki et al., 2008).  
Generally, there are three different versions of this assay used in this work. One version of the 
assay is referred to as in vitro rapamycin assay in this work and uses a permeabilization step 
before treatment of the cells with rapamycin and subsequent fixation of the cells. 
Here, HeLa P4 cells were seeded on coverslips at 30% confluency (70000 cells/24-well). The next 
day the cells were transfected with a plasmids coding for FKBP12-containing plasmid (Table 2, 
right) and a vector containing the protein of interest fused to an FRB cassette (Table 2, left) via 
the Ca-P method for 24 or 48 hours as indicated. After the transfection period, they were washed 
with PBS once and permeabilized with 0.007% digitonin in TPB (1x) including protease inhibitors 
(1 µg/ml Aprotinin, Leupeptin-Pepstatin, 0.1 mM PMSF) and 2 mM DTT for 5 minutes on ice. Cells 
were washed three times with TPB (1st wash: short; 2nd and 3rd wash for 3 minutes each). The 
permeabilization status was controlled on an additional slide with trypan blue solution. 
Afterwards, cells were treated with 200 nM rapamycin in TPB for 10 min on ice to allow 
dimerization between FKBP12 and the FRB domain. Again, cells were washed with TPB and once 
with PBS. Cells were fixed with 3.7% formaldehyde in PBS for 10 minutes at room temperature. 
After washing with PBS, cells were subjected to immunofluorescence microscopy. 
 
When this assay was carried out with the initial permeabilization step, followed by addition of 
rapamycin directly at the microscope with subsequent imaging of the effect on FKBP12-reporter 
protein distribution in real time, it is reffered to as in vitro-kinetics rapamycin assay. 
 
In contrast to the “in vitro”-versions, rapamycin can simply be added to the culture medium of 
living cells for 10 to 30 minutes, followed by a washing and fixation step. This assay is referred to 
as in vivo rapamycin assay, but was rarely used as explained in section 3.2.2.1. 
 





Table 2: Overview of expression constructs used for rapamycin assays. Left column shows all available 








3.1. Post-translational membrane insertion of putative tail-anchored proteins 
In this work, proteins destined for the INM were analyzed. As a first step, their cellular localization 
was determined (section 3.1.1.1), followed by anaylsis of their membrane insertion mechanism 
into the endoplasmic reticulum (ER) using biochemical membrane integration assays (section 
3.1.2). A specific set of membrane proteins (Table 3), among them the established INM-proteins 
emerin and LAP2β, was investigated in this project, which due to their similar sequence 
properties are proposed to belong to the group of tail-anchored proteins. 
Some of these proteins like emerin, LAP2β were confirmed to be integral membrane proteins of 
the nuclear envelope in a proteomics screen (Schirmer et al., 2003) and others like PTP1B, VAPB 
and LRRC59 have been reported to localize to the INM (Yip et al., 2012; Tran et al., 2012; Zhen et 
al., 2012), whereas LEMD1 was included in this study because it shares a characteristic LEM-
domain with other INM-proteins like emerin and MAN1 (Yuki et al., 2004). Furthermore, emerin, 
VAPB and PTP1B were predicted to belong to the group of TA-proteins in a bioinformatics screen 
(Kalbfleisch et al., 2007). A detailed description of these proteins can be found in section 1.2.5. 
 
Table 3: List of the investigated integral membrane proteins including characteristics and possible 






















Nuclear actin network, 
regulation of β-catenin 
signaling, β-tubulin medi-
ated linkage to centrosome 





regulation of lamina 
growth, transcriptional 
repression 





transport, UPR, cellular 
calcium homeostasis, sterol 
regulation 




UPR, regulation of ephrin 
receptor signaling and 
trafficking 
LEMD1 181 aa human 20  LEM-domain 
chromatin-binding,  
cancer progression 






factor transport to the 
nucleus, cell-cell adhesion 
Protein information was obtained from UniProt Protein Knowledgebase. 





3.1.1. Verification of the membrane localization of putative INM-proteins 
3.1.1.1. Localization of putative INM-proteins  
First of all, the selected proteins were analyzed for their localization in HeLa P4 cells by 
immunostaining for the endogenous membrane proteins, in so far as reliable and established 
antibodies were available for the protein of interest (Figure 8). Images were acquired at a 
confocal microscope. 
As a reference protein for nuclear envelope staining, lamin A/C was used. The staining of 
endogenous emerin revealed a localization at the nuclear envelope and a slight staining for ER 
membranes. For LAP2β as well a distribution at the NE and the ER could be observed. The protein 
LRRC59 showed a more prominent localization to ER membranes and less “nuclear rim” 
localization compared to the localization pattern of emerin and LAP2β. Furthermore, VAPB 
showed a localization at the ER, which compared to all other proteins was more punctate. All 
localization patterns obtained by immunofluorescence staining for endogenous proteins were in 
accordance with the observations made in literature. PTP1B and LEMD1 were not analyzed for 
their endogenous localization due to the lack of appropriate antibodies. Aside from this, LEMD1 
was reported to be a protein specifically expressed in testis (Yuki et al., 2004) and thus probably 
a detection in HeLa cells would not be possible. 
Another approach used to examine the membrane localization of the selected proteins, was the 
overexpression of recombinant proteins. In this case, HeLa P4 cells were transfected with 
mCherry- or hemagglutinin (HA)-tagged proteins. The well-studied proteins emerin and LAP2β 
were overexpressed as HA- and mCherry versions of the proteins and therefore required an 
immunofluorescence staining prior to imaging. Both versions of emerin and LAP2β localized to 
membranous structures. The morphological pattern observed for both proteins indicated a 
localization to the NE and the ER (Figure 9). The comparison of both variants (HA- and mCherry-
tagged) revealed a more prominent ER localization and a visible nuclear rim for emerin of its 
mCherry version, whereas the nuclear rim of the HA-protein was thinner and a fraction of emerin 
was found at the ER in a more “bulky” appearance. For LAP2β similar observations concerning 
the morphology of the two versions were made. The proteins PTP1B (Walton and Dixon, 1993), 
LRRC59 (Zhen et al., 2012), VAPB (Skehel et al., 2000) and LEMD1 were expressed with an N-
terminal mCherry tag. For the three first-mentioned proteins, the expected ER localization was 
observed in this experiment and additionally a moderate NE-rim was displayed in some cells. 
Especially LEMD1, which belongs to the LEM-domain containing proteins (Berk et al., 2013b), 
often showed, additionally to an ER localization aggregate-like dots around the nucleus and at 
regions of the ER. In context to the pronounced localization at the ER, which was observed for all 
proteins to a different extent, it was reported that overexpressed transmembrane-fusion 
proteins tend to accumulate in the peripheral ER presumably due to a saturation of their binding 
sites at the NE (Schirmer and Gerace, 2005). 
Altogether, immunostaining of endogenous proteins and overexpression of the investigated 
potential TA-INM-proteins revealed a localization at the ER and the nuclear envelope with varying 
ratios of ER to NE localization depending on the protein. The initial experiments proved an ER 
and NE localization of the investigated proteins, but were not sufficient to specify the localization 







Figure 8: Endogenous localization of investigated putative TA-INM-proteins in HeLa P4 cells. Primary 
anti-emerin (Genosphere), -LAP2β, -LRRC59, -VAPB and lamin A/C antibodies were used for 
immunostaining as indicated in section 2.1.7.1. Secondary AlexaFluor488 or 594-conjugated antibodies 
(see section 2.1.7.2) were used. Scale bars: 15 µm. The polyclonal anti-emerin antibody (Genosphere) was 
generated as a custom-specific product and characterized for its specificity (see Appendix, Supplementary 







Figure 9: Localization of overexpressed putative INM-proteins. HeLa cells were transfected with plasmids 
coding for differently tagged versions of emerin, LAP2β, mCherry-PTP1B, -LRRC59, -VAPB and-LEMD1. 





3.1.2. Membrane insertion mechanisms of putative INM-proteins 
In this chapter, the membrane integration mode of putative INM-proteins is studied. It focuses 
on the TRC40 insertion pathway as a main route taken by tail-anchored proteins. The proteins 
selected for investigation were chosen regarding their transmembrane domain characteristics. 
All examined proteins are specified by only one hydrophobic transmembrane segment, which is 
in close proximity to the C-terminus and therefore potentially belong to the class of TA-proteins 
(chapter 1.2.2.2.1). Therefore, the TRC40-pathway as a major possible route of ER membrane 
insertion was taken into account for the selected proteins (Table 3). 
As explained in section 2.2.2.6, two approaches were used to study membrane integration in this 
work. The first makes use of purified rough microsomes (RM) (Walter and Blobel, 1980) and for 
the second, semi-permeabilized HeLa cells (SPCs) served as a membrane source to test 
integration of putative TA-INM-protein. Furthermore, either in vitro translated (section 3.1.2.2.1) 
or purified TA-protein, which was bacterially expressed and purified in a complex with TRC40, 
was used. 
 
3.1.2.1. In vitro translated putative TA-INM-proteins integrated into rough 
microsomal membranes 
The in vitro transcription and translation reactions (TNT-kit, Promega), which are based on 
utilizing a reticulocyte lysate incubated with the plasmid encoding for the protein of interest, 
provided the potential TA-INM-proteins (section 2.2.2.5). The translated protein was added to a 
reaction mixture with rough microsomes in presence of ATP and the insertion reactions were 
incubated for 1.5 hours. Afterwards, the samples were subjected to SDS-PAGE followed by 
Western Blotting. Plasmids coding for the protein of interest, which were incubated with the 
reticulocyte lysate, also encoded a 13 amino acids long C-terminal opsin-tag (Adamus et al., 
1991). In this opsin-tag a glycosylation site was included and thus was used to detect the protein, 
which was post-translationally integrated into the membrane. The detection of the post-
translational modification is only possible if the C-terminal part of the protein is oriented to the 
luminal side of the ER. There, the oligosaccharyltransferase was responsible for the ER-specific 
N-glycosylation (Aebi, 2013) at the glycosylation site of the opsin-tag. Membrane inserted 
proteins could be detected by using an anti-opsin antibody. As a consequence of a membrane 
integration of a protein, a higher molecular weight band was detected by using the anti-opsin 
antibody. This shift in molecular weight occurred due to the N-glycosylation process after 
membrane insertion (chapter 2.2.2.6.1). For the proteins emerin, LAP2β, PTP1B and VAPB the in 
vitro expression and membrane insertion into RM was performed. 
First of all, emerin was studied for a possible post-translational membrane insertion (Figure 10 
A). The protein synthesis using the reticulocyte lysate was affected by addition of the 
translational inhibitor puromycin and protein synthesis of emerin was completely abolished 
(Figure 10 A, lane 1). To ensure that only post-translationally integrated proteins were detected, 
prior to performing the membrane insertion step and adding the RM, puromycin was added to 
block protein synthesis and exclude the possibility to detect a co-translationally ER-inserted 
substrate. After HZZ-emerin-opsin was synthesized in a cell-free system, it was detected in its 
higher molecular weight form. This glycosylated protein must have been membrane integrated 





membrane integrated emerin form was observed as well (Figure 10, A, lane 5, indicated by 
“opsinG”). These findings proved emerin to take a post-translational pathway for ER-membrane 
insertion. 
To further show that the reaction specifically depends on the TRC40-pathway, short, inhibitory 
fragments of the ER-membrane receptors of the TRC40-pathway were added to the insertion 
reaction, each at a concentration of 1 µM. WRBcc is the coiled-coil fragment of the ER-membrane 
receptor WRB (Vilardi et al., 2011) and CAML-N comprises a short amino-terminal portion of the 
ER-receptor CAML (Yamamoto and Sakisaka, 2012). Both fragments were shown to inhibit the 
membrane insertion of TA-proteins at the ER in the two abovementioned studies. The insertion 
of HZZ-emerin-op was inhibited or at least strongly reduced (Figure 10, A, lane 6 and 7), when 
the short, inhibitory fragments had been added. 
 
Figure 10: Membrane integration of in vitro translated HZZ-emerin-opsin and VAPB-ops28. By the use 
of an in vitro transcription/translation system (TNT-kit, Roche) HZZ-emerin (A) and VAPB-ops28 (B) was 
produced and subsequently a membrane insertion reaction with rough microsomal membranes was 
carried out in the presence of ATP. As indicated, rough microsomes (RM), the translational inhibitor 
puromycin (2.5 mM were incubated for 10 min prior to RM addition) or fragments of MBP-WRBcc and 
GST-CAML-N were added at the indicated concentrations. The glycosylated, higher molecular weight form 
of the protein is indicated by “opsinG” and was detected by SDS-PAGE followed by immunoblotting using 





Apart from emerin, VAPB, another predicted TA-INM-protein, was studied for its membrane 
insertion mechanism. The in vitro translation of VAPB was carried out using different plasmids 
for VAPB. First the plasmid encoding for HZZ-VAPB-opsin was tested for membrane insertion. The 
plasmid DNA is based on a pET328 vector and encoded for a VAPB version with an N-terminal 
His-ZZ-tag (HZZ) and a C-terminal 13 aa long opsin-tag (Favaloro et al., 2008) with a size of               
44 kDa.  
The protein was translated in the reticulocyte lysate and detected by SDS-PAGE followed by 
immunoblotting with the anti-opsin antibody as a prominent band observed running a bit higher 
than the 40 kDa protein standard. When this blot was carefully inspected, a second VAPB band 
could be observed even right after synthesis in all lanes (Figure 11, A, asterisk), which might be 
explained by a post-translational modification. The band at about 40 kDa for HZZ-VAPB-op could 
also be a cleaved variant, which lacks a typical N-terminal MSP-domain (14 kDa), whereas the 
higher band (Figure 11, B, indicated by a black triangle) could be the non-cleaved version 
(Gkogkas et al., 2011; Deidda et al., 2014). After incubation with RMs, even with or without 
puromycin treatment, only a very slight band with a higher MW was detected (Figure 11, A, 
indicated by red asterisk).  
Therefore, the expression and translation of the alternative construct VAPB-ops28 was carried 
out and the membrane insertion into RM was performed. The only difference between the two 
VAPB versions can be found in the N-terminal tag and the opsin-tag. The VAPB-ops28 (Fasana et 
al., 2010; Brambillasca et al., 2005) had no N-terminal tag and a longer version of the opsin-tag, 
which lacks the typical 19 instead of 13 aa long. Surprisingly, for VAPBops28 an additional, shifted 
band appeared (Figure 11, B, circle) in between the two initial bands, when proteins were 
detected with an anti-opsin antibody. No matter, whether puromycin was added or not, a shifted, 
higher MW band was observed (indicated by circle). The result implies a post-translational mode 
of membrane insertion for VAPB. Similar to the membrane integration assay for emerin, where 
inhibitory fragments of the ER-receptors WRB and CAML of the TRC40-pathway were added, 
VAPB-ops28 was integrated into RMs (Figure 11, B). By adding the same concentration of 1 µM 
of each fragment, no reduction of the shifted, glycosylated band (Figure 10, B, indicated with 
opsinG) was seen even if higher concentrations of the inhibitory fragments WRBcc and CAML-N 
were used (Figure 10, B, lane 8 and 10). In this case, the post-translational insertion of VAPB 
seemed to be unaffected by addition of the inhibitory fragments and was hence concluded to 
occur independently of TRC40. As a positive control substrate for a TRC40-dependent ER 
membrane insertion, emerin was used when performing the VAPB-ops28 integration reactions. 
 
The protein LAP2β was analyzed for its membrane insertion mode in RM, after a HZZ-LAP2β-
opsin version was expressed in vitro. After 1.5 hours of incubation with RM and ATP, indeed an 
additional band higher than 70 kDa was confirmed by using an anti-opsin antibody (Figure 11, 
C). A preincubation with the protein synthesis inhibitor puromycin (Figure 11, C, lane 3) did not 
abolish the shifted band, strongly indicating that the membrane insertion mechanism for LAP2β 
occurs via a post-translational mode. 
 
In case of the phosphatase PTP1B, a higher molecular weight band above 70 kDa was detected 
on the blot after incubation with RM (Figure 11, D, lane 2 and 3, indicated by opG). Especially for 





These “blurred” protein bands could perhaps be explained by a highly post-translationally 
modified protein. 
The detected higher MW band led to the conclusion that for PTP1B, a post-translational insertion 
is possible. Whether it uses the TRC40 or another post-translational pathway, remained unclear 
from results obtained in this work. 
 
 
Figure 11: Membrane integration of in vitro translated HZZ-VAPB-op (A), VAB-ops28 (B), LAP2β (C) and 
PTP1B (D) into RMs. A reticulocyte lysate based in vitro translation was performed for selected plasmids 
coding for proteins mentioned above and incubated with RM according to the protocol (chapter 2.2.2.5). 
As stated, rough microsomes (RM) and the translational inhibitor puromycin (2.5 mM was incubated for 
10 min prior to RM addition) were added besides ATP, which was present in all reaction (not indicated). 
After SDS-PAGE and immunoblotting, the membrane integrated proteins were detected by using an anti-
opsin antibody. “G” indicates the glycosylated, higher molecular weight form of a protein. Red asterisk (*) 
in (A) indicates a very faint, higher molecular weight band in lane 3 and 4 of VAPB and the triangle (▼) in 
(B) indicates a band detected by the opsin-antibody, which seemed to be irrelevant for membrane 
integration, whereas the glycosylated and membrane integrated band is indicated by a circle (○). 
Taken together, the in vitro translated proteins emerin, LAP2β, PTP1B and VAPB seem to 
integrate post-translationally into RMs. Especially for HZZ-emerin-op, a clear dependence on the 
TRC40-pathway was demonstrated, when inhibitory fragments of the TRC40-machinery were 
used. In contrast to this, membrane insertion of VAPB-ops28 seemed to occur independently of 
the TRC40-route, pointing to an alternative post-translational pathway. For LAP2β and PTP1B the 
specific mode of post-translational integration was not further investigated using in vitro 





3.1.2.2. Characterization of membrane insertion of emerin utilizing the TRC40-
pathway for membrane insertion at the ER as a tail-anchored protein 
This chapter focuses in more detail on the membrane integration process of the INM-protein 
emerin not only using an in vitro transcription and translation system (section 3.1.2.1), but also 
using co-expressed HZZ-emerin-op in complex with TRC40 purified from bacteria. This 
recombinant protein complex was subsequently used in membrane integration assays. 
Additionally, emerin can be produced in an in vitro transcription/translation system as was shown 
above. As well the insertion of emerin into rough microsomal membranes was studied. 
Moreover, the dependency of emerin on the TRC40-mechanism was examined in TRC40 
immuno-depleted cells. 
 
3.1.2.2.1. Membrane integration of bacterially expressed and purified emerin 
into RM and semi-permeabilized cells 
3.1.2.2.1.1. Co-expression of emerin with TRC40 
To express the membrane protein of interest, a well-established co-expression and -purification 
system was utilized to obtain a membrane protein in a soluble state (chapter 2.2.2.4). Proteins 
were expressed by use of a particular E. coli strain BL21AI, which allowed the induction of protein 
expression under control of a specific arabinose-inducible promotor. Initially, a pool of MBP-
TRC40 was induced for an hour, then the expression of a putative tail-anchored protein, here 
emerin, was selectively induced for 4 hours to form a complex with TRC40 (Favaloro et al., 2010). 
Below, a schematic view of a tail-anchored protein, mCherry-FRB-emerin*, complexed with MBP-
TRC40 is shown (Figure 12, A). 
The amylose resin eluted fraction, which is displayed in the rightmost lane of Figure 12, shows a 
80 kDa band representing MBP-tagged TRC40 and two lower bands at around 65 to 75 kDa 
belonging to mCherry-FRB-emerin. The appearance of the higher mCherry-FRB-emerin band was 
observed for other mCherry-fusion proteins in several other experiments as well, when samples 
(combined with SDS-sample buffer) were boiled at 95 °C. The identity of both bands was 
confirmed to belong to mCherry-FRB-emerin by using an anti-RFP and anti-emerin antibody (data 
not shown). Depending on the specific TA-protein co-expressed with TRC40, an amount of 5 mg 




















Figure 12: Co-expression and -purification of emerin in a complex with TRC40. A scheme of a co-purified 
emerin version together with TRC40 is depicted (A). The composition of the protein complex is indicated 
by colored and labelled boxes. The small, yellow box displays a 10x His-tag on the N-terminus of emerin. 
In (B), a typical protein purification is shown for mCherry-FRB-emerin. E. coli BL21AI cells were 
homogenized and the protein was purified using Ni-NTA and amylose resins according to the protocol 






3.1.2.2.1.2. Membrane integration of emerin into RM and SPC 
Due to its sequence features (section 1.2.5, Table 1) emerin was proposed to belong to the 
specific group of TA-proteins and assumed to use the TRC40-mediated membrane insertion 
mechanism to integrate into the ER, as a first membrane entry site of its transport process to the 
INM (Laba et al., 2014). 
In this context, the mode of membrane insertion was studied by using rough microsomes (Walter 
and Blobel, 1983) or semi-permeabilized cells as described in section 2.2.2.6. In comparison to 
the rough microsome membrane insertion assays performed with in vitro translated protein 
(section 3.1.2.1), a purified TRC40/emerin protein complex, as described in the previous chapter, 
was used. Being aware of the proposed classification of emerin as a TA-protein using the TRC40-
route for membrane integration, it was beneficial to use the bacterially produced emerin, 
because it already existed in a complex with an important component of this pathway. The 
purified emerin protein-complex, consisting of TRC40 bound to emerin, described in this 
paragraph, is compared to the reticulocyte lysate translated protein, a more pre-determined 
approach. The in vitro translation of membrane proteins in contrast is a more unbiased way of 
protein expression and therefore allows to study post-translational membrane insertion in 
general (e.g. unassisted or chaperone-dependent ways) and is not restricted due to a predefined 
binding to TRC40. In the following experiments, exactly this binding to TRC40 was used to 
facilitate membrane insertion reactions. 
His-ZZ-emerin-opsin in complex with MBP-TRC40 (Figure 13) was used in the insertion assays. 
The His-ZZ tagged version of this protein was used, because compared to other mCherry-tagged 
and purified emerin fusion proteins, the N-terminal tag is relatively short (13 kDa) in relation to 
emerin itself (29 kDa). In general, the assay conditions were tried to be kept as close to the 
physiological situation as possible. The most important feature of this emerin construct is the 
small, C-terminal opsin-tag (Adamus et al., 1991). This small portion is C-terminally fused to 
emerin and has a length of only 13 aa, as mentioned in context with the in vitro translation 
experiments. Due to the presence of a glycosylation site within the opsin-tag, the protein can be 
glycosylated. After the membrane integration assay was performed, the proper insertion of a TA-
protein at the ER membrane, facing the ER lumen with its C-terminal end, can be detected due 
to the glycosylation of the opsin-tag. A specific ER-lumenal glycosylation, referred to as N-
glycosylation is mediated by the oligosaccharyltransferase (Aebi, 2013). A glycosylated, higher 
molecular weight protein, which consequently must have been membrane-integrated, can be 
detected with an anti-opsin antibody, which was already used for the experiments with in vitro 








Figure 13: Schematic view of a protein complex consisting of HZZ-emerin-op and MBP-TRC40. Sizes of 
the single components are displayed according to their actual molecular weight. Legend explains 
individual portions and features of the fusion protein (box, right side). 
Bacterially translated emerin was first tested for membrane integration in rough microsomes. 
There, HZZ-emerin-opsin was observed to be glycosylated, seen by a shifted protein band 
(indicated with opsinG) in reactions including lithium ATP as an energy source and performed at 
30 °C (Figure 14, lane 3). 
 
 
Figure 14: HZZ-emerin-opsin is able to insert into rough microsomal membranes. The purified protein-
TA-protein complex was incubated with rough microsomes and lithium ATP for 30 minutes at 30 °C. The 
analysis of membrane insertion was done by SDS-PAGE and immunoblotting, using an anti-opsin antibody 
to detect HZZ-emerin-op. The protein in its membrane-integrated and glycosylated form could be 
detected by a higher MW band indicated with “opsinG”. 
The next step was to test HZZ-emerin-opsin membrane insertion in digitonin-permeabilized HeLa 
cells. The semi-permeabilized cells were obtained by treating HeLa P4 cells with digitonin for 
selective permeabilization (2.2.2.6.2) and represent another possible ER-membrane source than 
RM. A further advantage of using permeabilized cells is the fact, that they provide a more flexible 
system than RM. The possibility to modulate protein levels of distinct proteins by knockdown or 
overexpression experiments could be used to examine the influence on membrane insertion for 
instance. 
Additionally, to the energy-dependency of the insertion process observed in RM, the 
temperature, at which the reaction was performed, seemed to play an important role (Figure 15, 
lane 2), because cells incubated with the protein at 4 °C, did not show any insertion even though 
energy was provided. It was further shown that a portion of HZZ-emerin-opsin shifted to the 
glycosylated state at 30 °C upon ATP addition (Figure 15, lane 3). 
 
To specifically address the initial question, whether emerin is delivered and integrated by the 
TRC40-pathway, the influence of the short inhibitory fragments of the ER-receptors WRB and 





With both, the coiled-coil cytosolic domain of WRB (WRBcc) (Vilardi et al., 2011) and the amino-
terminal cytosolic portion of CAML (CAML-N) (Yamamoto and Sakisaka, 2012), the membrane 
integration of HZZ-emerin-opsin was inhibited, because a competitive situation for membrane 
insertion was created (Figure 15, lanes 5 and 9). The fragments were titrated in increasing 
concentrations to the insertion reactions. The more of an inhibitory fragment was used, the more 
the membrane integration of emerin was inhibited (Figure 15, lanes 5-12). Even a very low 
concentration of 30 nM GST-CAML-N, resulted in a visible reduction of membrane integrated 
HZZ-emerin-op and therefore strongly indicates that the TRC40-pathway plays a major role for 
membrane integration of emerin. 
To further ensure the higher MW band was caused by glycosylation of emerin, PNGaseF 
(Takahashi, 1977), a deglycosylating enzyme, was added to one-tenth of the reaction and 
incubated. Indeed, the shifted protein band must have been glycosylated, because nearly a 
complete reduction for the upper band was seen compared to the buffer control (Figure 16, lane 
3 and 4). Due to the use of PNGaseF, it could be ensured that only N-linked glycans were 
specifically removed from the protein and that as assumed emerin was integrated into ER 
membranes of the SPCs, which were intact and still contained the responsible 
oligosaccharyltransferase. 
All results obtained from the membrane insertion in either RM or SPCs using a purified 
TRC40/emerin complex indicate that emerin post-translationally integrates into ER-derived 
membranes via the TRC40-assisted route in an energy- and-temperature dependent manner 
(Stefanovic and Hegde, 2007) in vitro. 
 
 
Figure 15: Membrane insertion of HZZ-emerin-opsin into semi-permeabilized cell membranes. HeLa 
cells permeabilized with digitonin and incubated with the TRC40-co-purified protein HZZ-emerin-opsin at 
4 or 30 °C, with or without ATP as an energy source. MBP-WRBcc or GST-CAML-N was added in increasing 
concentrations (30 to 1000 nM). The pellet fractions of the membrane insertion samples were analyzed 
by SDS-PAGE followed by western blotting. Detection of protein was carried out using an anti-opsin 
antibody and the membrane-integrated, glycosylated protein was detected as a higher MW version of the 







Figure 16: Deglycosylation of HZZ-emerin-opsin integrated into semi-permeabilized cells. After 
performing a standard insertion reaction with ATP at 30 °C, the samples were subjected to carbonate 
fractionation (see section 2.2.2.6.2.1) and about 20% of the pellet fractionwas used to deglycosylate the 
protein with PNGaseF. Either only the PNGase buffer was used (10%) or the reaction was performed in 
the presence of the enzyme (PNGaseF; 10%) for 1.5 h. For protein input, entirely untreated protein was 
used. The amount loaded for the initial membrane insertion reaction at 30°C as a control (lane 2) was 
comparable to the deglycosylation samples. The samples were analyzed by SDS-PAGE followed by western 
blotting. Detection of protein was carried out using an anti-opsin antibody and the membrane-integrated, 






3.1.2.3. Membrane insertion of in vitro translated HZZ-emerin-op is affected by 
TRC40-depletion  
Due to the observation that the membrane integration of emerin, which is in a complex with 
TRC40, is inhibited by short fragments of the ER-receptors WRB and CAML in rough microsomes 
or semi-permeabilized cells, emerin most likely is a TRC40-dependent substrate. Therefore, 
emerin generated by the in vitro translation system was used to further support this finding. 
Therefore, a depletion experiment was carried out by Fabio Vilardi (Pfaff et al., 2016). The 
reticulocyte lysates, which are provided by the in vitro transcription and translation system, were 
depleted with antibodies against either TRC40 or Hsc70. The Hsc70 depletion was performed 
besides depletion of TRC40 to exclude emerin using an alternative mechanism for post-
translational insertion of TA-proteins (Abell et al., 2007; Rabu et al., 2008). Afterwards, the 
standard protocol for membrane insertion into rough microsomes was used to integrate HZZ-
emerin-opsin (section 2.2.2.5). 
A pronounced reduction of the glycosylated protein, seen as a higher MW band (Figure 17, 
indicated with “opG”) was observed for TRC40-depeleted lysates, while there was no change in 
Hsc70 depleted lysates and control treated lysates. 
The results once more strongly indicate that TRC40 has a crucial function for the post-




Figure 17: Membrane insertion of HZZ-emerin-op with immunodepleted reticulocyte lysate (performed 
by Fabio Vilardi, see Pfaff et al., 2016). Lysates used for in vitro transcription and translation were immuno-
depleted for TRC40 and Hsc70. Additional non-treated cells (mock) served as a positive control for 
membrane insertion. The membrane inserted protein was detected by using an anti-opsin antibody. 
 
3.1.3.  Investigation of INM-protein transport using an in vitro import assay 
In addition to the biochemically performed membrane integration assays described in the above 
section 3.1.2, an in vitro transport assay was used to investigate membrane localization or at 
least association of bacterially produced TRC40/TA-protein complexes in a microscopy-based 
approach. The reaction performed in this experiment can be seen as the analogous or 
“microscopic version” of the membrane insertion experiments in semi-permeabilized cells. This 
kind of in vitro transport assay used in this project, is a well-established method, which originally 
was used for studying either import or export of soluble proteins (Adam et al., 1990; Kehlenbach 
et al., 1998). 
Besides the biochemical membrane insertion assays, the in vitro import assays were also 





membrane integration, which was biochemically detected, could be visualized in cells as well. 
The proteins were purified and co-expressed by the same means as described for the HZZ-
emerin-opsin.  
In the following, the membrane association of different emerin variants as well as VAPB and 
PTP1B were examined in these in vitro import assays using confocal microscopy.  
Due to the specific co-expression and purification of the putative TA-protein of interest with 
TRC40, the proteins were in a kind of pre-determined state and were expected to also use the 
TRC40-pathway for membrane insertion. Therefore, a general localization of the studied proteins 
at least to the ER would be expected. Emerin, VAPB and PTP1B should not only be studied for 
being TA-proteins in terms of their membrane integration mechanism, but also in light of being 
INM-proteins and using the ER-membrane as a first entry site (Rapoport, 1992; Kutay et al., 1993) 
on their way to the INM. Furthermore, a localization not only to the ER but also to the nuclear 
envelope (seen by a “nuclear rim”) would consequently be expected for the selected proteins, 
given that “required” factors are available for targeting of a protein to the NE in this 
permeabilized cell-system. 
 
Three different emerin versions were tested in this assay. Import reactions for mCherry-emerin-
opsin, mCherry-FRB-emerin and a mCherry-Δ1-106-emerin-opsin each in a complex with MBP-
TRC40 were prepared and the only two components added apart from the protein was an energy-
regenerating system and cytosol (cytosolic extract from a HeLa suspension cell line). Each import 
reaction was performed directly on coverslips, on which HeLa cells were seeded one day prior to 
the assay. Generally, these import assays are performed at 37 °C and 4°C, because for all 
transport processes temperature can be a crucial parameter. 
The mCherry-emerin-opsin was used, because the mCherry-tag provides an easy possibility to 
detect the protein at the microscope and this variant can be immunostained additionally for its 
C-terminal opsin-tag to determine localization inside the cell.  
Furthermore, the MBP-TRC40/mCherry-FRB-emerin (section 3.1.2.2.1.1), was included, because 
of its possible usage in a rapamycin-INM-localization assay, which will be described in detail in 
chapter 3.2.2.1. Irrelevant of knowing the details and mechanism of this rapamycin assay, the 
localization of this variant compared to the first construct, which does not contain such a FRB-
domain, were compared. 
In addition to the full length (254 aa) versions of emerin, a shortened emerin variant with a 
deletion of the residues 1-106 was investigated, because it was reported to efficiently localize to 
the nuclear envelope even though, a large N-terminal portion of emerin was lacking            
(Tsuchiya et al., 1999). 
 
When the import assays were performed at 37 °C and an energy-regenerating system as well as 
cytosolic extract was added, for all different emerin variants a localization at the ER and a NE 
could be observed (Figure 18). According to this, the soluble control cargo-protein Atto488-BSA-
NLS showed a temperature-dependent import, which was seen by an accumulation of Atto488-
signal inside the nuclei and nucleoli. In contrast at 4 °C, the control protein showed no import 
into the nucleus and further for none of the emerin versions, a NE localization was detectable at 
this temperature. Instead a slight association of emerin to the ER seemed to occur and a 
“punctate” pattern was observed. The strongest NE-localization was could be observed with the 





localization of mCherry-FRB-emerin with the mCherry-emerin-opsin variant lacking the FRB-
cassette, no obvious difference in localization was seen, when looking at the anti-opsin compared 
to the anti-RFP staining (Figure 18, green signal). Altogether, for the analyzed emerin protein 
variants a localization or association at the ER membrane was detected and sometimes a more 
pronounced nuclear rim was observed indicating a localization at the nuclear envelope.  
 
Other proteins, which were investigated for the possibility of transport to the nuclear 
membranes, were VAPB and PTP1B. Both were expressed as HZZ-tagged proteins. After 
performing the import reactions under the same conditions as for emerin, VAPB localized to a 
structure, which is most likely the ER (Figure 19, upper panel). Compared to emerin, where at 
least some part was observed at the NE, VAPB did not reveal any “nuclear rim” localization. A 
similar observation was made for HZZ-PTP1B-opsin, which showed no NE localization at all, 
although a perinuclear localization was detected (Figure 19, mid panel). The pattern observed for 
PTP1B was even more discontinuous than the “ER” localization observed for VAPB, therefore 
contrary to the observations made with in vitro translated PTP1B in membrane insertion assays, 
under these specific in vitro import assay conditions PTP1B might hypothetically only be 
associated and not integrated into the membrane. 
Taken together, the membrane integration assays performed with in vitro translated proteins 
showed a possible post-translational insertion at the ER for emerin, LAP2β, VAPB and PTP1B. 
Focusing on the membrane protein emerin, it was demonstrated that with either in vitro 
translated or bacterially expressed protein together in a complex with TRC40, a post-translational 
membrane insertion was utilized by emerin but not by VAPB in comparison. After having a closer 
look on the specific post-translational mechanism, the membrane integration of emerin was 
shown to depend on the TRC40-pathway, when inhibitory fragments of WRB and CAML were 
used in RM or SPCs independent of what kind of emerin variant (in vitro translated or purified in 
complex with TRC40) was used.  
Additionally, depletion experiments showed, how strongly emerin depends on the TRC40 
machinery. As a consequence, emerin is strongly suggested to belong to the group of tail-
anchored proteins and seems to rely on the TRC40-mediated membrane integration. 
Corresponding to the biochemical assays, an ER localization and thus as well a localization at the 
ONM which is continuous to the ER, is most likely to be seen for emerin in the in vitro import 
assay.  
 
Overall, a statement about the exact subcellular localization of a protein is not possible on the 
basis of this method. These in vitro transport assays clearly illustrate the limitation of information 
provided concerning the exact subcellular localization of a protein. 
As a consequence of this, the next chapter addresses the available options to determine the 










Figure 18: In vitro transport assay to the NE using different emerin variants. Transport reactions of a TA-
protein together with TRC40 to the ER membranes or NE were performed directly on the coverslips. One 
day prior to the transport assay, HeLa P4 cells were seeded on coverslips. After digitonin-permeabilization 
of the cells, the transport reaction was set up. The amount of protein in a complex with TRC40 used per 
import reaction varied for all different emerin fusion proteins (mCherry-emerin-op: 5 µg (1.8 µM); 
mCherry-FRB-emerin: 1.8 µg (0.5 µM); mCherry-Δ1-106-emerin-op: 4.5 µg (2 µM)). The reaction was 
completed by addition of cytosol and ATP-regenerating system to the protein and the mixture was added 
to the cells. Transport was performed at 37 °C for one hour and an additional control reaction at 4 °C was 
prepared. Atto488-BSA-NLS served as a general control for the assay and should localize to the 
nucleoplasm as a soluble cargo protein. The fluorescent signal in the red (mCherry) or the green (α-opsin) 










Figure 19: In vitro transport assay to the ER and NE using VAPB and PTP1B expressed in a complex with 
TRC40. Transport reactions of a putative TA-protein together with TRC40 to the ER membranes or NE, 
were performed directly on the coverslips. One day prior to the transport assay, HeLa P4 cells were seeded 
on coverslips. After digitonin-permeabilization of the cells, the transport reaction was set up. The amount 
of TRC40/TA-protein-complexes used per import reaction was for VAPB 2.7 µg (0.6 µM) and for PTP1B      
1 µg (1 µM). The reaction was completed by addition of cytosol and ATP-regenerating system to the 
protein and the mixture was added to the cells. Transport was performed at 37 °C for one hour and an 
additional control reaction at 4 °C was prepared. Cy3-BSA-NLS served as a general control for the assay 
and should localize to the nucleoplasm as a soluble cargo protein. The fluorescent signal in the green 
channel (α-opsin) indicates integration of the protein into the ER and perhaps the NE. Scale bars: 10 µm. 
 
3.2. Localization of putative TA-INM-proteins 
This section deals with possibilities to specifically study the localization of putative TA-proteins 
to the inner nuclear membrane. Due to the close proximity of both ONM and INM (Franke et al., 
1981) and the fact that the ONM is continuous with the ER, it is not easy to discriminate to which 
of these membranes a protein exactly localizes. Using basic confocal microscopy does not allow 
the differentiation between these two membranes due to the restricted resolution caused by the 
diffraction limit. The localization patterns observed after immunofluorescence stainings, 
overexpression studies (Figure 8, Figure 9) or in vitro import assays (section 3.1.3) for example 
revealed emerin to be localized at the nuclear envelope or at least associated with the nuclear 
envelope and the ER, but whether the “nuclear rim” seen in these experiments pointed to an 
ONM or INM targeting could not be distinguished.  
Instead of using biochemical methods like subcellular fractionation experiments to determine 
the localization compartment of a protein inside a cell, in this study, two microscopy-based 
approaches were used to confirm the localization of a protein at the INM. 
By using a differential permeabilization approach (section 3.2.1) as well as a newly introduced 
version of a rapamycin-based dimerization assay (section 3.2.2) the subcellular distribution of 
proteins was investigated. 
 
3.2.1. Differential permeabilization approaches revealed emerin, LAP2β and LRRC59 to 
localize at the INM in contrast to the ER-membrane receptor WRB 
At the beginning of this study, the detection of endogenous putative TA-INM-proteins and the 
overexpressed versions of these proteins (chapter 3.1.1) revealed them to localize both at the ER 
and membranes of the NE. For proteins visualized in these experiments and found at the NE, it 
was not possible to make a clear statement about an ONM or INM localization. A prediction of 
the distinct membrane was not possible so far but would be essential for studying the transport 
of a protein to its destination. As already mentioned above, a commonly used method to get 
information about the subcellular localization of a protein is the differential permeabilization 
method. 
This method was used to characterize the subcellular localization of tagged versions of the 
proteins emerin, LAP2β and LRRC59 as putative TA-INM-proteins in detail. In general, proteins 
were visualized via their tag (either HA or mCherry), which in turn gave information about the 





not only localize to the NE, but to discriminate between ONM and INM, this differential 
permeabilization procedure was used, followed by immunostaining (see sections 2.2.4.2.1 and 
2.2.3.5). 
In this approach, Triton X-100 and digitonin were used as permeabilization reagents. On the one 
hand, cells were treated with Triton X-100 after fixation, which makes proteins of both the INM 
and ONM accessible for primary antibodies. In contrast to this, digitonin, as a mild detergent, is 
applied prior to fixation. Because of different amounts of cholesterol found in the plasma 
membrane compared to the membranes surrounding organelles like ER or the nucleus, a 
selective permeabilization of only the plasma membrane is caused by using digitonin (Nishikawa 
et al., 1984). 
Due to the fact, that only the plasma membrane is disrupted and other organelle membranes 
remain intact, the primary antibodies are not able to access the INM and the nuclear interior. By 
comparison of Triton X-100- versus digitonin-permeabilized cells, differences in the specific 
subcellular localization can be seen (Adam et al., 1990; Bengtsson and Otto, 2008; Buch et al., 
2009). 
 
To be able to differentiate between regions inside the cell the indirect immunofluorescence for 
mCherry-tagged proteins was performed with an anti-RFP antibody and for the other proteins an 
anti-HA antibody was used. Thus far, the ER-receptor WRB of the TRC40 route is known to reside 
at the ER membrane (Vilardi et al., 2011) and was therefore used as a negative control for INM 
localization. In comparing the outcome for both permeabilization conditions, for WRB-HA, a 
pattern of ER and NE localization was seen, which seemed to be very similar for the different 
detergents used (Figure 20). By contrast, the endogenous nuclear lamina component lamin A/C 
showed a prominent “nuclear rim” staining after Triton X-100 treatment (Figure 20, upper lane) 
but is not detected at the NE upon digitonin permeabilization. The well-studied proteins emerin 
and LAP2β showed independently of the size of their N-terminal tag (mCherry or HA), a 
distribution throughout the ER when treated with digitonin, whereas a NE localization was 
observed after Triton X-100 treatment. For mCherry-LRRC59 (Figure 20, bottom lane) the 
observed NE localization was not as distinct and pronounced as for emerin and LAP2β. Compared 
to the pattern demonstrated for emerin, the Triton X-100 treated mCherry-LRRC59 cells showed 
only slightly more nuclear rim staining than the digitonin treated cells. Thus, LRRC59 might not 
be present at the INM to the same degree like emerin indicated by a weak nuclear rim 
localization. Perhaps the abundance of LRRC59 at the INM is relatively low compared to emerin 
protein levels for example. 
 
On the basis of this experiment it was possible to distinguish the localization of a protein at the 
ER membrane or ONM versus a localization at the INM. With a Triton X-100 permeabilization, 
both tagged emerin and LAP2β versions, as well as LRRC59 could be shown to localize in addition 






Figure 20: Subcellular localization of membrane proteins. HeLa P4 cells were transfected with plasmids 
coding for WRB-HA and tagged versions of emerin and LAP2β and mCherry-LRRC59. Cells were 
permeabilized either with Triton X-100 or digitonin and immunostained against the HA or RFP tag. As a 
control for differential permeabilization the nuclear lamina component lamina/C was used, which is 





3.2.2. Discrimination between ONM and INM localization using a rapamycin-based 
localization assay 
3.2.2.1. Establishing a rapamycin-based INM-targeting assay  
For discrimination of membrane protein targeting to the INM or ONM, which is continuous with 
the ER membrane, a rapamycin based protein localization assay was established. With this 
approach, the localization of already established INM-proteins can be confirmed and the 
targeting of potential INM-proteins can be investigated. 
The kinase mTOR or FRAP (= FKBP-12-rapamycin associated protein), which is involved in many 
signaling pathways, can interact with FKBP12 (= 12 kDa FK506/rapamycin-binding protein) via a 
macrolide, termed rapamycin (Chiu et al., 1994; Stan et al., 1994; Choi et al., 1996). The structural 
basis of this binding between FKBP12-rapamycin to the FKBP12-Rapamycin- Binding (FRB) 
domain was investigated by Choi et al. (1996), Liang et al. (1999) and La Banaszynski et al. (2005) 
in detail. It was shown that in presence of rapamycin, FKBP12 is bound by the drug first, then 
FKBP12-rapamycin is able to bind to mTOR. Rapamycin (= Sirolimus) is produced by the bacterium 
Streptomyces hygroscopicus and is known for its antifungal properties (Singh et al., 1979). The 
rapamycin dimerization mechanism has been successfully used for trapping of reporter proteins 
at the nuclear lamina (Ohba et al., 2004). Furthermore, this fusion system was utilized in an 
anchor-away (AA) approach in yeast to deplete a protein of interest from the nucleus and bind it 
to an abundant cytoplasmic protein (Haruki et al., 2008). 
 
In the approach used in this work, a two-component system is defined as the following: One 
component is a small portion of mTOR, termed FRB domain (Chen et al., 1995; Zheng et al., 1995). 
It has a size of 11 kDa and was cloned into a plasmid together with the protein of interest (“TA-
protein”) e.g. mCherry-FRB-emerin. The second component is FKBP12, this dimerization partner 
is expressed in a GFP-tagged version containing an NLS (Figure 21). Several constructs for the 
rapamycin-dimerization assays were created for the FKBP12 reporter and expression constructs 
containing the FRB domain of several investigated membrane proteins are available (Table 2).  
When rapamycin is added to the specific experimental setup, the nuclear, soluble FKBP12 
reporter is recruited to the protein of interest containing the FRB cassette at the INM, if it is 
indeed present at the nuclear rim (Figure 21). Upon rapamycin addition, a change in localization 
of EGFP2-GST-NLS-FKBP12 from a homogenous distribution inside the nucleus to a localization at 






Figure 21: Schematic view of the rapamycin-based dimerization of FKBP12- and FRB- containing-
proteins at the INM. Upon addition of rapamycin (RAP, orange), the soluble GFP-NLS-containing FKBP12 
reporter protein is able to localize to the nuclear periphery and binds to the FRB cassette of a protein 
localized to the INM. The “TA-protein” of interest (e.g. emerin) is integrated via its transmembrane 
domain (TMD, blue) into the INM as depicted in the scheme. 
 
During development and optimization of this assay, the first rapamycin assays were carried out 
in living cells. These experiments were performed by using emerin as an INM model protein. 
mCherry-FRB-emerin was co-transfected with EGFP2-NLS-FKBP12 in HeLa P4 cells for one day, 
afterwards rapamycin was added to the culture medium to living cells. 
This assay was thus referred to as in vivo rapamycin assay. The overexpressed mCherry-FRB-
emerin was localized at the INM (Figure 21, displayed by mCherry-FRB- “TA-protein") and a 
soluble EGFP2-GST-NLS-FKBP12 could bind to the FKBP12 cassette of the GFP-reporter via 
interaction with rapamycin and therefore a peripheral FKBP12 rim was detected (in vivo data not 
shown). An important observation made during analysis of this assay was, that the FKBP12 
reporter did not completely localize inside the nucleus. In quite a few cells, the FKBP12 protein 
was found as well to a certain degree in the cytoplasm. This might be explained by the presence 
of newly synthesized protein occurring in the cytoplasm, as the FKBP12 reporter (EGFP2-GST-NLS-
FKBP12) was intentionally designed to contain several tags to increase the size of the protein and 
prevent a passive diffusion mechanism. 
In accordance with this idea, in EGFP2-GST-NLS-FKBP12 transfected cells, the reporter mainly 
localized to the nucleus and was retained inside the nucleus most probably due to its size, which 
is above the diffusion limit of the NPC (Paine et al., 1975), but there obviously was some FKBP12 
reporter localizing in an unintended way as it was clearly observed in the in vivo study. 
To address the problem of cytoplasmic localization of FKBP12, the conditions of the assay were 
changed from an in vivo situation to a situation using semi-permeabilized cells for the rapamycin 





As a consequence, this kind of approach was named in vitro rapamycin assay (2.2.4.2.2). To 
ensure a proper localization of the GFP-FKBP12 reporter protein inside the nucleus, a 
permeabilization of the cells with digitonin was performed. Due to the permeabilization the 
cytosol content was released and most of the background FKBP12 fluorescence in the cytoplasm 
was removed. 
 
Based on the idea of the in vitro rapamycin assay, a third version of this rapamycin system was 
tested and referred to as in vitro-kinetics rapamycin assay. To specifically confirm the FKBP12 
reporter to be present inside the nucleus only, this assay was performed under real time 
conditions. The cells were selected and imaged before addition of rapamycin, which allowed to 
control the correct targeting of EGFP2-GST-NLS-FKBP12 inside the cells for the chosen area. Upon 
rapamycin treatment, images were taken after pre-determined time points. Due to the series of 
images taken, information about the kinetics of the rapamycin induced dimerization reaction for 
the soluble GFP-FKBP12 could be obtained. 
Taken together, all types of developed rapamycin-assays, only allow to make a qualitative but 
not quantitative statement about the localization of a protein of interest to the INM. A nuclear 
rim of EGFP2-GST-NLS-FKBP12 can be seen as a confirmed localization at the INM. No change in 
localization of the FKBP12 reporter protein is judged as the protein not being present at the INM. 
In context to this, it has to be mentioned that the amount of protein being present at the INM 
might be a limiting factor for detection of the protein in this system and therefore, very low 
amounts of protein at the INM might not be detected in this specific assay setup. In the following, 
the in vitro rapamycin assay versions were frequently used to obtain information about protein 
localization at the INM. 
 
3.2.2.2. Analysis of INM-localization of emerin, LAP2, PTP1B, LRRC59, VAPB and 
LEMD1 using an in vitro-kinetics rapamycin assay 
Due to the limitations given by methods like immunofluorescence and overexpression studies it 
was not easy to verify if a protein localizes specifically to the inner nuclear membrane as 
mentioned in chapter 3.2.1.  
As a consequence of this, a newly developed rapamycin based assay was utilized to confirm the 
localization of a protein at the INM. Using a differential permeabilization assay an INM 
localization was already shown for emerin, LAP2β and LRRC59. 
In this section, all of the selected putative TA-INM-proteins (Table 1) were also studied with this 
localization assay. For the proteins emerin, LAP2β, PTP1B, LRRC59, VAPB and LEMD1 in vitro-
kinetics rapamycin assays were carried out. As described in section 3.2.2.1, the advantage 
compared to the regular in vitro assay version is, that prior to the addition of rapamycin, the cells 
can be chosen specifically concerning their transfection efficiency and morphology for both the 
mCherry-FRB-TA-protein and the “GFP-FKBP12” reporter. Due to the permeabilization step prior 
to the rapamycin treatment and the choice of specific cells for imaging, it can be ensured that in 
the imaged cells no residual cytoplasmic GFP-reporter is left, which could in turn bind to proteins 
at the ONM/ER and provide false positive results.  
After co-transfection of the putative TA-protein together with the EGFP2-GST-NLS-FKBP12 
reporter and permeabilization of the cells, cells were selected and an image was taken prior to 





was monitored until no further change in distribution of FKBP12 could be visually detected 
anymore. After a series of images were taken, a final image was acquired representing the post 
rapamycin state (indicated as +rap condition in Figure 23). 
As a well-studied INM-protein, emerin was analyzed for its INM-localization in the role of being 
a positive control for targeting to the INM (Figure 22). For emerin, the shift and recruitment of 
the FKBP12 reporter occurred rapidly. Already after 7 seconds post rapamycin addition and 
starting a time series, first stages of rim formation were visible (Figure 22, arrow). 
 
 
Figure 22: Time course of rapamycin-induced change in localization of the GFP-FKBP12 reporter in 
emerin transfected cells. An image time series of the change in GFP-FKBP12-reporter localization in 
mCherry-FRB-emerin transfected cells is shown over a time span of 120 seconds. Images were taken every 
7 seconds, but only specific time points are illustrated above. The displayed images show the kinetics of 
the experiment performed for emerin in Figure 23. The localization of emerin for each specific cell seen 
above can be inspected for-/+ rapamycin conditions in Figure 23. The arrow indicates the initial “INM-
rim” formation. Scale bar: 20 µm. 
 
Generally, all above mentioned proteins were detected at the INM and showing a formation of a 
GFP-rim at the nuclear periphery accompanied by a reduction of GFP-signal inside the nucleus 
(Figure 23). The percentage of cells not responding at all to rapamycin treatment varied between 
the different constructs. 
Further it could be seen that the extent to which the EGFP2-GST-NLS-FKBP12 reporter protein-
recruitment to the nuclear periphery occurred, differed a lot between the investigated proteins. 
For LAP2β a very distinct FKBP12-rim staining was observed and already after 25 seconds the first 
“rims” appeared to be visible. Similar to LAP2β, a shift in FKBP12-reporter localization to the INM 
was detectable for PTP1B after 20 seconds upon addition of rapamycin. An additional 





at certain spots throughout the NE. The detected rim was not as homogenous as observed for 
emerin or LAP2β. 
According to the experiment, VAPB can be localized to the INM as well, but shows an overall less 
efficient recruitment of FKBP12 to the NE. GFP-rims were already visible after 30 seconds.  
LRRC59 shows a change in distribution for GFP-FKBP12 after about 40 seconds upon rapamycin 
treatment in some cells, although in general more residual GFP-reporter can be observed 
compared to LAP2β or emerin. Imaging LEMD1 revealed as well a localization to the INM, even 
though the “nuclear rim” seemed to be thinner and not as prominent as for strongly reacting 
proteins like emerin. The reaction time until first rims were visible for LEMD1 was about                     
2 minutes, which is compared to all other proteins quite long.  
 
Using this in vitro-kinetics rapamycin assays to follow changes in GFP-FKBP12 distribution in a 
real-time, it was possible to confirm all selected proteins, including emerin, LAP2β, PTP1B, 
LRRC59, VAPB and LEMD1 to be present at the INM. Most of them have been implicated to reside 
at the INM at least partially by literature and were reported to localize to the ER, which was as 
well seen by looking at the localization pattern of the mCherry-tagged protein itself. In future, 
other proteins can be easily examined for INM-localization by performing this assay, but it has to 
be said that the assay only allows a qualitative statement about INM localization due to the 










Figure 23: Emerin, LAP2β, PTP1B, LRRC59, VAPB and LEMD1 can be found at the INM using an in vitro- 
kinetics rapamycin assay. HeLa cells were transfected with the mCherry-FRB-versions of emerin, LAP2β, 
PTP1B, LRRC59, VAPB and LEMD1 together with the EGFP2-GST-NLS-FKBP12 reporter for 48 h and the in 
vitro-kinetics rapamycin assay was performed. Cells were imaged prior to rapamycin addition (-rap) and 
several minutes after rapamycin treatment (+rap) until no further change in FKBP12 distribution could be 
detected anymore. The time indicated in seconds refers to the duration until first GFP-FKBP12 rims 
appeared to be visible for this specific experiment. Arrows indicate cells responding on rapamycin 
treatment, indicated by a nuclear “GFP-rim”. Scale bars: 15 µm. 
 
3.2.2.2.1. Confirmation of INM localization of emerin using the in vitro 
rapamycin assay 
Emerin was used as a model protein to establish and optimize the rapamycin-assay. Therefore, 
mCherry-FRB-emerin and HA-FRB-emerin were cloned (Table 2) to find the optimal design for the 
FRB-containing protein, as a counterpart a soluble, NLS-containing fluorescent FKBP12 reporter 
protein was created. Plasmids coding for the larger version EGFP2-GST-NLS-FKBP12 and a smaller 
protein EGFP2-NLS-FKBP12 were used for the co-transfections with the FRB-containing protein in 
HeLa P4 cells.  
The in vitro rapamycin assay showed a clear difference in localization for both the mCherry-FRB- 
and HA-FRB-emerin versions before and after treatment with rapamycin at a concentration of 
500 nM for 10 minutes on ice. Instead of being homogenously distributed in the nucleoplasm, 
the soluble reporter EGFP2-GST-NLS-FKBP12 was found at the nuclear periphery upon addition 
of the drug (Figure 24). For both emerin versions, their FRB-cassettes were accessible at the INM 
and could bind to the soluble FKBP12 reporter upon rapamycin addition. The signal detected for 
the FKBP12-protein was observed as a green “nuclear rim” after rapamycin treatment, whereas 
it was homogenously localized inside the nucleus without rapamycin treatment (Figure 24). This 
indicates that the “nuclear rims” seen for mCherry-FRB- or HA-FRB-emerin are indeed “INM rims” 
and the proteins are present at the INM. For mCherry-FRB-emerin the rapamycin assay was 
performed with two different kinds of FKBP12 reporters (EGFP2-GST-NLS-FKBP12 and EGFP2-
NLS-FKBP12), which both showed a very similar extent of responsiveness and nuclear periphery 
localization upon rapamycin treatment (Figure 24, upper panels). 
In this experiment, additionally WRB-FRB-HA was investigated for a possible INM localization. 
WRB, the ER-receptor of the TRC40-membrane insertion mode, was reported to mainly localize 
at the ER (Vilardi et al., 2011) and to our knowledge was not shown or implicated to localize to 
the INM. In the assay, WRB-FRB-HA cells did not show any other distribution for the green 
reporter before and after applying the rapamycin solution (Figure 24, lower panel). 
Corresponding with the reports about WRB until now, this result indicated WRB not being 
detectable at the INM with this assay. According to a predicted topology model for WRB inside 
the ER membrane (Vilardi et al., 2011), the FRB-cassette was positioned together with the HA-
tag on the C-terminus of WRB in case of the WRB-FRB-HA construct. Therefore, FRB should be 
facing the cytoplasmic side as seen in other studies for example in case of a WRB-CFP expression 
construct (Vilardi et al., 2011). The observation of WRB not being present at the INM or at least 
not being visually detectable within the context of the rapamycin assay, WRB was used as a 





In addition to using WRB as a negative control, the INM protein LBR was tested besides emerin 
as a possible positive control. LBR, as a typical multi-spanning INM-protein, was transfected as 
mCherry-FRB-LBR together with a EGFP2-GST-NLS-FKBP12 reporter protein. As expected, the 
FKBP12 was observed to form a nuclear “GFP-rim” at the INM upon rapamycin addition (data not 
shown). 
To further show that dimerization of the FRB cassette with an FKBP12 construct is not restricted 
to the inside of the nucleus, a short GFP-FKBP12 reporter was expressed. Its localization was 
observed all over the cell, present inside as well as outside of the nucleus (Figure 25, right panel, 
-rap). When co-expressed with mCherry-FRB-emerin and treated with rapamycin, for this GFP-
FKBP12 reporter a “GFP-nuclear-rim” was found, but also a ER-like pattern was observed on the 
cytoplasmic side for the green reporter. It is plausible to obtain such a pattern on the cytoplasmic 
side, because mCherry-FRB-emerin localizes as well to the ER and binding of the FKBP12 cassette 
should be possible at this compartment (Figure 25, right panel, +rap). 
Furthermore, the localization of mCherry-FRB-emerin was tested in an in vivo-rapamycin 
approach using U2OS cells stably expressing the EGFP2-GST-NLS-FKBP12 reporter protein 
(Appendix, Supplementary figure 1). As expected, the GFP-FKBP12 reporter shifted to the nuclear 
periphery upon addition of rapamycin implying emerin to be present at the INM (Appendix, 
Supplementary figure 2). In the light of this assay performed in vivo, it was repeatedly noted that 
many cells showed additionally to the nuclear distribution a cytoplasmic localization of the 
FKBP12-NLS containing reporter. Thus, it cannot be excluded that the FKBP12 reporter had bound 
to the FRB-cassette of mCherry-FRB-emerin, which localized as well at the ER/ONM. 
This experiment illustrated again that the rapamycin assay performed in living cells is a relatively 
simple and quick way to gain a first impression, whether a protein can be localized at the INM. 
Digitonin permeabilization should be considered as cells sometimes display a considerable 
amount of FKBP12 reporter outside the nucleus. As a consequence of this, the cytoplasmic 
FKBP12 cassette can also bind to proteins localized at the ER or ONM as shown for the short 
FKBP12-reporter mentioned above (Figure 25). A “false positive” nuclear rim pattern of the 
FKBP12 could not be excluded. With respect to these observations, the in vitro-version of the 
rapamycin assay using permeabilized cells, can be seen as the more reliable type of assay and 
was primarily carried out. 
Altogether, mCherry-FRB-emerin was also shown to localize to the INM using the time-saving in 
vitro-version of the rapamycin assay. Further, the ER-receptor WRB was tested for a possible INM 
localization, but was not detected at the INM in agreement with its functions reported in 
literature. WRB-FRB-HA was therefore used as a negative control for INM-localization. In contrast 
to that, a second positive control examined was the multi-spanning protein LBR, which showed 
indeed a localization at the INM, but was not regularly used due to a very low transfection rate 
and low expression in cells (Figure 26). Moreover, the functionality of the FRB-FKBP12 
dimerization system was demonstrated to occur outside the nuclear compartment as well with 
a reporter, that was recruited to an FRB-protein at the ER membrane. 
In summary, for every new protein investigated in the rapamycin assay, emerin, as an established 
INM protein (Manilal, 1996; Yorifuji et al., 1997), was used as a positive control to compare the 
efficiency of the FKBP12 recruitment to the INM. Based on the rapamycin assays with emerin, 
the newly established rapamycin assay was demonstrated to be a system, which can be 
performed in its in vitro-version to obtain valuable information about a localization of a protein 










Figure 24: In vitro rapamycin-based INM-localization assay for emerin and WRB. HeLa cells were 
transfected with either mCherry- or HA-FRB-emerin and WRB-FRB-HA and a GFP-FKBP12 reporter protein 
for 24 h and the rapamycin assay was carried out as in the in vitro-version (see section 2.2.4.2.2). Cells 
were either untreated (-rap) or 500 nM rapamycin (+rap) was added for 10 minutes. Proteins were either 
detected by their mCherry-tag or an immunostaining was performed using an anti-HA antibody. Arrows 




Figure 25: A short, soluble FKBP12 reporter is functional in other compartments than the nucleus and 
can bind the ER-fraction of mCherry-FRB-emerin. HeLa P4 cells were transfected with mCherry-FRB-
emerin and either EGFP2-GST-NLS-FKBP12 or a short version EGFP-FKBP12 for comparison of localization. 
An in vitro rapamycin experiment was performed. Cells were either untreated (-rap) or 200 nM rapamycin 
(+rap) was added for 10 minutes. Arrows indicate the FKBP12 reporter binding at the ER.                               






3.2.2.2.1. Alternative FKBP12 reporters can be used to determine the 
localization of a protein to the INM 
Additionally, to the standard EGFP2-GST-NLS-FKBP12 reporter, alternative FKBP12 constructs 
(Table 2) were tested in the rapamycin assay in the following section during the optimization 
process of the rapamycin assay. As a standard FKBP12 reporter, a long version containing EGFP2-
GST-NLS-FKBP12 was used. For this construct a predominant nuclear localization was observed, 
but also a fraction was observed to be present in the cytoplasm probably due to its synthesis 
there. In the in vitro performed rapamycin assays using digitonin-permeabilized cells, this 
cytoplasmic background fluorescence of the GFP-FKBP12 reporter was eradicated by 
permeabilization followed by several washing steps. Nonetheless two alternative FKBP12-
reporter proteins were examined for a more distinct localization and reactivity when used for the 
rapamycin assay.  
 
An EGFP2-GST-M9-FKBP12 was used as it contains a M9 non-classical NLS (section 1.1.2), which 
can be recognized by transportin (Pollard et al., 1996). The import therefore would be facilitated 
not by the classical transport receptors of the importin β family. The M9-FKBP12 was tested in 
combination with emerin, LAP2β and PTP1B. No difference between the M9-FKBP12 (Figure 26, 
left column, -rap) compared to the standard NLS-FKBP12 reporter (Figure 23, -rap) localization 
per se was observed in permeabilized cells looking at conditions without rapamycin, both 
displayed a homogenous nucleoplasmic localization. When the M9-FKBP12 was used in 
combination with an mCherry-tagged protein, a recruitment of FKBP12 to the nuclear periphery 
could be observed to the same extent as for the NLS-FKBP12 reporter. Therefore, M9-FKBP12 
can be recommended for use in future rapamycin assays as well. 
 
The second FKBP12 version tested, was an FKBP12-Histone1-GFP (FKBP12-H1-GFP) reporter 
protein. Histone H10 (Doenecke & Tonjes, 1986) was used, because of its known nuclear 
localization, assuming it to be retained more in the nucleus than the soluble FKBP12 versions 
used before. The localization pattern observed without any treatment was nuclear, but in 
contrast to the previous described FKBP12 reporter very inhomogeneous with pronounced 
nucleolar localization. When performing a rapamycin assay for this specific construct together 
with cells co-transfected with emerin, only a slight change in the localization of the Histone-
FKBP12 to the nuclear rim could be observed (Figure 26, right upper panel, arrows). For LAP2β 
and PTP1B a barely detectable change in fluorescence distribution could be observed as well. The 
rapamycin effect was most visible, when looking at the prominent nucleolar localization (-rap), 
which disappeared upon rapamycin treatment (+rap) observed for example with mCherry-FRB-
PTP1B (Figure 26,+rap, circle). 
 
Testing the alternative FKBP12-reporter proteins showed that the EGFP2-GST-M9-FKBP12 can be 
used as a standard, nuclear localized FKBP12 reporter and showed as well a similar extent of 
reactivity and change in distribution upon rapamycin addition as the NLS-containing FKBP12 did. 
In contrast to the EGFP2-GST-M9-FKBP12 reporter, the FKBP12-Histone1-GFP seemed to localize 
to the nucleus, but due to an initial inhomogeneous localization inside the nucleus (Figure 26, 
right panel, -rap), it is not useful for the detection of a protein at the INM, which is the main 










Figure 26: Alternative FKBP12-GFP reporter proteins are functional in the rapamycin-assay.                     
HeLa P4 cells were transfected with the alternative FKBP12 constructs (GFP2-GST-M9-FKBP12 or FKBP12-
Histone1-GFP) for 24 h and used in an in vitro-kinetics rapamycin assay. Arrows indicate cells responding 
on rapamycin treatment, indicated by a “GFP-rim”. Scale bars: 15 µm.                                                                                                                                                                             
* The polytopic INM-protein LBR serves as an alternative positive control. Independent images for +/- 
rapamycin are shown for mCherry-FRB-LBR due to the fact that very little transfected cells were found 
and attempts to initially select cells (as it is done in the in vitro-kinetics rapamycin assay), which in the end 
responded upon rapamycin treatment, failed. 
 
3.3. Characterization of INM-trafficking of emerin 
Among all studied putative TA-proteins, emerin was confirmed to be a TA-protein and was by far 
the protein with the most distinct results for membrane integration (section 3.1.2.2) as well as in 
INM-localization experiments (sections 3.2.1, 3.2.2.2.1). As a consequence, it was selected for 
further characterization of the transport process to the INM (Pfaff et al., 2016). 
First of all, the influence of the TRC40-machinery on nuclear envelope targeting of emerin was 
studied (section 3.3.1). Along these lines, emerin was examined for its interactions with 
components of the TRC40-mediated route in an in situ approach (section 3.3.2). Because the 
localization of emerin at the INM was reported to be affected by mutations in emerin and 
especially in or close to its transmembrane domain, a set of emerin mutations associated with 
the neuromuscular disease Emery-Dreifuss muscular dystrophy, was selected for further 
investigation (3.3.3.1). These emerin mutants were first biochemically characterized for their 
TRC40-dependent membrane integration (3.3.3.2) and secondly investigated for their targeting 
to the INM by using microcopy-based approaches (3.3.3.3). 
 
3.3.1. Depletion of TRC40 and WRB reduces the levels of emerin at the NE 
A knockdown of the key protein of the post-translational protein insertion pathway, TRC40 was 
performed and emerin was examined on protein level as well as by immunostaining and analyzed 
by confocal microscopy. 
After a knockdown (for method description see section 2.2.3.4.1) for TRC40 was performed with 
different siRNAs (section 2.1.8 ), a reduction of about 95% (see Figure 28; B) was observed on 
protein level and the endogenous TRC40 pattern was nearly completely abolished on the cellular 
level (Figure 27, upper panel). The total protein levels of emerin remained unchanged in TRC40-
depleted cells (Figure 28, A). In contrast to this, indirect immunofluorescence revealed an effect 
on emerin localization resulting in a loss of NE fluorescence intensity (Figure 27, upper panel 2nd 
column) compared to cells treated with a non-targeting control siRNA (nt siRNA, see 2.1.8). As a 
negative control, the INM-protein LBR was used. It is a polytopic membrane protein and 
predicted to insert co-translationally into membranes (Laba et al., 2014). LBR protein levels and 
localization remained unaltered by TRC40 knockdown, as expected (Figure 27, upper right;  
Figure 28). 
In addition to the TRC40 depletion, as the soluble part of the post-translational machinery, the 
membrane-receptor WRB was downregulated (Yamamoto and Sakisaka, 2012). After the 
downregulation of WRB was performed, about 90% decrease on protein level was detected via 





the lack of a reliable WRB antibody. Emerin localization was reduced at the nuclear envelope and 
the rim staining occurred to be not as continuous and strong compared to control siRNA treated 
emerin cells (Figure 27, B) and as well the protein level for emerin was not significantly changed 
as seen with a TRC40 knockdown (Figure 28, D). The oligosaccharyltransferase STT3B was 
unaffected in immunofluorescence staining, because it wasproposed to use the SRP-Sec61-
dependent co-translational membrane insertion pathway for membrane insertion instead 
(Figure 27, B). Surprisingly, the downregulation of WRB resulted in a significant reduction of 
TRC40 both by western blot detection and by immunofluorescence staining (Figure 27, upper 
left; Figure 28). Almost entirely the localization of TRC40 was abolished similar to the pattern 
observed with a TRC40 knockdown.  
In summary, this RNAi studies strongly indicated that the nuclear envelope localization of emerin 
depends on the TRC40-pathway. For the first time in this work an influence of the TRC40-pathway 
on the targeting of emerin was shown in vivo. 
 
 
Figure 27: Downregulation of TRC40 and WRB affect the localization of emerin at the NE. HeLa P4 cells 
were transfected with a siRNA against TRC40 (siTRC40, 40 nM) (A) and WRB (siWRB; 10 nM) (B) for 96 h. 
The localization of endogenous TRC40, emerin, LBR and STT3B was analyzed in knockdown and control 






Figure 28: Emerin protein levels are unaffected by downregulation of TRC40 or WRB. RNAi mediated 
knockdown of either TRC40 (A, B) or WRB (C, D) was performed for 96 h at 4 different concentrations      
(5, 10, 20, 40 nM) in HeLa P4 cells as indicated. (A) Representative western blot of TRC40 RNAi (5 nM) is 
shown. (C) Western blot of WRB, emerin and TRC40 protein levels for different siRNA concentrations in 
WRB knockdown cells is shown (B, D) Quantification of protein levels for either TRC40, emerin and LBR in 
TRC40 knockdown cells or WRB, emerin and TRC40 in WRB knockdown cells. Protein levels of control       
(nt siRNA) treated cells compared to knockdown cells are shown and protein levels were normalized 
against GAPDH (loading control). Analysis was done by SDS-PAGE followed by western blotting using the 
indicated antibodies. Error bars indicate the standard deviation of the mean protein levels of 4 different 





3.3.2. Emerin interacts with TRC40 in an in situ approach 
The results obtained from the RNAi experiments in the previous section not only confirm the 
dependency of emerin on the TRC40 mechanism for ER membrane integration, but strongly 
suggest an influence of the TRC40 system on the localization of emerin at the INM in vivo. It most 
probably can be seen as a crucial process on its way to the INM. 
A proximity ligation assay (PLA) (Fredriksson et al., 2002) was therefore used to analyze, if an 
interaction of emerin with TRC40 can be detected in situ. 
The experiment was performed by Cara Jamieson and details as well as further controls included 
in the experiment are reported in Pfaff et al., 2016. In this PLA experiment, TRC40-myc was 
transfected in HeLa P4 cells. The single antibodies used for detection of TRC40-myc, emerin, 
Sec61β and STT3B were pre-tested and incubated with PLA-probes to exclude unspecific 
interaction for the assay (Figure 29, A). In this assay, Sec61β served as a positive control for TRC40 
interaction (Favaloro et al., 2008; Stefanovic and Hegde, 2007) and the oligosaccharyltransferase 
STT3B was supposed to use an SRP-dependent ER insertion mechanism and was thus being used 
as a negative control. To substantiate the signal specificity of emerin interactions, the well-known 
interaction partner lamin A was tested for its interaction with emerin (data not shown,                   
see (Pfaff et al., 2016)). 
When the proximity ligation reactions were performed for emerin, Sec61β and STT3B together 
in cells, which overexpressed TRC40-myc (Figure 29, A, right panel), for all of the three proteins 
interaction sites were observed (red dots). The principle behind this technique is, that proteins 
which are in close proximity (30-40 nm apart), can be ligated and interaction spots can be 
detected due to the fact that light is emitted, when a rolling circle DNA amplification was initiated 
by ligation of the PLA probes bound to the primary antibodies against the specific proteins.        
Red dots can be counted and the specific position of interaction is displayed in situ. 
For the positive control substrate Sec61β, interactions with TRC40-myc were found in high 
number (about 50 dots per cell) (Figure 29, B) as expected. Contrary to this, very few dots per 
cell were counted for STT3B. Within these two extreme numbers of dots emerin-TRC40 
interactions were observed with approximately 12 dots per cell. The localization of the emerin-
TRC40 interaction was mainly observed outside the nucleus, which would correspond with the 
subcellular localization of TRC40 reported together with its function in the cytoplasm of carrying 
out protein delivery to the ER membrane. 
In summary, it can be stated that the proximity ligation assay revealed an interaction of 
endogenous emerin and overexpressed TRC40-myc in situ. This strongly supports the in vivo 
findings, which showed that the knockdown of TRC40 resulted in a reduction of emerin at its 
destination, the INM. Furthermore, PLA allowed the visualization of the place of interaction, 






Figure 29: Emerin interacts with TRC40-myc in situ (performed by Cara Jamieson (see Pfaff et al., 2016)). 
(A) Single PLA antibody controls for labelling of binding partners of interest are shown (A, left panel). They 
were pre-tested to determine specific dilutions and to exclude unspecific interactions. PLA experiments 
with transfected TRC40-myc were performed for emerin and the control proteins Sec61β, STT3B to detect 
possible interactions (A, right panel). Both antibodies corresponding to the potential interaction partners 
were used accordingly and incubated with the appropriate PLA probes. Each dot represents a single 
protein-protein interaction. Nuclei were stained with DAPI. Scale bars: 10 µm. (B) Dot plot of PLA 





3.3.3. Investigation of effect of changes in the C-terminal portion of emerin on targeting 
to the INM 
After having illustrated the importance of the TRC40-system for the membrane insertion and 
targeting of emerin in vitro (section 3.1.2.2.1.2) and also in a more physiological approach for 
living cells (section 3.3.1), the C-terminal portion of emerin, which is required for membrane 
anchoring and integration, was examined. This single transmembrane segment at the very C-
terminus was specifically looked at in terms of the process of trafficking to the INM in considering 
the characteristics of this C-terminal portion of emerin like the hydrophobicity (Table 1). Two 
major localizations for emerin were reported. It is mainly localized at the INM, but also a defined 
role for emerin at the ER was reported (Salpingidou et al., 2007). Considering that C-terminal 
added protein-tags can affect the post-translational membrane insertion and localization 
mechanism of emerin, the focus of studying the influence of the C-terminus was to possibly 
detect differences for NE-targeting by changes on the amino acid level. Related to this, there 
were reports about several changes in the TMD region of emerin associated with the 
neuromuscular disease Emery-Dreifuss muscular dystrophy (EDMD) (Emery and Dreifuss, 1966; 
Emery, 1989). Accordingly, a selection of mutations related to EDMD was analyzed for their 
membrane insertion, subcellular distribution and targeting to the INM in the following sections. 
 
3.3.3.1. Characteristics of the selected emerin mutant variants 
For some emerin mutations associated with EDMD a changed subcellular distribution compared 
to wild-type emerin has been reported. Analysis of these mutants could therefore provide a 
possibility to gain more insight in emerin targeting  
All emerin mutants that were selected for characterization of their localization and distribution 
at the INM (Figure 30, A) have been reported to be involved in Emery-Dreifuss muscular 
dystrophy and  range from single point mutations to mutants almost entirely lacking the TMD 
(Yates, JR et al., 1999) (Manilal et al., 1998; Nagano et al., 1996; Mora et al., 1997; Nigro et al., 
1995; Ognibene et al., 1999; Vohanka et al., 2001; Ellis et al., 1999; Yates, JR et al., 1999; Tarpey 
et al., 2009). These emerin mutants were chosen based on the presence of a mutation in the C-
terminal portion of the protein, which harbors the transmembrane segment. As the 
hydrophobicity of a TMD is known to play a crucial role in membrane integration of TA-proteins 
(Rabu et al., 2008; Rabu et al., 2009; Johnson et al., 2013), the hydrophobicity was calculated for 
each mutant (Figure 30, B). 
Changes in the hydrophobicity or complete deletion of the TMD is expected to have drastic 
effects on the membrane localization of a protein. Therefore, the mutant Trp226* (Nagano et 
al., 1996) completely lacking the TMD, mutant ΔVal236-Phe241 (Manilal, 1999), where half of 
the TMD is missing and the mutants Leu225Arg-FS (Yates, JR et al., 1999) and Phe240His-FS 
(Vohanka et al., 2001), which contain a frame-shift were selected. For the mutant ΔVal236-
Phe241 where only half of the TMD is still present a drastic reduction in hydrophobicity of the 
TMD was found. To test whether the regions flanking the TMD can also have an effect on proper 
membrane targeting, the mutants Pro183Thr and Pro183His (Ellis et al., 1999; Yates, JR et al., 
1999) were chosen as the mutations are located upstream of the transmembrane domain. The 
Pro183Thr mutant was shown to have a decreased binding affinity for SUN, another INM-





of important binding partners (Lamin and BAF) at the INM to be unaffected (Haraguchi et al., 
2004). Due to that, this particular region might be important for EDMD not only because of 
localization defects, but in terms of proper function of emerin at the INM. Furthermore, the self-
assembly function of emerin was reported to be influenced for both mutants (Herrada et al., 
2015). Finally, the mutant Gln228His (Tarpey et al., 2009) was selected, as it contains only one 
mutation in the TMD region and shows a similar hydrophobicity of the TMD as wild-type emerin. 
Potentially the glutamine at position 228 is a key residue for interaction with components of the 
TRC40 pathway. This diverse set of emerin mutations, which show differences for their predicted 
hydrophobicity, was used to analyze the membrane insertion of emerin in the next chapter. 
 
 
Figure 30: Schematic view of emerin mutant variants and the predicted hydrophobicity of their C-
terminal region. (A) Schematic drawing of emerin WT (254 aa) compared to mutant versions. The TMD 
(red), as well as the position of the mutation within the C-terminal sequence is indicated (bar or 
highlighted). (B) A hydropathy plot of the C-terminal portion of emerin (aa 170-254) is shown for all emerin 
mutants. Hydropathy (data were calculated by using Membrane Protein Explorer (MPEX) (Snider et al., 





3.3.3.2. TRC40-dependent membrane insertion of emerin mutants 
The membrane insertion of wild type emerin was shown to strongly depend on the post-
translational TRC40-mediated mechanism (chapters 3.1.2.2.1, 3.1.2.3). Further RNAi 
experiments in vivo demonstrated that targeting of emerin to the INM was affected upon knock-
down of TRC40. (section 3.3.1). In the view of these results, the emerin mutants were examined 
for their TRC40-dependent membrane insertion in vitro. 
 
3.3.3.2.1. Purification of emerin mutants in a complex with TRC40 
For membrane insertion experiments, which are performed in the next section, the described 
emerin mutants were co-expressed with TRC40 and purified in bacteria as it was already shown 
in section 3.1.2.2.1.1. The specific purification experiment shown was performed by Jhon Rivera. 
The subset of emerin mutants (as HZZ-“emerin mutant”-opsin version) was purified in a complex 
with MBP-TRC40 (Figure 31). For the point mutation variants Pro183Thr, Pro183His and 
Gln228His a moderate amount of protein compared to the wild type was co-purified, whereas 
for the frame-shift mutant Leu235Arg-FS hardly any protein was detectable. The mutants 
Trp226* and ΔVal236-Phe241, were assumed to have a low probability for membrane-
association based on their lower hydrophobicity (Figure 30, B) and indeed a reduced binding to 
TRC40 was detected. For the emerin mutant Phe240His-FS, a reduced hydrophobicity was 
calculated and therefore an impaired binding to TRC40 and the low amounts seen for the co-
expression are not surprising (Figure 31). According to the calculated hydrophobicity and the 
available information about properties of the individual mutants, the observed binding of TRC40 
to the mutated emerin versions was as expected. 
 
 
Figure 31: Co-purification of emerin mutants with TRC40 (performed by Jhon Rivera, see Pfaff et al., 
2016). Comparable amounts of eluted fractions of the indicated emerin mutants in complex with TRC40 
are shown. Detection of co-purified emerin mutants was performed by SDS-PAGE, followed by western 
blotting using an anti-opsin antibody. 
 
3.3.3.2.2. Membrane integration of emerin mutants in RM 
The co-purification of emerin mutants with TRC40, showed that almost all selected mutants were 
able to bind to the TRC40, which is involved in the delivery of the proteins to the ER membrane. 
To examine not only the possible binding of TRC40 to emerin mutants, membrane insertion 





In this membrane integration assay rough microsomes as an ER-derived membrane source were 
used (experiment was performed by Jhon Rivera). The aim of the experiment was to analyze the 
membrane integration competence of these emerin versions. 
In general, all emerin mutants tested resulted in a reduced insertion of the proteins into rough 
microsomes compared to wild type emerin (Figure 32). It should be mentioned that the emerin 
mutants Leu235Arg-FS and Trp226* were not studied for their membrane insertion due to the 
low amounts of protein obtained in the purification, anyway the Trp226* mutant probably would 
not be able to insert into membranes due to the absence of the TMD. The proline mutations 
upstream of the transmembrane domain showed a reduction of glycosylated protein of about 
40% compared to the wild type. A more severe effect on membrane integration ability was found 
for the ΔVal236-Phe241 (approx. 70% decrease) and the Phe240His-FS variant (> 90% decrease), 
which corresponded to the low efficiency in binding to TRC40 demonstrated in the co-expression 
experiment above. With respect to the results obtained by this experiment, all mutants studied 























Figure 32: Emerin mutants show an altered membrane integration (performed by Jhon Rivera, see Pfaff 
et al., 2016). (A) Membrane insertion reactions were performed in rough microsomes using the purified 
protein complexes for the indicated HZZ-emerin-opsin variants according to the protocol 2.2.2.6.1. Trp226 
and Leu225Arg-FS mutants, which do not contain a TMD, were excluded due to low protein amounts 
obtained by purification. Detection of membrane integrated protein was performed by SDS-PAGE, 
followed by western blotting using an anti-opsin antibody. “opsinG” indicates the higher MW, 
glycosylated and membrane integrated form of the protein. (B) Quantification of the membrane insertion 
results in (A). Error bars indicate the standard deviation of four independent experiments.                    





3.3.3.3. Targeting of emerin mutants to the NE 
 
3.3.3.3.1. Morphology and localization of emerin mutants within cells 
As all purified emerin mutant versions showed reduced binding to TRC40 and also defects in the 
efficiency of post-translational insertion into RM membranes, the next step was, to investigate a 
possible effect of the altered membrane insertion on localization of the protein inside the cell. In 
particular, the INM localization was to be addressed by performing differential permeabilization 
assays. As shown for other membrane proteins in section 3.2.1, the subcellular localization of 
wild type HA-emerin compared to emerin mutants was examined. HeLa P4 cells were transfected 
with plasmids coding for HA-emerin or mutant variants. After two days of transfection the cells 
were processed according to the protocol (section 2.2.4.2.1). In this experiment digitonin 
selectively permeabilizes the plasma membrane and only allows detection of proteins within 
compartments facing the cytoplasm, whereas Triton X-100 permeabilizes all cellular membranes 
and proteins present in the nuclear interior, can be accessed as well and visualized. 
In this experiment, endogenous laminA/C was immunostained as a control. Digitonin-treated 
cells did not show any lamin A/C signal, but with Triton X-100 permeabilization the nuclear 
membrane was perforated as well and antibodies were able to access the INM (Figure 33, upper 
panel). 
The localization pattern obtained for wild type HA-emerin with digitonin permeabilization was 
predominantly showing ER and a slight nuclear rim (Figure 33), whereas using Triton X-100, a 
pronounced nuclear rim staining could be observed and hardly any ER was detectable. This NE 
envelope staining can be seen as a prominent localization of emerin to the INM, which would not 
be accessible with digitonin permeabilization only. Compared to the wild type, for mutant 
Pro183Thr and Pro183His as well as for Gln228His a similar cellular distribution could be observed 
(Figure 33). The Pro183Thr/His variants showed additional dots around the ER, which could not 
be seen for emerin wild type. 
Further, for the TMD lacking Trp226* variant, the frame-shift mutant Leu225Arg-FS and variant 
with a partially deleted TMD ΔVal236-Phe241 no nuclear envelope localization was observed 
using Triton X-100 permeabilization. These three mutants were distributed inside and outside 
the nucleus, with no clear localization to a distinct cellular compartment (Figure 33). 
Surprisingly, the frame shift variant Phe240His-FS, which bears the mutation at the very C-
terminal part of the protein, clearly showed a membrane localization with both permeabilization 
methods. With Triton X-100 permeabilization a more distinct nuclear rim localization and less ER 
could be observed (Figure 33, most bottom panel). Taken together, compared to the NE-rim 
localization of emerin wild type, also the emerin variants Pro183Thr, Pro183His, Gln228His and 
Phe240His-FS seemed to localize to the inner nuclear membrane, indicated by a nuclear rim. 
Against expectations from the membrane insertion assay, the Phe240His-FS was able to localize 
to the NE (INM) even though a weak insertion to the ER was demonstrated. Considering the 
results of the differential permeabilization assays, it can be concluded that certain emerin 
mutations, which affect the membrane integration at the ER, can also have a strong influence on 










Figure 33: Subcellular localization of emerin mutants. HeLa P4 cells were transfected with plasmids 
coding for HA-emerin variants for 24 h. Cells were differentially permeabilized with Triton X-100 or 
digitonin as indicated and subjected to indirect immunofluorescence. An anti-HA antibody was used for 
detection of the emerin variants. As a marker for the nuclear interior, endogenous lamin A/C was used. 
Scale bars: 15 µm. 
 
3.3.3.3.2. Mutations of emerin affect targeting to the INM 
In the previous chapter, the emerin mutants were analyzed for their subcellular distributions 
using a differential permeabilization approach. To substantiate the results obtained for a possible 
INM localization of several emerin mutants, the newly established in vitro rapamycin assay 
(section 3.2.2.1) was used. For other putative TA-INM proteins, this assay already provided 
valuable information about the localization at the INM. Consequently, the in vitro rapamycin 
assay was performed to test for an INM localization and to allow for differentiation of a possible 
ONM-rim. Emerin versions were cloned into the mCherry-FRB expression vector background. 
Cells were transfected with mCherry-FRB-“emerin mutant” together with the EGFP2-GST-NLS-
FKBP12 reporter protein. After the proteins were expressed, the rapamycin assay was performed 
in permeabilized HeLa cells. 
Indeed, it could be shown, that emerin point mutation variants (Pro183Thr, Pro183His, 
Gln228His) and the emerin Phe240His-FS mutant localize to the INM (Figure 34). This was 
observed by a shift of the GFP-FKBP12 reporter protein from a homogenous distribution (Figure 
34, -rap) to a concentrated “nuclear rim” localization upon rapamycin addition. Knowing that the 
rapamycin assay only allows qualitative statements, for the purpose of comparing the emerin 
wild type with the mutants for its efficiency in GFP-FKBP12 INM-“rim” formation, a semi-
quantitative analysis of nuceli positive for “rim”-formation was performed (Table 4). The 
Phe240His-FS protein only showed a slight GFP-reporter “rim” in some cells. This indicates a 
reduced efficiency of INM-targeting compared to emerin wild type. In opposition to the previous 
mentioned mutants, the deletion mutations ΔVal236-Phe241, Trp226* and the frame-shift 
version Leu225Arg-FS showed no change in GFP-FKBP12 localization (Figure 34). The ΔVal236-
Phe241 mutant was found in aggregates throughout the cell and according to this, no 
recruitment of FKBP12 to the INM upon rapamycin treatment was anticipated. 
As expected from the distribution of Leu225Arg-FS all over the cell with a pronounced 
nucleoplasmic localization in the differential permeabilization (section 3.3.3.3.1), the absence of 
this mutant at the INM was not surprising. Localization inside the nucleus for constructs lacking 
the TMD has previously been reported by Tsuchiya et al. (1999).  
Studying the EDMD-associated emerin mutants with the in vitro rapamycin assay, the targeting 
of several mutants (Pro183Thr, Pro183His, Gln228His, Phe240His-FS) to the INM as already 
observed in the differential permeabilization assay could be confirmed. Nevertheless, the 
efficiency of INM-targeting varied a lot between the examined mutants. This assay clearly 
showed, that the final INM-targeting is impaired for example in the Phe240His-FS mutant      
(Table 4, +), even though a prominent nuclear rim staining was observed in the differential 
permeabilization assay with both detergents (Figure 33). Therefore, it is important to 
discriminate between an observed “nuclear rim” staining and correct targeting to the INM, which 





Taken together, the investigation of emerin mutants in comparison with the wild type protein 
provides valuable insights for the targeting process of emerin to the INM. Differences in the 
efficiency of INM-targeting might rely on the C-terminal part of emerin and most probably 
distinct regions within the TMD. The reduced INM-targeting efficiency revealed by several 
mutants might therefore be connected to a defective transport process or a reduced retention 










Figure 34: Localization of emerin mutants revealed by in vitro rapamycin assay.                                                   
HeLa P4 cells were transfected with emerin wild type or Pro183Thr, Pro183His, Leu235Arg-FS, Trp226*, 
Gln228His, ΔVal236-Phe241 and Phe240His-FS emerin mutants together with the EGFP2-GST-NLS-FKBP12 
reporter. The cells were treated according to the in vitro rapamycin assay protocol (2.2.4.2.2). A change 
in localization of the GFP-reporter inside the nucleus can be observed, when cells are treated with 
rapamycin (+rap) compared to non-treated cells (- rap) and the particular mutant is present at the INM. 
Arrows indicate nuclei of cells, which showed the typical altered GFP-reporter distribution.                           





Table 4: Semi-quantitative analysis of the rapamycin-effect on EGFP2–GST–NLS-FKBP12. +++, clear rim 
in essentially all cells; ++, visible rim in most cells but residual nuclear signal; +, visible rim in some cells, 
signal mostly nuclear; and −, no nuclear rim). Between 20 (Trp226*) to 100 cells (WT, Phe240His-FS) from 









The transport of proteins destined for the INM was studied in this work and the group of tail-
anchored proteins was depicted to examine the initial process of membrane insertion at the ER 
membrane. Furthermore, with emerin, a proposed TA-protein of the INM, as a model protein the 
targeting to the INM was characterized. On the basis of assays established for investigation of 
INM targeting of emerin, other putative TA-proteins of the INM were analyzed the same way. 
 
4.1. Membrane insertion mechanisms of putative INM-proteins 
In this work, a set of integral membrane proteins was studied with respect to their localization at 
the inner nuclear membrane. The first part of this study dealt with the insertion mechanism of a 
set of membrane proteins, which were chosen because of their single TMD close to the C-
terminus.  
Their role as putative tail-anchored proteins of the INM was investigated, using robust techniques 
for the analysis of post-translational membrane insertion of single-pass integral membrane 
proteins at the ER (Favaloro et al., 2010; Vilardi et al., 2011). 
As a general established place for insertion of membrane proteins into a lipid bilayer, the ER 
membrane plays an important role. For either mono-or multi-topic transmembrane proteins, the 
ER provides a first entry site into cellular membranes via co-or post-translational integration 
mechanisms (Rapoport, 1992; Kutay et al., 1993). 
To test the ability of a protein to integrate into an ER-derived membrane either rough 
microsomes or semi-permeabilized cells were used in combination with bacterially produced and 
purified protein complexes (see section 3.1.2). 
Alternatively, in vitro translated proteins were combined together with the ER-derived 
membranes for a membrane insertion reaction. The bacterial expression of TRC40-TA-protein 
complexes compared to the in vitro translated version has the advantage of producing much 
larger amounts of the integral membrane protein and therefore proteins could also be used for 
binding studies, where high amounts of protein are required. Furthermore, knowing the exact 
concentration of protein, as well as the ratio of TRC40 to TA-protein, allows for using 
standardized amounts for each integration reaction. By using the in vitro translated protein 
instead, the exact amount of protein translated in the reticulocyte lysate and further used for 
membrane integration is not known and can vary between different reactions. 
Another advantage of the pre-formed TA-protein-TRC40 complex is that the risk of aggregation, 
which membrane proteins are prone to, is reduced due to the binding and chaperone function 
of TRC40. On the other hand, due to this pre-formed co-purification together with TRC40, the 
examined protein is in a way forced to use the TRC40-pathway, which might not happen for some 
substrates in vivo. In contrast to this, the in vitro translated protein, together with rough 
microsomes offers a less biased approach to study the specific kind of post-translational insertion 
(TRC40-, chaperone or unassisted pathway).  
 
The membrane proteins emerin, LAP2β, VAPB and PTP1B were tested for their insertion potential 
in this work and in general were shown to follow a post-translational insertion mechanism, 





Previous tail-anchored protein studies, which dealt with the possible post-translational insertion 
mechanisms of different proteins, showed that the hydrophobicity of the transmembrane 
segment of a protein can be a crucial feature in determining the mode of insertion. With 
decreasing hydrophobicity of the TMD, a protein would more likely insert via an unassisted or 
chaperone-mediated pathway (Johnson et al., 2013; Rabu et al., 2008; Rabu et al., 2009). To 
determine the hydrophobicity of the investigated proteins the Membrane Protein Explorer 
(MPEX) tool was used for calculation by using the difference in the apparent Gibbs free energy 
(ΔG) (Hessa et al., 2007). The more negative a ΔG value is, the more hydrophobic a TMD of a 
protein of interest is predicted to be (Table 1). 
 
For emerin, a well-studied protein of the INM, an in vitro transcription/translation system using 
rabbit reticulocyte lysate was utilized. Emerin was observed to be integrated into rough 
microsomes. The integration was indicated by a shift in higher molecular weight due to 
glycosylation of the small opsin-tag attached to the carboxy-terminus of the protein. 
Furthermore, the membrane integration process of emerin seemed to be an energy- requiring 
step (Figure 10), which was reported to be crucial for other TA-proteins like synaptobrevin as well 
(Kutay et al., 1995). In addition, a bacterially co-expressed emerin construct in complex with 
TRC40 was shown to integrate in both rough microsomes and ER-membranes of semi-
permeabilized HeLa cells (Figure 14, Figure 15). Using degylcosylation by PNGaseF, we could 
verify that the shifted, higher molecular weight band of emerin was indeed based on an ER-
specific N-glycosylation (Figure 16). HZZ-Emerin-opsin was shown by the above-described assays 
to use a post-translational mechanism for insertion into the ER and it was strongly indicated to 
belong to the class of TA-proteins. Specifically, the TRC40-mediated pathway is involved in 
membrane-integration of emerin, because the short, inhibitory fragments of the ER-receptors 
WRB and CAML (WRBcc and CAML-N) (Vilardi et al., 2011; Yamamoto and Sakisaka, 2012) 
affected the membrane insertion of bacterially produced as well as in vitro translated emerin 
(Figure 15, Figure 10). The inhibition of membrane insertion of emerin was more efficient using 
the CAML-N fragment compared to WRBcc. This might be explained by the finding that the CAML 
to WRB ratio was found to be 5:1 in mammalian cells (Colombo et al., 2016). With respect to the 
different amounts of CAML and WRB, less of the CAML-N fragment might be required to severely 
affect the membrane integration or binding of the TRC40-emerin-complex to the receptor 
subunit. Concerning the hydrophobicity of the TMD, emerin is predicted to be even more 
hydrophobic than RAMP4, an established TRC40-substrate. Following the argumentation by 
Johnson et al. (2013), this would be another indication that emerin takes the TRC40- route for 
membrane insertion. 
 
LAP2β, a known INM-protein, was used due to its characteristic TMD and investigated as well.   
In vitro synthesized LAP2β could be integrated into rough microsomes, which was detected by a 
shift in MW (glycosylation of the opsin-tag) by using an anti-opsin antibody (Figure 11). The 
membrane integration of LAP2β into the ER occurs by a post-translational mode. LAP2β most 
probably uses the TRC40-pathway, because the hydrophobicity of the transmembrane segment 
is still moderately high compared to the TMD of the ER-TA-protein RAMP4 (Table 1). 
 
The protein VAPB is known to localize mainly to the ER and is proposed to be a TA-protein, 





translated VAPB was shown to integrate post-translationally into rough microsomal membranes 
(Figure 11, C & D). In this study, two different plasmids coding for VAPB were used for in vitro 
translation assays and subsequent insertion into RM. One was HZZ-VAPB-opsin and the other 
was VAPB-ops28, which has a longer, 19 aa opsin tag (Fasana et al., 2010; Brambillasca et al., 
2005), whereas the opsin-tag of HZZ-VAPB-opsin includes only 13 aa. 
The HZZ-VAPB-opsin translated in vitro, but after membrane insertion into RM, only a very faint 
band (red asterisk) of the higher MW and glycosylated form of VAPB could be detected (Figure 
11, C). Thus, VAPB-ops28 was used in insertion assays in parallel and surprisingly, a visible amount 
of integrated (shifted) VAPB-ops28 was detectable with the α-opsin antibody (ops28G, red 
asterisk). An explanation for the low efficiency in integration, indicated by glycosylation of the 
HZZ-VAPB-op construct, could be a conformational hindrance, which might not be given in the 
ops28 construct due to the six additional amino acids. To test whether the post-translational 
integration into RM is facilitated by the TRC40-pathway, VAPB-ops28 was translated in vitro and 
in addition to the standard insertion protocol in RM, different amounts of the short inhibitory 
fragments of the TRC40-pathway receptors, WRB and CAML, were added (Figure 10). 
Even when using high inhibitor concentrations of 10 µM MBP-WRBcc, no reduction of the 
glycosylated and therefore membrane-integrated VAPB-ops28 was observed. VAPB-ops28 seems 
to be unaffected by the TRC40-mediated integration of proteins. In agreement with this, Fasana 
et al. (2010) already had shown that VAPB is not able to insert into pure liposomes but instead 
into rat liver microsomes post-translationally. 
Taking the hydrophobicity of the TMD of VAPB into account, it was reported by Fasana et al. 
(2010) that VAPB has a moderately hydrophobic region and thus an ER integration via an assisted 
pathway was suggested. In conformity with this, VAPB harbors a less hydrophobic TMD 
compared to the segment of emerin (Table 1). 
 
The experiment with the short ER- membrane-receptor fragments VAPB-ops28 membrane 
integration showed an integration into the ER membrane independently of the TRC40-
mechanism (Figure 10). Further experiments, addressing a chaperone-mediated mode of 
integration like the Hsc70/Hsp40 route, would be needed to confirm an alternative assisted 
insertion mechanism for VAPB. Another fact pointing against a TRC40-involvement of the 
membrane insertion of VAPB is a structural feature of VAPB, the Major Sperm Protein (MSP) 
domain. 
At the amino-terminus of VAPB the 125 amino acids long MSP domain is located. It is named after 
an abundant C. elegans MSP protein and was reported to be cleaved in neuronal cells having a 
function in signaling (Deidda et al., 2014; Tsuda et al., 2008). This domain was reported to interact 
with proteins containing FFAT-motifs like oxysterol-binding proteins. Concomitantly, it was 
shown that VAPB can bind an FFAT-like motif of TRC40 via its MSP domain, but not its C-terminal 
TMD, even though it is a TA-protein (Baron et al., 2014). The binding of TRC40 to VAPB seems to 
be independent of a function in ER-membrane insertion and presumably fulfills another not yet 
identified function of a TRC40-VAPB complex. In the same study, the TRC40-VAPB complex 
localized to the perinuclear space. In theory, the MSP domain (14 kDa) could be proteolytically 
cleaved and a shortened version of VAPB (only about half of the size of the full-length protein) 
might be found at the ER membrane, if insertion is carried out by another assisted membrane 
insertion mechanism (e.g. Hsc70/Hsp40). With respect to these findings, several populations of 





ER membrane or perhaps in a chaperone function to shield the bound protein (e.g. VAPB) from 
the cytosolic environment or retain it there. In context to this, TRC40 already has been implicated 
in quality control mechanisms 
For the yeast homolog of TRC40 (Get3) it has been reported, that in situations, where energy is 
depleted (e.g. oxidative stress), TRC40 does not deliver TA-protein to the ER membrane anymore, 
but instead is able to serve as a chaperone. It can shield unfolded proteins, prevent aggregation 
and protect proteins from oxidative stress (Powis et al., 2013; Voth et al., 2014). The involvement 
of TRC40 in a quality control mechanism could very well be an explanation for the presence of a 
TRC40-VAPB complex. 
 
PTP1B was also examined in membrane integration studies and could be found inserted into 
rough microsomal membranes when the protein was synthesized in vitro (Figure 11, B).  
Generally, for membrane integration of HZZ-PTP1B-opsin either in vitro or bacterially expressed 
proteins were used, but in all cases the membrane integrated protein bands observed for PTP1B 
were blurry and not distinct. It has been reported that PTP1B is highly modified depending on 
the signal pathway or process it is involved in and thus perhaps this observation could be 
explained (Bakke and Haj, 2015).  
PTP1B was reported to exist in a non-transmembrane state with catalytical function and as an 
integral membrane protein at the ER (Chernoff et al., 1990; Brown-Shimer et al., 1990; Guan et 
al., 1990). The hydrophobic region or TMD of PTP1B was identified at the C-terminus with a 
length of 35 aa (Frangioni et al., 1992). Latest studies about the C-terminal anchor segment 
revealed that the TMD cannot be defined by a fixed sequence, but instead is moveable within 
several amino acids and furthermore the TMD length as well as its hydropathy is crucial for 
localization at the mitochondrial outer membrane (Anderie et al., 2007; Fueller et al., 2015). The 
predicted 35 amino acids TMD is compared to emerin notably less hydrophobic (Table 1). This 
property of the TMD of PTP1B supports the idea of an unassisted insertion mechanism into 
membranes like seen for cytochrome b5, which has a similarly low hydrophobic TMD (Table 1). 
 
Brambillasca et al. (2006) already showed in an in vitro approach that PTP1B inserts into 
liposomes via an unassisted mode and that its integration was strongly dependent on the 
cholesterol amount in the membrane. With increasing amounts of cholesterol used, insertion 
into membranes was inhibited as seen for the TA-protein cytochrome b5 with similar 
hydrophobicity. Furthermore, Brambillasca et al. (2006) did show that a nucleotide-independent 
insertion for PTP1B is possible. It has been proposed that proteins shedding the TMD in the 
cytoplasm before the spontaneous insertion can occur and that cytosolic proteins most probably 
would not need much energy to keep PTP1B in the steady-state. In addition to the unassisted 
pathway suggested for PTP1B, it was shown that it can exploit the Hsp40/Hsc70-mediated 
membrane insertion route when a high amount of these chaperones is present. In the same 
experiment, also the basal levels of insertion were quite high and pointed again to a spontaneous 
ER integration mode. Especially for the unassisted pathway, which PTP1B most probably uses, 
the lipid composition of a membrane as well as cytosolic factors are important. To further analyze 
the non-assisted ER membrane insertion mode, cytosolic factors need to be identified, which 
would be able to control the spontaneous insertion process of PTP1B and to recognize the correct 






For LEMD1, which has a typical LEM-domain like emerin, membrane integration was not 
investigated so far. By virtue of the calculated hydrophobicity of the TMD of LEMD1, it possesses 
a slightly more hydrophobic TMD than LAP2β (Table 1). Based on this it could be sorted into the 
group of moderate hydrophobic TMDs, which might very well be inserted into the ER via an 
assisted pathway. 
 
LRRC59 was not addressed for its membrane insertion mechanism in this study, but unpublished 
data from C. Jamieson, K. Rajanala and M. Blensky support a post-translational membrane 
insertion. Regarding to the characteristics of LRRC59 it could be a borderline TA-protein, because 
its TMD is found about 42 aa upstream of the C-terminal end and has a moderately hydrophobic 
TMD (Table 1). A threshold of about 30 aa following the TMD was proposed to define a protein 
as a TA-protein which uses a post-translational ER insertion mechanism (Borgese et al., 2003). 
Due to the fact that about 39 aa of the nascent protein are protected inside the large ribosomal 
subunit during translation (Blobel and Sabatini, 1970), the TMD cannot be more than 30 aa apart 
from the carboxy-terminus depending on the length of the TMD itself. In future, an involvement 
of the translocon and SRP-dependent pathway therefore needs to be elucidated for LRRC59. 
 
4.2. Verification of localization of proteins to the inner nuclear membrane protein 
using a rapamycin-based dimerization assay 
4.2.1. Applications of a newly developed rapamycin-induced dimerization assay 
In chapter 3.2.2.1, the rapamycin-based INM localization assay was introduced. Previously, the 
rapamycin system was utilized in several approaches connected to research concerning the 
nucleus, but so far not for studying the targeting and localization of INM-proteins. Studies have 
been performed dealing for example with the characterization of nuclear export of the protein 
Tap (Schmitt and Gerace, 2001), trapping of reporter proteins at the nuclear lamina (Ohba et al., 
2004) or in yeast, the system was utilized for depletion of a protein from the nucleus with an 
anchor-away approach (Haruki et al., 2008). 
The two-component rapamycin system, which is used in this work consists of mCherry-FRB-TA-
protein and an EGFP2-GST-NLS-FKBP12 reporter protein. For the specific experimental setup, it 
means that in presence of rapamycin, the soluble FKBP12 reporter binds to the FRB cassette of 
the protein of interest at the INM. Concerning the parameters used for this assay, the 
concentration of 200 nM rapamycin used for this assay for 10 minutes at the longest can be seen 
as a moderate concentration, which was used also for an approach, where proteins were 
inactivated by rapamycin treatment (Robinson et al., 2010). Due to the speed of action that can 
be seen for shifting of the homogenously distributed nucleoplasmic FKBP12-reporter to the 
nuclear periphery (depending on the FRB-TA-protein within 20 seconds) upon rapamycin 
addition in vitro, the risk of side effects induced by rapamycin can be considered as relatively low 
(Putyrski and Schultz, 2012). 
Another observation made for the rapamycin assay was, that the responsiveness of the cells upon 
rapamycin treatment varied a lot between different constructs, but also for the same FRB-protein 
transfected. This seemed to be independent of the transfection level of the FRB- protein inside 





A reason that often some residual GFP-staining is found inside the nucleus, could be the 
expression rate of the GFP-reporter. If a highly GFP-reporter protein expressing cell is treated 
with rapamycin, an incomplete shift in localization can be observed maybe because binding sites 
at the INM are limited. 
Furthermore, there could be differences in the efficiency of binding between the FRB and FKBP12 
reporter hypothetically caused by interactions of FKBP12 and endogenous mTOR. mTOR is 
reported to reside at different compartments of the cell like the cytoplasm or the nucleus (Malik 
et al., 2013; Betz and Hall, 2013). Levels of mTOR could of course differ depending on the cell 
cycle stage and a competitive situation between FRB-TA-proteins constructs at the INM and 
soluble endogenous mTOR cannot be completely excluded. 
Especially in malignant cells, mTOR is found inside the nucleus (Zhang et al., 2002) applying to 
the cell lines used in this work. By contrast, endogenous mTOR was detected equally distributed 
between nucleus and cytoplasm for the HeLa P4 and U2OS cells used in this study (data not 
shown). Therefore, it is very unlikely that endogenous mTOR inhibited the binding to FRB-TA-
proteins at the INM.  
Rapamycin was primarily known for its immunosuppressive properties and it became important 
for basic research with respect to its use in FRB-FKBP12-dimerization experiments to address 
various cellular processes in the last years. Due to its influence on cellular processes like 
regulation of mTOR mediated cell growth and proliferation or upregulation of autophagy 
(Tanemura et al., 2012), cells cannot be used in an unbiased manner. Thus, alternative modified 
chemical inducers for dimerization (CIDs) were developed, which are called rapalogs. The 
advantage of these new rapamycin analogs is that they can be very useful in approaches, where 
an influence on endogenous mTOR and other downstream pathways need to be excluded. 
Taken together, the rapamycin-based dimerization assay established in this work represents a 
reliable and solid approach to monitor localization of a protein of interest to the INM. It allows 
to make a qualitative statement about the localization of a protein, however a quantitative 
analysis and comparison between different proteins is only possible to a limited extent because 
the transfection efficiency and expression levels of both FRB and FKBP12 constructs on the single 
cell level cannot be controlled. 
 
4.2.2. Localization of emerin, LAP2β, VAPB, PTP1B, LEMD1 and LRRC59 at the INM 
After the post-translational membrane integration of the subset of proteins was analyzed, the 
proteins should be confirmed to exist not only at the ER membrane, but also at the INM. By using 
either a differential permeabilization assay (see chapter 3.2.1) and the rapamycin-based 
dimerization assay (see chapter 3.2.2.2), the subcellular localization of the proteins emerin, 
LAP2β, VAPB, PTP1B, LEMD1 and LRRC59 was examined. Some of the investigated proteins could 
only be referred to as localized to the nuclear envelope and for others like LAP2β instead EM 
studies (Furukawa et al., 1995) revealed it to be clearly localized to the INM. 
 
The membrane integration assays showed that emerin uses the TRC40-pathway for membrane 
integration as a bona fide TA-protein, but localization to the INM was not investigated in this 
work so far. By virtue of a differential permeabilization experiment, emerin was shown to be 
present at the INM seen by a predominant localization at the “nuclear rim” compared to digitonin 





given by the rapamycin assay using. mCherry-FRB-emerin (Figure 24). As a well-studied INM-
protein (Manilal et al., 1996; Nagano et al., 1996), emerin was shown to mainly localize to the 
INM by immuno-gold labeling EM (Yorifuji et al., 1997; Tsuchiya et al., 1999), but also a pool at 
the ER and ONM could be observed, which was also seen by Salpingidou et al. (2007). 
LAP2β was tested for its insertion ability into the ER membrane (see section 3.1.2) and shown to 
be integrated post-translational at the ER membrane. Early studies have demonstrated LAP2β to 
be a protein of the nuclear envelope and especially the INM shown by EM studies (Foisner and 
Gerace, 1993; Furukawa et al., 1995; Senior and Gerace, 1988). The subcellular localization assay 
confirmed LAP2β to localize at the nuclear envelope with a prominent “nuclear rim” staining 
compared to cells only permeabilized with digitonin (Figure 23). In the rapamycin-assay LAP2β 
was as well found to be localized at the INM with nearly all of the GFP-FKBP12 reporter shifted 
to the INM after applying rapamycin (Figure 23). The extent, to which the dimerization reaction 
occurred, is comparable with the well-established protein emerin. Because of reports dealing 
with an interaction of LAP2β and lamins (Furukawa et al., 1998; Senior and Gerace, 1988), the 
influence of a lamin A/C downregulation for 48 hours on the localization of LAP2β at the NE was 
examined, because a lamin A/C knockdown resulted in a severe reduction of emerin at the NE 
(Supplementary figure 3). No influence on LAP2β NE localization was observed (Appendix, 
Supplementary figure 3), confirming that LAP2β INM localization is not depending on lamin A/C. 
Instead it has been reported to be retained at the INM by B-type lamins, which were not tested 
in this work (Foisner and Gerace, 1993). Moreover, other properties of LAP2β, like its 
chromosome-binding domain have been reported to play a role in retention of LAP2β at the INM. 
 
The vesicle-associated membrane protein (VAMP)-associated protein B (VAPB) was 
demonstrated to localize at the ER shown by EM (Stoica et al., 2014), the ERGIC (Tran et. al., 
2012) and to endosomes (Soussan et al., 1999; Skehel et al., 2000). For overexpressed mCherry-
FRB-VAPB a localization at a reticular structure around the nucleus, most probably the ER and a 
nuclear envelope “rim” staining was observed (Figure 9 and Figure 23). So far, VAPB has been 
reported to influence the targeting of NE components emerin and the nucleoporin Nup214 and 
a mutant version of VAPB causing amyotrophic lateral sclerosis has been shown to influence 
spacing of INM and ONM (Tran et al., 2012). This indicates an effect of VAPB on the INM. In the 
same study, it was demonstrated to localize to the ER and the nuclear envelope for wild type and 
a VAPB mutant. Indeed, in the rapamycin-assay the FKBP12 reporter was detected as a faint “rim” 
at the nuclear periphery upon rapamycin treatment. The change in distribution of GFP-FKBP12 is 
an indirect evidence for the localization of mCherry-FRB-VAPB at the INM. Compared to the 
FKBP12-reporter translocation of emerin or LAP2β, no complete translocation of FKBP12 to the 
INM was observed and for most of the cells residual GFP-fluorescence could be seen. It can be 
concluded that exogenous VAPB can be found at the INM in vivo. Due to previous reports about 
an influence of VAPB on INM-protein and nucleoporin targeting, the presence of VAPB at the 
INM might be explainable by functioning in this context. 
 
A long variant of the phosphatase PTP1B containing a transmembrane domain is investigated in 
the localization assay. According to immunofluorescence and subcellular fractionation 
experiments it was reported to localize mainly at the outer leaflet of the ER. Furthermore, EM 





pattern reported for PTP1B did not only include reticular structures but also a nuclear membrane 
distribution was observed (Frangioni et al., 1992). 
For the overexpression of mCherry-FRB-PTP1B per se, an ER-staining and a nuclear envelope 
“rim” was observed similar to the pattern of mCherry-FRB-emerin (Figure 9). In presence of 
rapamycin, the transfected EGFP2-GST-NLS-FKBP12 was shifted from the nucleoplasm to the 
periphery, but not to the same extent in all cells. For most of the cells expressing the mCherry-
FRB-PTP1B recombinant protein at a low or moderate level, the co-transfected GFP-FKBP12 
reporter translocated almost entirely to the INM (Figure 23). By contrast, in cells strongly 
expressing PTP1B, a large fraction was observed at the ER and relatively low levels of nuclear 
“rim” staining could be monitored upon rapamycin treatment. Interestingly, PTP1B was found to 
bind to emerin and to regulate its tyrosine phosphorylation at the INM. This was analyzed by co-
localization studies with lamins and biochemically in fractionation experiments (Yip et al., 2012). 
The INM pool of PTP1B was observed to be sumoylated and thus proposed to be in its 
enzymatically inactive state. PTP1B as a TA-protein is able to bind to and regulate emerin being 
as well another TA-protein of the INM. 
Yip et al. (2012) indicated PTP1B to have a function at the INM, where it was confirmed to be 
localized at in the rapamycin experiments (Figure 23). PTP1B was indeed proven to exist at the 
INM and can use a post-translational pathway (Figure 11, D), most probably an unassisted mode, 
for membrane insertion. Therefore, it is classified as a tail-anchored protein of the INM, no 
matter if the INM could be only an intermediate destination for PTP1B in contrast to emerin, 
which is retained there. 
 
LEMD1 was investigated as an INM-protein owing to its characteristic LEM-domain, which it has 
in common with emerin. Due to its structural properties being a C-terminal single pass 
transmembrane protein, it was proposed to belong to the group of TA-proteins. Yuki et al. (2004) 
first identified this protein and reported it to play a role in cancer. Furthermore, LEMD1 was 
found as a testis-specific expressed protein and overexpressed LEMD1F, a short isoform of 
LEMD1, could be found localized at the nuclear membrane together with the DNA-binding 
protein BAF. Since no further localization studies of LEMD1 were available, this was the only 
information about the distribution at the nuclear envelope. Like for other proteins, the in vitro 
kinetics/time course rapamycin assay was performed directly at the microscope in permeabilized 
cells. Transfected mCherry-FRB-LEMD1 itself could be clearly found at the NE and at reticular 
structures, probably ER, around the nucleus. The assay revealed that mCherry-FRB-LEMD1 is 
present at the INM, because a distribution of the GFP-FKBP12 reporter at the nuclear periphery 
was observed after rapamycin addition (Figure 23). For LEMD1 a complete shift of the GFP-
reporter from the nucleoplasm to the INM was never observed to the extent as seen for emerin. 
This could indicate a lower amount of the protein at the INM compared to emerin. On the other 
hand, a low amount of LEMD1 at the INM could as well be caused by the possibility that the 
construct design itself is not the best choice for investigating LEMD1. By far, LEMD1 had the 
lowest transfection efficiency compared to all other mCherry-FRB constructs. The protein has a 
molecular weight of 20 kDa and thus the mCherry-tag with a size of 27 kDa would be larger than 
the protein itself. For all other constructs, the tag was never larger than the protein size itself. 
Another explanation for a reduced amount of LEMD1 at the INM might be that the size of the 





channel of the NPC (Holmer and Worman, 2001; Ohba et al., 2004). The N-terminaI portion of 
mCherry-FRB-LEMD1 would be about (55 kDa) and close to the threshold reported to be at  
60 kDa. In line with this, LEMD1 with a smaller N-terminal portion could be designed and tested 
in rapamycin assays. Nevertheless, using the rapamycin dimerization system, LEMD1 was shown 
to localize to the INM. 
 
LRRC59 was studied as a putative TA-protein, because first experiments about the topology of 
the protein using RM, indicated it to have a very C-terminal TMD and no signal sequence 
throughout the N-terminal part (Ohsumi et al., 1993). Furthermore, Skjerpen et al. (2002) and 
Zhen et al. (2012) showed the protein to localize to the ER and the nuclear envelope in U2OS 
cells, but it has not been examined by immunoelectron microscopy. Using an mCherry-FRB-
LRRC59 for the rapamycin experiment, as well a localization at the ER and nuclear rim was 
detected. After rapamycin treatment, the GFP-FKBP12 reporter shifted to the periphery of the 
nucleus, strongly indicating the presence of LRRC59 at the INM (Figure 23). Again, as observed 
for LEMD1, not all the cells showed a strong translocation of the GFP-reporter to the INM. This 
was also correlated to the expression levels of exogenous LRRC59 in individual cells. Concerning 
the function of LRRC59 at the INM to our knowledge not much is known so far, except its 
involvement in shuttling the growth factor FGF1 to the nuclear interior (Zhen et al., 2012). 
Due to the use of the rapamycin-dimerization assay all investigated mCherry-FRB-tagged proteins 
were demonstrated to localize to the inner nuclear membrane in HeLa cells under in vivo 
conditions. 
 
4.3. Targeting of emerin from the ER to the INM 
This work focused on the characterization of membrane insertion and transport of tail-anchored 
proteins to the INM. Along these lines, emerin was investigated in detail as a model protein 
because there is plenty of information interaction partners. In the following, the outcome of a 
TRC40-dependent membrane integration at the ER and the localization of wild type emerin as 
well as emerin mutants related to Emery-Dreifuss muscular dystrophy are discussed with respect 
to possible INM-targeting models. 
 
Emerin is a substrate of post-translational membrane insertion machinery involving TRC40 
 
Emerin is a C-terminal, monotopic transmembrane protein belonging to the class of TA- proteins. 
Even though several post-translational modes of membrane insertion at the ER were reported 
for TA-proteins (section 1.2.2.2), the most recently identified TRC40- or Get3-mediated pathway 
is supposed to be a prominent route. To elucidate whether emerin is using the TRC40-pathway, 
emerin was expressed together with TRC40 and could be co-purified as a stable TA-protein-
TRC40-complex (see Figure 12). This complex would resemble the proposed in vivo situation in 
mammalian cells except of the pre-targeting complex factors Bag6, TRC35 and Ubl4A, when 
TRC40 captures and shields the TMD of emerin as soon as it exits from the ribosomal tunnel after 
translation. After having the protein produced in way that it could use the TRC40-pathway, 
emerin was tested for its ability to integrate into ER-derived membranes. Accordingly, either dog 
pancreas derived rough microsomes or semi-permeabilized HeLa cells were used to test the 





types, a detection of emerin as a higher molecular weight band (integrated into membranes), 
caused by ER-luminal N-glycosylation of the C-terminal opsin-tag of the HZZ-emerin-opsin, was 
possible (Figure 14, Figure 15, Figure 16). Moreover, the insertion of emerin could be inhibited 
at these membranes, when short fragments of the TRC40-pathway receptors WRB and CAML 
were added (Figure 15), which also supported the requirement of TRC40 for membrane insertion 
of emerin. To not merely use a pre-determined TRC40-emerin complex, emerin was translated 
in rabbit reticulocyte lysate in vitro and HZZ-emerin-opsin could be membrane integrated in RM 
(Figure 10). For TRC40-depleted reticulocyte lysate a reduced membrane insertion of emerin was 
observed (Figure 17). With TRC40 depleted reticulocyte lysates the membrane insertion capacity 
of emerin was lowered. By contrast Hsc70 depletion left the membrane integration of emerin 
unaffected compared to control treated lysates. This corroborates the dependency of emerin on 
TRC40 regarding its membrane insertion mode under the present conditions.  
Presuming the nature of binding between TRC40 and its substrate TA-protein (e.g. emerin) to be 
a transient and rapid process, conventional co-immunoprecipitation studies are rather difficult 
to carry out. Therefore, an in situ approach was used to confirm the most likely transient 
interactions between exogenous TRC40 and emerin (Pfaff et al., 2016). By using a proximity 
ligation assay, the interaction of overexpressed TRC40-myc with endogenous emerin was 
monitored in comparison to the TRC40-independent substrate STT3B. STT3B is supposed to use 
a co-translational SRP-dependent membrane insertion mode instead. As a positive control, 
Seb61β, a well-established TRC40-substrate, was used (Figure 29). Areas, where emerin and 
TRC40 were present in close proximity, could be visualized and for TRC40-myc-emerin 12 
interactions in a cell and for TRC40-myc- Sec61β 56 interactions per cell were scored. 
Unfortunately, a direct comparison of interactions between emerin-TRC40 and Sec61β-TRC40 is 
not possible, because factors like the abundance of the proteins inside the cell or the quality of 
the antibodies used cannot be taken into account for a quantitative statement. A general 
advantage of this method was, that it is possible to see directly, in which compartment or at 
which site emerin and TRC40 interact, meaning that the PLA probes of both proteins are present 
in a range of 40 nm. For both TA-proteins together with TRC40, signals occurred almost entirely 
in the cytoplasm close to the ER membrane as it was expected for the TA-protein delivery to the 
ER via the TRC40-pathway. 
 
Effects of TRC40 and WRB depletion on the localization of emerin at the NE  
Beyond the in vitro membrane integration experiments, the influence of the TRC40-pathway as 
a post-translational ER membrane integration mechanism on emerin was examined in living cells. 
The siRNA-mediated knockdown of two components of the TRC40-pathway, TRC40 and WRB, 
resulted in reduced emerin levels at the nuclear envelope, detected by indirect 
immunofluorescence (Figure 27). In contrast to the reduction of emerin seen by microscopic 
analysis, the total protein levels were found to be unaffected by the depletion of both TRC40 and 
WRB (Figure 28). The reduction of emerin specifically at the NE (Figure 27) observed with 
downregulation of TRC40 and WRB together with the finding that the total protein levels of 
emerin remained stable, could be explained by a dilution effect for emerin and a localization to 
other compartments like the ER. Furthermore, a cause for the overall unchanged protein levels 
could be the capacity of emerin to use alternative membrane insertion pathways. It most likely 





Leznicki et al., 2011) used by emerin, could be the reason for the overall unaffected emerin 
protein levels. Supportive for this is, that in membrane insertion assays using semi-permeabilized 
cells or RM it was specifically displayed that emerin depends on the TRC40-mechanism, when 
short inhibitory fragments of the membrane receptors WRB and CAML were added and 
interfered in the membrane insertion of emerin (Figure 15, Figure 10). 
Recently, the role of both endogenous receptors CAML and WRB as well as their concentration 
and stoichiometry in mammalian cells was investigated (Colombo et al., 2016). The authors of 
this study found that with an up-or downregulation of one receptor subunit, the other was 
affected as well in a mutual manner.  
In the light of this study and the possibility of a mutual influence of components of the TRC40-
machinery, the finding that TRC40 total protein levels are reduced itself, when WRB is depleted 
(Figure 28), is not as surprising. 
According to this TRC40 reduction, indirect immunofluorescence showed an almost entirely lack 
of TRC40, similar to a TRC40 knockdown (Figure 27). As mentioned in section 3.3.1, this reduction 
could be caused by a possible feedback-mechanism regulating the expression and controlling the 
ratio of the membrane-bound components WRB and CAML to the TRC40 pool in the cytoplasm. 
In contrast to this, it has not been reported so far that depletion of TRC40 itself influences the 
protein levels of WRB and CAML. In this context, a possible role of CAML, the second ER-
membrane receptor of the TRC40-pathway, in sensing downstream signals and controlling TA-
protein biogenesis has been proposed (Yamamoto and Sakisaka, 2015). With respect to this 
potential new function of CAML, WRB together with CAML could be seen as a functional unit and 
perhaps a signaling effect initiated by this unit explains the regulation of TRC40. A further 
possibility to explain, why overall TRC40 levels are found to be reduced, could be that not only 
the expression of the protein is modulated and less protein is translated, but certain degradation 
processes e.g. via the proteasome could be initiated to remove not required protein from the 
TRC40 pool. 
 
Possible INM trafficking pathways for INM-proteins and emerin 
 
After insertion of emerin as a TA-protein via the post-translational TRC40-mediated pathway into 
the ER membrane, it still has not reached its final destination, the INM. As described in section 
1.2.4 (Figure 7) several models for transport to the INM have been proposed. One of the most 
discussed models for INM-transport is the diffusion-retention mechanism (Powell and Burke, 
1990; Smith and Blobel, 1993; Soullam and Worman, 1993). An INM-protein is proposed to travel 
after insertion into the ER membrane in a membrane-bound mode to the INM. From the ER 
membrane, which is continuous with the ONM, it reaches the ONM and uses peripheral channels 
of the NPC (Maimon et al., 2012) to insert into the INM. There, the INM-protein is retained by its 
interaction partners e.g. lamins (Haraguchi et al., 2001; Lee et al., 2001). So far, no exclusive 
mode of trafficking to the INM was studied for INM-proteins belonging to the group of TA-
proteins. For emerin, being a very well-characterized INM-protein (Berk et al., 2013b; Bengtsson 
and Wilson, 2004), its mobility inside membranes was investigated by microscopic approaches 
using fluorescence recovery after photobleaching (FRAP) and fluorescence loss in photobleaching 
(FLIP) (Östlund et al., 1999). A clear reduction in mobility was found for the fraction of emerin 
residing at the NE (INM) compared to the ER and plasma membrane fraction. The authors found 





movement was observed, which was faster than that of rather immobile lamins. Further studies 
addressing the mobility of other INM-proteins (e.g. LBR, MAN1) at the distinct locations inside 
the cells showed a distinct behavior in their mobility due to distinct interaction partners at the 
INM (Soullam and Worman, 1993; Ellenberg et al., 1997; Östlund et al., 2006; Zuleger et al., 
2011).  
The studies of Östlund et al. (1999) and Ungricht et al. (2015) used C-terminally tagged INM-
protein versions for the bona fide tail-anchored proteins emerin and LAP2β, which due to the 
tags should not use a post-translational membrane insertion mechanism anymore. Whether the 
general membrane targeting mode or at least the mobility and movement is influenced by the 
mechanism of insertion into the ER-membrane due to the positioning of the fluorescent tag of 
the protein, would be interesting to test. In addition, general information about the possible 
changes caused by tagging of proteins at different positions in relation to their distribution and 
localization could be obtained. 
According to the above reports, as well with a knockdown of lamin A/C, the localization of emerin 
to the NE was disrupted (Supplementary figure 3) and proper localization of emerin at the INM 
seemed to rely on binding to its interaction partner lamin A, which was shown for lamin knockout 
mice and fibroblasts treated with shRNA for lamin A/C (Sullivan et al., 1999; Östlund et al., 2006; 
Moiseeva et al., 2011). Furthermore, for emerin an interaction with chromatin was shown and 
could be seen besides lamin as another “retention factor” at the INM (Shumaker et al., 2001; Lee 
et al., 2001). 
Recently, two reports about the requirements of diffusion-retention based INM-protein targeting 
taking protein mobility and nuclear architecture like NPC number, permeability as well as the 
existence of nuclear binding sites into account, supported this targeting model (Ungricht and 
Kutay, 2015; Boni et al., 2015).  
For some INM-proteins, energy requirement and temperature-dependency was reported to be 
crucial for transport to the INM (Ohba et al., 2004). With respect to this, the mobility of emerin 
was shown to be affected by ATP depletion. Not the translocation step to the INM, but instead a 
process of maintaining the ER structure could be energy-requiring and a limiting step (Ungricht 
et al., 2015). Further, ATP-depletion was shown to influence emerin and its mobility in the ER. 
Sequences required for the ATP-dependent step were allocated to the nucleoplasmic region of 
emerin (Zuleger et al., 2011). Related to this, all membrane insertion steps performed throughout 
the work were shown to be dependent on ATP as an energy source (Figure 15 and Figure 10) and 
even the membrane association shown for emerin in the in vitro transport assays was shown to 
require an ATP-regenerating system (Figure 18). 
 
Another feature regulating and influencing transport to the INM, is the existence of an INM-
sorting motif (see section 1.2.4). It was found to be able to promote targeting to the INM e.g. for 
LBR (Katta et al., 2014; Saksena et al., 2006; Braunagel et al., 2007), but no experimental data 
testing the predicted INM-sorting motif of emerin (Katta et al., 2014) are available. 
Another structural feature critical for targeting to the INM can be the existence of intrinsic FG-
repeats (Zuleger et al., 2011). According to this, FG-repeats were found to be present and 
enriched in NE transmembrane proteins (Schirmer et al., 2003), but especially for INM-trafficking 






When a protein like emerin inserts post-translational via the TRC40-pathway, the question arises 
whether emerin could conceivably be integrated directly at the INM from the inside of the 
nucleus. To address this, emerin would need to be transported by means of its predicted, non-
classical NLS (Katta et al., 2014) as a soluble protein. The insertion step into the INM from within 
the nucleus would probably need to occur in an assisted process mediated by a membrane 
receptor. This membrane receptor might probably be an unidentified protein, because the ER-
receptor WRB, which is crucial for membrane integration from the cytoplasmic side, is indicated 
to be present only at the ER or ONM (Figure 24). According to results of the rapamycin assay for 
WRB, a shift of the GFP-FKBP12 reporter to the nuclear periphery was not observed. This 
suggested that overexpressed WRB is not present at the INM or at least in such low amounts that 
a change in localization for GFP-FKBP12 could not be monitored in this microscopic approach 
(Figure 24). Speaking against a soluble mode of targeting from the nucleoplasmic side is the 
observation that TRC40-myc alone was found to localize predominantly cytoplasmic, not 
nucleoplasmic. Also, TRC40 together with endogenous emerin was found to be mainly localized 
in the cytoplasm near the nucleus, not many interaction signals could be seen inside the nuclei 
in situ (Figure 29). 
The transport-factor mediated pathway results in translocation to the INM by passing the central 
channel of the NPC with assistance of NLS-recognizing classical transport receptors and was 
indicated to apply for the INM-protein SUN2 and the yeast proteins Heh1 and Heh2 (Turgay et 
al., 2010; Theerthagiri et al., 2010; King et al., 2006; Meinema et al., 2011). 
Other than that, INM-protein transport can be facilitated via the diffusion-retention mechanism, 
which was suggested to be the most probable route for LAP2β INM-transport. In general, 
targeting to the INM by the diffusion-retention model was found to depend on the maintenance 
of an elaborate ER network, translocation through a peripheral channel of the NPCs and the 
presence of retention partners at the INM (Ungricht et al., 2015). 
Considering the different possibilities of trafficking of emerin from the ER to the INM, in light of 
the dependency of emerin on A-type lamins for proper localization at the NE, the diffusion-
retention model is favored. For emerin, the retention and localization at the INM was shown to 
be directly affected by a lamin A/C knockdown (Supplementary figure 3) (Sullivan et al., 1999). 
As well, with emerin being found at the ER-membrane and revealing differences in mobility 
between emerin at the ER and NE (Östlund et al., 1999), the diffusion process along the ER is very 
likely to happen. 
Overall, targeting of INM-proteins was shown to require distinct factors like temperature and 
energy, proteins as-co-factors or to depend on harboring specialized internal sequences. 
Different types of INM-proteins might utilize distinct routes for trafficking from the ER-
membrane as initial point of membrane insertion and a single, uniform route to enrich at the 
INM is very unlikely to exist (Antonin et al., 2011). So far, the initial membrane integration 
process of proteins was studied intensively, but whether this step can be critical in determining 





4.4. Disease-related emerin mutants exhibit decreased targeting efficiency to the 
inner nuclear membrane 
Apart from wild type emerin, a subset of X-linked Emery-Dreifuss muscular dystrophy mutations 
in emerin were examined with respect to their membrane integration and their targeting to the 
INM. 
Because it was reported that the features of the TMD of TA-proteins and its adjacent regions 
might have a particular role in post-translational membrane insertion (Beilharz et al., 2003; 
Borgese et al., 2001)), emerin mutants with different TMDs and C-termini were investigated. 
The emerin mutants showing a frame-shift occurring in the TMD (Leu225Arg-FS, Phe240-His-FS) 
or partially (ΔVal236-Phe241) and completely (Trp226*) lacking the TMD, all showed a reduced 
binding to TRC40, when they were co-expressed together with TRC40 in bacteria compared to 
the wild type protein (Figure 31). Related to this, an impaired membrane insertion into RM 
(Figure 32) was observed as well. For Leu225Arg-FS, Trp226* and ΔVal236-Phe241 no nuclear 
localization at the NE could be detected when using a differential permeabilization approach. 
Instead a more nucleoplasmic, as well as cytoplasmic distribution for emerin was monitored. The 
localization of these mutants to the nucleoplasm can perhaps be explained by the finding that 
amin acids 110-147 might be crucial for import into the nucleus. Either a non-canonical NLS can 
be found at aa position 110-147 of emerin, which could be bound by a transport receptor or this 
region could associate with an NLS-bearing partner (Östlund et al., 1999; Berk et al., 2013a). 
An unexpected observation was made for the Phe240His-FS mutant. Even though a lowered 
membrane insertion and decreased protein purification efficiency with TRC40 was shown, it was 
obviously able to localize to the NE and membranes in the differential permeabilization assays 
(Figure 32) and the hydrophobicity of the TMD was definitely reduced (Figure 30). Additionally, 
the rapamycin assay showed that the protein can be found at the INM (Figure 34), albeit the 
extent of translocation of the GFP-FKBP12 reporter was reduced compared to wild type emerin. 
The discrepancy between the low efficiency in membrane insertion of Phe240His-FS using 
bacterially expressed protein in a complex with TRC40 and the ultimate localization of this 
mutant version at the NE, raises the question whether Phe240His-FS might use an alternative 
pathway for membrane insertion than the TRC40 mode. As mentioned above, the hydrophobicity 
is highly reduced for this mutant and an assisted pathway for tail-anchored protein insertion like 
the Hsc70/Hsp40-based pathway could be used like it was reported above for the tail-anchored 
protein PTP1B (Brambillasca et al., 2006). To address the potential role of the chaperone-assisted 
pathway in the ER insertion of the emerin mutant Phe240His-FS, reticulocyte lysates could be 
depleted for Hsc70/Hsp40 and tested for post-translational membrane insertion compared to 
control, TRC40- and SRP-depleted lysates. Alternatively, co-localization studies or proximity 
ligation assays for Hsc70/Hsp40 and emerin could be performed. 
Furthermore, the Pro183Thr and Pro183His point mutations of emerin revealed a reduced 
membrane integration capability, as opposed to this a localization at the NE, meaning the INM, 
was confirmed for these mutants by differential permeabilization and a change in FKBP12-GFP 
reporter protein distribution in the rapamycin assay (Figure 34). 
Moreover, for both mutants in some cells additionally to the membrane distribution, a punctate 
pattern was observed. After transient expression of these mutants, a partial co-localization of 
these dots with the autophagy and lysosomal marker Lamp2, could be seen (data not shown). 





Regarding the hydrophobicity of both mutants compared to the wild type protein, it can be said 
that they are equally hydrophobic. In fact, even a single amino acid change upstream the TMD 
can obviously affect the membrane integration capacity and localization of emerin. With regard 
to the aggregates observed in some cells, a recent study reported both mutations being 
responsible for oligomerization, aggregation and mitochondrial localization of emerin (Herrada 
et al., 2015). 
Additionally, Lee et al. (2001) showed the capacity of emerin to bind lamin A and the DNA-binding 
factor BAF to be unaffected by this mutation. Further, it was proposed that the disease-relevance 
for these mutants might be explained by the disruption of a binding domain in the last third of 
emerin to a yet unidentified binding partner.  
Another analyzed emerin mutant had a point mutation (Gln228His) inside the TMD. This 
substitution of only one aa resulted in a significantly reduced membrane integration capacity 
(Figure 32). Targeting to the INM was still possible, even though the rapamycin-assay revealed 
an incomplete shift of the GFP-FKBP12 reporter to the INM. Thus, the mutant can reach the INM 
but compared to the wild type maybe not to the same extent, which could be seen by the number 
of cells responding to the rapamycin treatment (Table 4). Moreover, a specific localization of the 
mutant to one side of the nucleus was often seen for mCherry- or HA-emerin Gln228His. Due to 
the pattern observed, it was tested for a possible co-localization with the Golgi-marker GM 130, 
which is known to cycle between ERGIC and cis-Golgi (Barr et al., 1998). Indeed, a considerable 
fraction of the protein co-localized with the Golgi apparatus (data not shown). Perhaps mutant 
emerin is localized at the ERGIC/Golgi compartment and modified or processed there until an 
unknown co-factor mediates the transport to the INM. Hypothetically, the TA-protein VAPB could 
play a role in transport of this mutant emerin from ERGIC to the NE, because VAPB has been 
implicated in the retrograde membrane protein transport of wild type emerin and Nup214 from 
ERGIC to the NE (Tran et al., 2012). 
Having analyzed these different emerin mutants for membrane insertion and final targeting to 
the INM, especially the mutant with a single aa change inside the TMD (Gln228His) or a shortened 
version of emerin (Phe240His-FS) were still able to localize to the INM, although results of the 
performed TRC40-based protein expression showed the amount of mutant emerin Phe240His-FS 
to be in complex with TRC40 much lower than for wild type emerin. The membrane insertion 
experiments for Phe240His-FS showed only a little amount of integrated protein. For emerin 
Gln228His a complex with TRC40 could be obtained and the membrane integration was only 
slightly reduced compared to wild type emerin. Therefore, it was not surprising to find emerin 
Gln228His localizing to the INM, but the presence at the INM was less than expected. Probably 
somehow the region around residue 228 could be crucial for the efficiency of targeting. Thus, 
concluded from the observations of the differential permeabilization assay and the rapamycin-
INM targeting experiments possibly the mode of membrane protein integration at the ER could 
affect the efficiency with which the protein is targeted to the INM. 
Emerin, as an inner nuclear membrane protein, was implied in several cellular functions like gene 
expression regulation, mRNA splicing, signaling, mechanosensing via an indirect connection to 
the cytoskeleton, nuclear architecture as well as regulating autophagy (Demmerle et al., 2013; 
Holaska and Wilson, 2007; Deroyer et al., 2014). It was also proposed to have a general function 
in anchoring protein complexes at the INM (Bengtsson and Wilson, 2004) and reported to have 
self-interacting properties (Berk et al., 2014). How crucial the correct targeting of INM-proteins 





localization can result in a neuromuscular disease like X-linked EDMD. In general, the stability of 
emerin at the INM could be altered in different mutants compared to the wild type. The stability 
of course is strongly affected by the interaction of emerin with several binding partners at the 
INM. As a consequence, emerin could be found more abundant at the ONM and the ER. A loss of 
emerin at the INM, disrupted or at least reduced binding of emerin to its interaction partners at 
the INM and mislocalization of emerin variants to other organelles or aggregate formation could 
contribute to the pathologic phenotypes of EDMD. As emerin has been characterized as a tail-
anchored protein, it is important to know that TA-proteins can mislocalize to the outer 
mitochondrial membrane (Schuldiner et al., 2008). TA-proteins localized to mitochondria were 
shown to have highly toxic potential and special AAA-ATPases were reported to be required for 
maintenance of mitochondrial integrity (Okreglak and Walter, 2014; Chen et al., 2014b). All 
possible reasons for the outcome of diseases connected to emerin like the loss of protein, 
mislocalization or the lack of interactions with binding partners at the INM need to be considered 
when elucidating the targeting of emerin to the INM for wild type as well as for EDMD mutants. 
 
Altogether, the membrane insertion mechanism of emerin was shown to depend on the TRC40-
mediated post-translational pathway. It was possible to target emerin to the INM and verify its 
localization specifically at the INM by establishing a rapamycin-based localization assay. 
Concomitantly, emerin mutants implied in EDMD were analyzed for their membrane integration 
properties and targeting to the INM. According to the results obtained from these experiments, 
there are indications that the efficiency of ER membrane insertion might have an influence on 
proper targeting to the INM and in turn a weak binding of mutated emerin to TRC40 not 
necessarily results in abrogated localization to the nuclear envelope. Besides emerin, which was 
the model protein this work focused on, other putative TA-INM proteins like Lap2β, LEMD1, 
PTP1B, VAPB or LRRC59 were characterized along these lines and all have been shown to localize 








This study provided information about the targeting of proteins to the INM focusing on the 
important aspect of membrane integration and the relevance of the TRC40-pathway for emerin 
as a tail-anchored protein.  
Membrane insertion assays for emerin were performed in RM and semi-permeabilized cells.  
Using digitonin-permeabilized cells can be of advantage for investigating the mode of post-
translational insertion of a protein, because knockdown experiments for several pathway 
components can be performed and a possible influence on membrane integration can be 
examined directly. Accordingly, it might be helpful to gain detailed insight in the dynamics of 
membrane insertion in terms of spatial and temporal resolution for the substrate binding, 
delivery and ER-membrane integration steps. 
In addition, it would be very interesting to examine in detail, how the mode and efficiency of 
insertion into the ER membrane would affect the targeting and localization of a TA-protein to the 
inner nuclear membrane. This seems especially interesting because a discrepancy between 
membrane integration and final localization at the INM was observed for some mutants of the 
TA-protein emerin.  
Furthermore, the dynamics of the trafficking process of emerin and selected putative TA-INM-
proteins might be addressed by microscopic approaches as described by Theerthagiri et al. (2010) 
or Ungricht and Kutay (2015) using fluorescently tagged proteins with a protease cleavage site 
and a controlled cleavage process by a NusA-tagged TEV protease. 
During this study, the established rapamycin-based INM-localization assay turned out to be a 
solid and relatively quick microscopy based method, therefore it might be used for different 
aspects of nuclear transport in future as well. In this work, the rapamycin assay was carried out 
at a low concentration with a short incubation time, nevertheless it cannot be excluded 
completely that other cellular pathways are affected by the rapamycin treatment. Thus, 
alternative modified chemical inducers for dimerization (CIDs) were developed, which are called 
rapalogs. The advantage of these new rapamycin analogs is, that an influence on the endogenous 
mTOR and other downstream pathways can be excluded. For future applications, the current 
rapamycin assay could be modified and photoactivatable rapalogs should be tested (Putyrski and 
Schultz, 2012). These compounds would allow to only activate and dimerize proteins in specific 
areas of the cell, which would be helpful in investigating the INM-protein trafficking. 
Moreover, a combination of the in vitro import and the rapamycin assays using bacterially 
expressed proteins containing the FRB-portion in combination with the NLS-containing FKBP12-
reporter would allow to target a protein to the NE and confirm its localization at the INM. So far, 
mCherry-FRB-emerin in complex with TRC40 was produced in bacteria and shown to associate 
with membranes, most probably the ER and NE, of semi-permeabilized cells in vitro (Figure 18). 
Additionally, the approach would provide a possibility to reconstitute the requirements of 
transport to the INM for individual proteins. 
With regard to the question, which model for INM-targeting emerin and the selected set of 
proteins favor, the TRC40 localization would need to be examined in further detail. Along these 
lines, it would be interesting to see, whether TRC40 would be found inside the nucleus. It would 
be important to analyze, whether the ER-membrane receptors WRB and CAML can be detected 





within the nucleus. In this context, PLA interaction studies for various TA-INM-proteins and 
TRC40-pathway receptors WRB and CAML could be performed and first insights of the cellular 
distribution of the interaction might be gained. Potentially, a yet unidentified receptor, which 
can facilitate INM-protein integration, could exist at the INM. Microinjection experiments could 
be performed to address this possibility. For that, one option would be blocking of nuclear import 
by using the lectin wheat germ agglutinin (WGA) or inhibit transport through the NPCs. A 
fluorescently tagged TA-INM-protein of interest could then be microinjected into the nucleus and 
monitored for its localization in vivo. 
Accordingly, the temporal and spatial aspects of trafficking to the INM could be analyzed by 
performing for example FRAP (fluorescence recovery after photobleaching) experiments. This 
would give insight into whether membrane integration occurs prior to translocation to the INM 
or the protein in its “soluble” state translocates and integrates directly into the INM. 
INM-proteins described in this study, which were reported to be involved in very dynamic 
processes (e.g. VAPB, PTP1B, LRRC59), might localize at the INM “transiently“. These proteins 
need to be further characterized in terms of trafficking to the INM. In detail, requirements for 
transport like dependency on soluble factors, energy or structural components of the NPC could 
be addressed using in vitro import assays. Furthermore, RNAi experiments of nucleoporins 
associated with the central or peripheral channel of the NPC or overexpression studies could be 
performed to also gain insights into the mechanism the protein uses for translocation to the INM. 
Besides the investigated proteins, other putative TA-INM proteins, which have been reported at 
the NE like otefin, bocksbeutel or ORP8 could be studied with the established assays. 
Focusing in this study on the specific group of TA-proteins of INM-protein, which shared the 
common feature of a post-translational membrane insertion, was a good way to explore possible 
targeting pathways to the INM. Based on reports of the selected proteins being implicated in 
various cellular functions, a possibility for investigating proteins using different kinds of transport 
mechanisms was given. In long-term, the transport of multi-spanning INM-proteins like LBR or 
MAN1 would need to be compared to the transport of single-pass INM-proteins to identify 
possible preferences of each group for one of the insertion and targeting mechanisms or to 
establish differences in the specific requirements for both types of INM-proteins. 
Gaining more insight into the molecular mechanisms of protein targeting to the INM would help 
to complete the picture of the INM as an important entity of the nuclear envelope. It was not 
only reported to have a structural function but also shown to provide a place for sequestration 
of transcription factors due to direct binding of INM-proteins and can therefore influence gene 
expression considerably (Heessen and Fornerod, 2007). Consequently, the availability of a 
protein at INM would control sequestering of distinct transcription factors at the INM. In case an 
INM-protein is lacking or mutated as described for Emery-Dreifuss muscular dystrophy (EDMD), 
the outcome could be an aberrant gene expression perhaps contributing to the pathology of the 
disease.  
Overall, elucidating the transport of INM-proteins would help to get a better understanding of 
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I. Development of a stable cell line expressing the FKBP12-reporter protein 
 
As a rapamycin-based INM-localization assay was established in this work and transient 
transfection of both, the FKBP12- and FRB-containing reporter proteins were performed. In 
prospect of a more homogenous FKBP12-expression level than observed by transient 
transfection methods, stable expressing FKBP12 cells were selected. As described in section 
2.2.3.7, U2OS cells were chosen due to their large and flat cell morphology and selected for cells 
expressing the EGFP2-GST-NLS-FKBP12 reporter, which is needed to detect an INM-localization 
with the rapamycin assay. After selection of several G418-resistant U2OS cells colonies, a mixture 
of cells expressing the FKBP12 was obtained. To enrich the GFP-positive and G418-resistant 
fraction of cells, the cells have been sorted at the Cell Sorting Facility of the UMG. The initial 
fraction of GFP-positive cells (expressing the FKBP12 reporter) was shown to be about 20% of the 
cell mixture (Supplementary figure 1, A). The localization of the sorted U2OS cell population was 
analyzed by using fluorescence microscopy. In U2OS cells, the GFP-reporter seemed to localize 
predominantly to the nucleus (Supplementary figure 1, B). 
Furthermore, these stable cell lines were used in an in vivo rapamycin assay and the model 
protein emerin was transfected in the U2OS stable “cell line”. Upon rapamycin addition, the 
reporter localized to the nuclear periphery (Supplementary figure 2), but overall compared to 
experiments in HeLa cells, it was only very little FKBP12 reporter localizing to the INM. Another 
drawback was that a considerable fraction of the reporter localized to the cytoplasm and 
therefore could provide false information about an INM localization. The U2OS cells, even though 
their flat morphology, which is very useful for microscopy- based approaches, do not provide a 






Supplementary figure 1: U2OS cells stably expressing the EGFP2-GST-NLS-FKBP12 reporter were 
selected. U2OS cells stable cells were obtained by the protocol described in section 2.2.3.7. They were 
selected with the antibiotic gentamycin (G418) and the cells were sorted for GFP-positive and G418 
resistant cells. (A) Analysis of the U2OS cell sorting process. (B) Localization of the GFP-FKBP12 reporter 
inside U2OS cells. Scale bar: 20 µm. 
 
Supplementary figure 2: In vivo rapamycin-based INM-localization assay for emerin in U2OS cells stably 
expressing the long version of the GFP-FKBP12 reporter. U2OS cells were transfected with mCherry-FRB-
emerin and the rapamycin assay was carried out for 10 minutes at 37°C in living cells. Images reflecting 





II. Knockdown of lamin A/C influences the localization of emerin at the NE 
 
Besides studying the effect of the TRC40-machinery on targeting on emerin to the NE, as well the 
effect of lamin A/C downregulation was studied by RNAi. Lamin A/C was reported to be one of 
the interaction partners of emerin at the INM and supposed to have a role in retention of emerin 
at the INM (Vaughan et al., 2001). This knockdown experiment confirmed a downregulation of 
emerin at the nuclear envelope (Supplementary figure 3). At the same time LAP2β did not show 
any change in localization, which was to be expected because only an interaction of LAP2 with 
lamin B has been shown (Furukawa, 1998) and was used as a control for this experiment. This 
result supports that the enrichment of emerin at the INM most likely requires a retention process 
at the INM. 
 
Supplementary figure 3: Lamin A/C knockdown affects the localization of emerin at the INM. HeLa P4 
cells were transfected with an siLaminA/C (20 nM) with Lipofectamine for 48 h. Endogenous protein 






III. Characterization of a custom-specific emerin antibody 
 
 
Supplementary figure 4: Characterization of a custom specific anti-emerin antibody (Genosphere) by 
immunofluorescence. A custom-specific emerin antibody was ordered from Genosphere Biotechnologies. 
As a peptide for immunization following sequence was used: ‘N’-CFPDADAFHHQVHDDDLL (18 aa).                               
(A) Endogenous emerin can be detected in HeLa P4 cells using the anti-emerin antibody at a dilution of 
1:500. Emerin localizes at the nuclear envelope, which is displayed by a prominent nuclear rim.                      
(B) The emerin antibody is compared to a well-established anti-emerin antibody from Proteintech for 
specificity on protein level. Both antibodies recognize endogenous as well as recombinant emerin protein, 
but for the Genosphere antibody additional bands appear. The band which is indicated by an asterisk is 
recognized by both antibodies at the predicted size (35 kDa), at which emerin can usually be detected by 
western blotting. For immunoblotting the anti-emerin antibody detects compared to the Proteintech 
antibody many unspecific bands therefore further testing and optimization of the immunofluorescence 
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